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Metabolic engineering of Escherichia coli is a sustainable and renewable approach to 
produce a variety of highly-valued fine chemicals. Considering the complex genetic 
networks and biochemical interactions in the host, a multivariate-modular approach to 
engineering the biochemical pathways is an essential step in the identification and 
modulation of conditions for the optimal production of the desired compounds. 
Simultaneous multivariable perturbation can be technically challenging as well-
designed, characterized and convenient molecular tools are not readily available. 
Furthermore, for such highly interactive focused systems, combinatorial approaches 
are favored over heuristic approaches, which further high-light the need of such tools 
to enable the rapid identification and mitigation of potential barriers limiting high 
productivity.  
This thesis is focused on the development of novel enabling technologies for the 
combinatorial multivariate-modular approach to engineering metabolic pathways in 
Escherichia coli. Such convenient and useful tools complement existing technologies. 
One such tool was used to monitor transcriptional changes in biochemical pathways 
by quantitative PCR without the need to first isolate total RNA, thus reduced 
variability in pre-analytics and increased profiling through-puts. Another tool enabled 
the cross-lapping in vitro assembly (CLIVA) of multiple fragments of DNA encoding 
as many as 16 pathway genes into plasmids as large as ~21 kb in a single step, with 
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3BSUMMARY 
exceptionally high efficiency in about 2 days. Yet another tool was developed for the 
simultaneous and systematic tuning of the expression of multiple genetic modules 
using specific controllers (promoters). As there was a need to scale-up the production 
of isoprenoids, a compatible antibiotic-free multi-plasmid system (CAMPS) that 
enabled the stable co-existence of unlimited number of artificially engineered 
compatible plasmids in a genetically modified host in the absence of antibiotic was 
established.  
By using such tools, an integrated workflow was developed to enable the rapid 
identification and construction of large optimal genetic constructs for the scale-up 
production of isoprenoids. Firstly, the CLIVA method was used to assemble 
combinations of genetic modules encoding enzymes in the DXP pathway. The 
overexpressions of certain combinations of modules were found to be inhibitory to the 
production of isoprenoids. The inhibition was largely due to the accumulation of a 
previously unsuspected metabolic pathway intermediate, methylerythritol 
cyclodiphosphate (MEC). Productivity was enhanced by the overexpression of 
downstream enzymes of the co-factor supply system where the levels of intracellular 
MEC were reduced. Secondly, with the use of “univariant controllers”, the 
combinatorial optimization of either DXP or MVA pathway at the gene expression 
levels was carried out by tuning at two orthogonal dimensions, modulating the overall 
expression levels and the expression ratios of the modules. The optimization resulted 
in significant enhancements in the production of isoprenoids (> 40 fold for DXP 
pathway and > 1000 fold for MVA pathway). From such multidimensional analyses, 
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3BSUMMARY 
it was clear that there were major confounding boundaries as well as global optima 
that defined conditions for high productivity.  
The multivariate-modular approach and the workflow developed in this thesis not 
only aid in the identification of optimal conditions for the engineering of metabolic 
pathways but also reveal useful properties of the engineered system, thus, serving as 
valuable guide for the further studies. In addition, the optimal combinations of finely 
tuned metabolic pathway modules can be used to scale-up the production of fine 
chemicals without the need of antibiotic selection with novel engineered plasmids/ 
host systems. 
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Chapter 1 Introduction and literature review 
1.1 Background 
1.1.1 Metabolic engineering 
Microorganisms, in their native forms, have long been used for food and beverage 
preparations such as the production of cheese, wine and diary. Some microorganisms 
naturally accumulate useful end point metabolites during fermentation processes 
where microbes like Aspergillus Niger fungi [1] and the Lactic Acid bacteria [2] have 
been used in the chemical industry for the production of citric acid and lactic acid, 
respectively. In these examples, the utilities are limited to their natural metabolisms. 
To increase the productivity of such desirable products some microorganisms are 
genetically modified chemically or by irradiation to induce mutations, and the mutant 
strains overproducing the desired metabolites are then identified and selected [3, 4]. A 
significant limitation with this technique is that the metabolic pathway involved is 
usually not analyzed, and hence, constraints on production and relevant pathway 
bottlenecks to be modified are unknown.  In recent years, Metabolic Engineering, the 
practice of optimizing genetic and regulatory processes within cells, has been used to 
increase the productivity of metabolites of interest. This approach attempts to analyze 
the metabolic pathways of an organism and to determine the biochemical constraints 
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on the production of the desired metabolite. These constraints are then relieved by 
genetic engineering and the manipulation of the growth medium [4]. 
The recent progress in sequencing technology [5, 6] has enabled the determination of 
the whole genome sequence of an unknown organism rapidly and economically. 
Along with this advancement is the unprecedented developments in the ‘omics’ 
(genomics, transcriptomics, proteomics, and metabolomics) [7], bioinformatics [8] 
and as well as functional genomics [9] which now helped to define genomic structures 
and annotate genes in the genome of an organism. Such ‘omic’ studies along with the 
detailed biochemical and enzymatic data has led to the reconstruction of metabolic 
networks at the genome scale level. Currently, there are public databases (e.g., 
MetaCyc [10], KEGG PATHWAY [11] and BRENDA [12]) that provide knowledge 
of molecular interactions and detail of reaction networks for various organisms. In 
model microorganisms such as the Escherichia coli (E. coli) [13] and Saccharomyces 
cerevisiae (Yeast) [14], the mechanisms involved in gene expressions, replications 
and regulations are well studied and with the availability of such database recourses, it 
is now possible to manipulate their metabolic pathways with ease.  
Besides randomized mutations, it is now a common practice to specifically modify the 
genome of a microorganism by insertion or deletion of genes using recombination 
systems [15, 16]. With the availability of large numbers of naturally occurring 
plasmids [17] and in vitro engineering tools including the polymerase chain reaction 
(PCR) [18], these recombinant plasmids are now routinely used for cloning and 
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expression of gene of interest (GOI). These plasmids are modified to also encode 
different types of regulatory elements, such as promoters that regulate transcription 
and ribosomal binding sites (RBS) that regulate translation of GOI for reconstruction 
and reconfiguration of the metabolic pathways in vivo [19].  Recently, with the 
reduction of cost and the increase in the efficiency of the gene synthesis [20], it is 
now possible to  chemically synthesize the whole bacterial genome in a short period 
of time [21]. With these genetic modification tools as well as the use of analytical 
tools including mass spectrometry for the measurement of metabolites and reverse 
transcription-quantitative polymerase chain reaction (RT-qPCR) [22] for 
transcriptional measurements, a more systematic approach to engineering  
biochemical pathways to increase the production of  desired metabolites can now be 
achieved. 
Thus, the ability to engineer a biological system by manipulating the metabolism of a 
heterologous system is an attractive approach to the development of sustainable 
processes for the production of chemicals, fuels and materials from renewable 
resources [23, 24]. 
1.1.2 The Escherichia coli platform  
A bewildering number of hosts are available for the production of biomolecules and 
natural products [25]. Among these, Yeast and E. coli are the most commonly used 
heterologous hosts where there are greater fundamental understanding of the cellular 
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genetics and biochemistry. In addition, there are large collections of genetic 
engineering tools available and the cost effectiveness and ease in scaling up 
productions make the choice of using these hosts attractive.  
Yeast has several advantages over E. coli where the former has post-translational 
modification systems and the presence of subcellular compartments for site specific 
production [26]. However, E. coli is still the most extensively used host in 
biotechnology [23, 27] for reasons including the simplicity of the metabolic pathways 
and better known regulatory systems.  
Various kinds of chemicals have been produced in E. coli by the introduction of 
recombinant pathways consisting of native and/or heterologous enzymes. Several 
strategies have been applied to optimize the metabolic flux from economical carbon 
sources to produce valuable products [28]. Besides natural end-point metabolites such 
as organic acids and major intermediates like amino acids, a variety of non-native 
products including bulk chemicals like biofuels, fine chemicals like sugar alcohols, 
biopolymers and complex secondary metabolites like isoprenoids, polyketides have 
also been produced.  
Expanding the native metabolism, metabolic engineering approaches have been 
applied to optimize the glycolytic pathway including the tricarboxylate (TCA) cycle 
so as to enhance the accumulation of various kinds of organic acids. These acids are 
important building-blocks for chemical industry including pyruvate [29, 30], lactic 
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acid [31] and succinic acid [32]. The use of E. coli has economic and ecologic 
advantages as compared to the traditional chemical synthesis approaches [33].  
Another example is the production of low abundance but high-value organic acids as 
secondary metabolites, such as shikimic acid [34] and glucaric acid [35]. 
Another class of organic acid produced by E. coli is the amino acids which have 
important applications in pharmaceutical, cosmetic and food industry. Amino acids 
are not easily produced by chemical synthesis due to chirality issues [36]. As the 
fundamental building blocks of cells, the synthetic pathways of amino acids are 
highly coupled and regulated [37]. Both pathway specific and system level methods 
have been applied to optimize the production of amino acids including L-Threonine 
[38, 39], L-Phenylalanine [40, 41] and L-Valine [42]. 
A large class of organics produced using cells is the biofuels which include hydrogen 
and liquid fuels. With the realization of the finite reservation of fossil fuels and the 
necessity to develop renewable and sustainable energy sources, microbial 
fermentation that converts renewable carbon sources to fuels has emerged as an 
attractive solution [43].  As a clean and high density energy source, various attempts 
have been made to enhance the production of hydrogen by E. coli [44, 45] but the 
current yield is still too low to be commercially viable. Similarly, efforts have been 
made to enhance the production of ethanol from various kinds of sugars in E. coli 
with limited success [46-48].  However, several kinds of advance biofuels (mainly 
higher alcohols – four to five carbons) with similar properties as petroleum based 
C h a p t e r  1                                              P a g e  6 
 
fuels have already been produced in E. coli by either fermentative or non-fermentative 
pathways. Examples of these high energy density alcohols include 1-butanol [49, 50], 
2-methyl-1-butanol [51], 3-methyl-1-butanol [52, 53], isobutanol [54, 55], 1-propanol 
[50] and isopropanol [56, 57].  
Besides biofuels, some other kinds of useful alcohols can also be produced in E. coli 
including xylitol [58, 59], mannitol [60], 1,3-propanediol [61], 1,2-propanediol [62], 
2,3-butanediol [63] and 1,4-butanediol [64]. In addition, high amounts of functional 
biopolymers such as polyhydroxyalkanoate polymers [65-67] and polylactic acid 
polymers [68, 69] have been produced in engineered E. coli strains which carrying out 
the biosynthesis of the monomers and the polymerization reactions simultaneously. 
Other than the above mentioned compounds with relatively simple structures (less 
than six carbons), more complicated natural secondary metabolites with critical 
applications in food, agriculture and medicine industry have also been produce in E. 
coli including polyketides [70, 71], nonribosomal peptides [72] and isoprenoids [73].    
A potential hurdle to commercialize products made by E. coli is the market perception 
that the host is a bacterium. Fortunately, E. coli has already been used to produce 
therapeutically important products (e.g. insulin) and has favorable Food and Drug 
Administration (FDA)-approved status for human applications [74]. Furthermore, E. 
coli K-12 strain (used in this study) meets the safety requirements for GILSP (Good 
Industrial Large Scale Practice) of OECD (Organization of Economic Co-operation 
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and Development) regulation and is exempted from EPA review [75] under TSCA 
(Toxic Substances Control Act). 
1.1.3 Isoprenoids 
Isoprenoids (terpenoids) are a large family (more than 55,000) of naturally occurring 
organic compounds with highly diversified and complex structures. Isoprenoids play 
varying roles in physiological processes of microbes, plants and animals. Most of 
these isoprenoids are aromatic and volatile compounds found in essential oils and 
TCMs (Traditional Chinese Medicine) [76-78]. Some isoprenoids have other 
important commercial uses [79] such as fragrances, favors, insecticides [80], 
nutraceuticals and pharmaceuticals (Table 1.1 ).  
Table 1.1 Commercial available isoprenoids ingredients 
Monoterpenoid (C10) Sesquiterpenoids (C15) Triterpenoids (C30) 
Diterpenoids (C20) 
Tetraterpenoids (C40) 
Geraniol Farnesol Abietic acid 
(+)-Linalool Farnesene Levopimaric acid 
Iridodial Nerolidol Neoabietic acid 
Myrcene Bisabolene Palustric acid 
Loganin Santalene Isopimaric acid 
Secologanin Germacrene Aphidicolin 
Loganate Geosmin Casbene 
Geniposidic acid Capsidiol Sclareol 
Asperuloside Valencene Plaunotol 
Carvone Selinene Geranylgeraniol 
Pulegone Patchoulol Abietinol 
Neomenthol Caryophyllene Lycopene 
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Menthol Longifolene Carotene 
Menthone Humulene Canthaxanthin 
Perillyl alcohol Diplopterol Astaxanthin 
Limonene Amyrin Zeaxanthin 
Terpineol Lupeol Lutein 
Comphene Dammarenediol II  
 Taraxerol  
 
Lycopene (Figure 1.1), a 40 carbon isoprenoid mainly found in tomatoes and some 
other red fruits as well as some vegetables, is a nutraceutical with broad health 
benefits including antioxidant [81] and anticancer [82] properties. It also has a unique 
spectral characteristic (red) that makes it an important replacement for many 
traditionally used chemical colorings. The recent unanticipated changes in the food 
regulation and labeling rules have resulted in the increase in demand of natural 
colorant as food additives and nutraceuticals. Recently, LycoRed, a commercial entity, 
has developed new applications for lycopene as replacement for insect-derived color – 
carmine but the production exploits natural resources which are both inefficient and 
unsustainable. 
Another isoprenoid, artemisinin (Figure 1.1), a 15 carbon isoprenoid and the most 
effective anti-malaria drug, was initially discovered in TCM (Artemisia annua). 
Artemisinin-based combinatorial therapy (ACTs) is the standard treatment 
recommended by the WHO for Malaria. The demand of ACTs is on the rise and there 
is a global shortage of artemisinin due to limited production from plant sources. The 
consequences of market fluctuations and the uncontrollable environmental variables 
C h a p t e r  1                                              P a g e  9 
 
have further accentuated the problem and resulted in the growing demand for a 
sustainable supply of artemisinin. 
Taxol (paclitaxel, a trademarked product of Bristol-Myers Squibb, Figure 1.1), is a 
complex isoprenoid which is synthesized from a 20 carbon diterpenoid precursor, 
taxadiene. It was isolated from the bark of the pacific yew tree in a plant screening 
program by National Cancer Institute in the United State and is a widely used cancer 
chemotherapeutic for solid tumor. The major taxol supplier (Bristol-Myers Squibb) 
has switched from plant extraction to plant cell fermentation [83, 84] which requires 
strict growth condition and the cells suffer from gradual ageing issues during 
production. 
All the isoprenoids described above accumulate in insignificantly low quantities 
naturally. For example, ~ 70-200 µg of lycopene is extracted from a gram of tomato 
[85],  ~ 30-710 µg of artemisinin is extracted from a gram of dry leaf of Artemisia 
annua [86] and only ~ 0.064-8.032 g of taxol is extracted from a 100 years old yew 
tree [87]. Thus, it is un-economic and un-ecological to produce them agriculturally. 
Because of the complex structures, with multiple chiral centers (Figure 1.1), the total 
chemical syntheses of taxol [88] or artemisinin [89] are in extremely low yield. 
Lycopene is less structurally complex and can be synthesized chemically [90]. The 
main suppliers (BSAF and DSM) provide chemically synthesized lycopene with 
compromised stereo selectivity and may suffer from unfavorable public perception in 
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the near future due to the global shift towards natural colorants. Furthermore, there is 
a growing demand for sustainable and renewable supply of lycopene and other 
colorants [91]. 
Recently, alternative efforts to reconstitute the biosynthetic processes to produce 
isoprenoids through the use of E. coli, with unmatched growth kinetic and engineering 
potential, have met with some success.  
 




Lycopene (all-trans lycopene ) 
Taxol (paclitaxel) 
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1.1.4 Biosynthesis of isoprenoids 
Facilities and operations for microbe fermentation are much simpler and more 
environmental friendly than those for plant extraction or plant cell fermentation. In 
order to establish a sustainable and economical supply of isoprenoids, E. coli has been 
extensively explored as a host to produce these metabolites from cheap carbon 
sources.  
Biosynthesis of isoprenoids starts with two building molecular blocks, isopentenyl 
diphosphate (IPP) and dimethylallyl diphosphate (DMAPP). These precursors are 
synthesized by mevalonate (MVA) pathway which is present in all higher eukaryotes 
and some bacteria or 1-deoxy-D-xylulose-5-phosphate (DXP) pathway which is 
present in most of the prokaryotes and plant chloroplasts (Figure 1.2). Starting from 
two central metabolites in the glycolytic pathway, pyruvate and 1-deoxy-D-xylulose 
5-phosphate (DXP), the DXP pathway produces equal molar of IPP and DMAPP by 
seven consecutive enzymatic steps in E. coli. On the other hand, the MVA pathway 
uses three molecule of acetyl-CoA (AcCoA) in the Tricarboxylic Acid Cycle (TCA) 
to produce one unit of IPP that can be further converted to its isomer, DMAPP, by 
isopentenyl pyrophosphate isomerase (idi).  The first step in the MVA pathway 
produces acetoacetyl-CoA (AcAcCoA) by combining two AcCoA is catalyzed by a 
thiolase which is present in the E. coli and encoded by the gene atoB. The rest of the 
intermediate steps are not endogenous in E. coli but can be introduced as heterologous 
enzymes from organisms such as Yeast.    
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Figure 1.2 Biosynthetic pathway of isoprenoids 
Pathways for the synthesis of isoprenoid: the 1-deoxy-D-xylulose 5-phosphate (DXP) pathway and 
mevalonate (MVA) pathway. A solid arrow represents a single enzymatic step, while a dashed arrow 
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represents multiple enzymatic steps. The enzymes are represented as underlined words. Abbreviations 
for metabolites: CMP: Cytidine monophosphate, CoA: coenzyme A, G3P: glyceraldehyde 3-phosphate, 
DXP: 1-Deoxy-D-xylulose 5-phosphate, MEP: 2-C-methylerythritol 4-phosphate, CDPME: 4-
diphosphocytidyl-2-C-methylerythritol, CDPMEP: 4-diphosphocytidyl-2-C-methyl-D-erythritol 2-
phosphate, MEC: 2-C-methyl-D-erythritol 2,4-cyclopyrophosphate, HMBPP: (E)-4-Hydroxy-3-
methyl-but-2-enyl pyrophosphate, DMAPP: Dimethylallyl pyrophosphate, IPP: Isopentenyl 
pyrophosphate, AcCoA: acetyl-CoA, AcAcCoA: acetoacetyl-CoA, HMG-CoA: 3-hydroxy-3-
methylglutaryl-CoA, MVA: mevalonate, PMVA: 5-phosphomevalonate, PPMVA: 5-
pyrophosphomevalonate, GPP: geranyl pyrophosphate, FPP: farnesyl pyrophosphate, GGPP: 
geranylgeranyl pyrophosphate. Enzymes: dxs: 1-Deoxy-D-xylulose 5-phosphate synthase, dxr: 1-
Deoxy-D-xylulose 5-phosphate reductase, ispD: 4-diphosphocytidyl-2-C-methyl-D-erythritol synthase, 
ispE: 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase, ispF: 2-C-methyl-D-erythritol 2,4-
cyclodiphosphate synthase, ispG: (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate synthase, ispH: 
(E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate reductase, idi: isopentenyl pyrophosphate isomerase, 
atoB: thiolase, hmgS: 3-hydroxy-3-methylglutaryl-CoA synthase, hmgR: 3-hydroxy-3-methylglutaryl-
CoA reductase, MK: mevalonate kinase, PMK: phosphomevalonate kinase, MVD: mevalonate-5-
pyrophosphate decarboxylase, GPPS: geranyl pyrophosphate synthase, FPPS: farnesyl pyrophosphate 
synthase, GGPPS: geranylgeranyl pyrophosphate synthase.   
The two global building blocks (IPP and DMAPP) can be combined to produce 
geranyl pyrophosphate (GPP, C10 – 10 carbons) which can then be modified to 
farnesyl pyrophosphate (FPP, C15) and further to geranylgeranyl pyrophosphate 
(GGPP, C20) by adding one unit of IPP at each step. In E. coli, the enzyme ispA 
synthesizes GPP and FPP but not GGPP. With various kinds of terpenoid synthase 
and other side chain modification enzymes, monoterpenoid (C10) can be synthesized 
from GPP, sesquiterpenoid (C15), triterpenoids (C30) can be synthesized from FPP 
while diterpenoid (C20) and tetraterpenoids (C40) can be synthesized from GGPP 
(Figure 1.2).  
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1.2 Metabolic engineering methodologies 
Metabolic engineering aims to create a cell with the desired property or phenotype. To 
achieve this, the genetic and biochemical systems which control fundamental cellular 
functions are modified. These modifications can be implemented at the levels of 
defined biochemical pathways or at the global cellular level, where the former 
approach is more focused but the latter is less biased.  
1.2.1 System level pathway engineering 
In the past, there were limited ways to increase the productivity of a desired 
metabolite. A microorganism was usually genetically modified by chemical 
(mutagens) or by physical (radiation) methods to induce mutations randomly and the 
mutant strains that overexpressed the desired metabolite were then selected [92-94]. 
Today, there are a number of  advanced genetic engineering technologies which serve 
similar purposes like the directed evolution [95, 96] and various targeted DNA 
mutagenesis methods [97]. These approaches are high-throughput, combinatorial but 
still require good selection tools to identify the best strain. These purely random 
screening methods, lacking predictive values, are often difficult to replicate between 
different systems and between laboratories.    
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Due to the complexity and intricacies of the connections in the biological networks, 
engineering a living cell to produce the desired metabolites remains a significant 
challenge and it is necessary to globally manipulate the metabolic pathways at  
multiple levels [98]. Thereafter, to expedite the identification of optimal conditions 
for high yield production, focused global level perturbations can be used to accelerate 
this process. In addition, reverse engineering approaches to identify potentially 
beneficial targets to reveal the possible causative mechanisms can also be exploited 
and the knowledge can allow the construction of new systems to enhance productivity. 
A prime example is the method of global transcription machinery engineering (gTME) 
[99, 100] where the global transcriptional regulators were reprogrammed to perturb 
the transcriptome and the strains with enhanced phenotypes were selected from the 
mutant library. By targeting the global transcription factors, the mutant library is 
manageable in size and yet possesses sufficient coverage to enable the global 
perturbation of the metabolism. With the method, the lycopene production in E. coli 
(Figure 1.3, A) as well as the ethanol tolerance property of Yeast (Figure 1.3, B) were 
successfully enhanced. More importantly, gTME can be used in combination with 
other focused approaches such as single gene knockouts (Figure 1.3, A). 
Unfortunately, the reverse engineering of gTME by quantitative analyses of the 
transcriptome using microarray did not yield informative guide to enable rational 
choice of beneficial targets for further engineering. Therefore, in the practice, gTME 
is required to be repeated at each engineering cycle where some other beneficial 
modifications were made to the system. There are other ways to engineer the global 
gene expression machinery like the use of randomized zinc finger motifs as artificial 
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transcription factors [101] and engineered ribosome libraries to modulate the global 
translation mechanisms [102, 103]. Again, the findings with these examples are 
difficult to be mapped out logically onto known cellular mechanisms as no specific 
gene targets could be verified by reverse engineering. 
 
Figure 1.3 Global transcription machinery engineering (gTME) 
(A), the enhancement of lycopene production by the combination of gTME and single gene knockout 
in E. coli [99]. (B), the enhancement of Yeast’s tolerance to ethanol and glucose with gTME [100]. 
Some types of global perturbation approaches may appear to be easier to reverse 
engineer. An example is the randomized overexpressions and knockouts where the 
modified genetic targets can be conveniently identified and correlated to specific 
phenotypes. Overexpression libraries can be created by randomized transformation of 
plasmids carrying pieces of modified genome [104-107]. The knockout or knockdown 
libraries can be generated by either transposon mutagenesis [108, 109] that randomly 
modifies the genome or by randomly silencing transcripts using anti-sense RNAs 
[110]. Unfortunately, the size of genome is too large to be extensively modified 
A B 
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completely by current overexpression or knockout technologies and as a result these 
libraries have limited low coverage of the overall genetic landscape. Although the 
targets involved in the generation of modified phenotypes can be quickly identified, 
they are difficult to be linked sensibly to reveal cohesive and specific cellular 
mechanisms. For example, the random overexpression and knockout screenings of 
genes targets for lycopene production in E. coli [111] yielded a list of targets where 
only two were DXP pathway genes (dxs and idi) which are related to lycopene 
biosynthesis (Figure 1.4). Furthermore, by simply manipulating multiple of the targets 
found, the production of lycopene was not increased as one would hope. Instead, a 
tedious combinatorial trial was necessary to identify the best combinations (Figure 1.4, 
B). In this way, only limited number of candidates can be tested at each condition so 
that only empirical optimum could be identified. 
 
Figure 1.4 Multi-dimensional gene target search [111] 
(A), systematic diagram of the two-dimensional target identification method. (B), combinatorial test of 
overexpression and knockout targets on lycopene production by E. coli. 
A B 
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These global methods aim to tackle biological networks at system level, with the hope 
to identify unknown targets and to reveal useful mechanisms. However, the cruel fact 
is that the complexity of the cellular network confounds such endeavor, even with 
well-studied and simpler system like E. coli.  
Efforts have been made to aid the engineering of global metabolic network by the use 
of in silico computational models (stoichiometric model or kinetic model) [98, 112] 
based on known metabolic pathways. Examples in E. coli are the use of flux balance 
analysis (FBA) to identify knockout targets for optimizing of the growth of E. coli 
[113] (Figure 1.5, A) and the optimization of lycopene production with flux scanning 
based on enforced objective flux (FSEOF) method that identifies gene overexpression 
targets [114] (Figure 1.5, B). These methods model metabolic networks constructed 
with discrete and disparate information which are unlikely to be representative of the 
systems under different circumstances. Furthermore, the regulatory networks which 
are highly dynamic after perturbation such as metabolic burden or stress caused by 
protein overproduction [114-116] are usually not included in the models. Due to the 
limitation of what we know today, these models are successfully used to predict some 
but not most conditions studied and this is invariably a challenge when extending to 
new systems where detail of the kinetics and pathways are not well characterized. 
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Figure 1.5 Metabolic engineering aided with mathematical models. 
(A), the use of flux balance analysis (FBA) for the optimization of the performance of E. coli’s growth 
[113]. (B), the flux (FSEOF) method for the identification of gene overexpression targets for lycopene 
production in E. coli [114].  
 
1.2.2 Focused pathway engineering 
The lack of in-depth understanding of the workings of cellular networks restricts 
rational engineering of the pathways at the global system level (top-down approach). 
Instead, the opposite bottom-up approach is to engineer the specific pathway 
A B 
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mechanisms. An attractive option for the optimization of the production of desired 
metabolites is to focus on local biochemical pathways around selected and putative 
targets. Based on known mechanisms that may contribute to the production of desired 
metabolites, hypothesis driven approaches can be formulated to predict the result of 
overexpression or knockout of these targets. Although being focused and limited in 
the number of  targets and aspects to be tested at any one time, this highly knowledge-
based method provide greater chance of success as compared to the global 
randomized approaches, thus is favored by most of the researchers. The most 
straightforward method is to overexpress the rate limiting enzymes in the pathways 
(central metabolism, local metabolism, redox balancing and transportation) that are 
directly involved in the production of the metabolites.  
The central metabolism can be modulated to enhance the supply of precursor to the 
DXP pathway [117]. By overexpressing the pps, pck genes and knocking out pykF, 
pykA genes, more phosphoenolpyruvic acid (PEP) in the glycolytic pathway is made 
available for the conversion to glyceraldehyde 3-phosphate (G3P, the precursor of 
DXP pathway) and predictably improved the production of lycopene (Figure 1.6, A). 
Another example is the manipulation of the pathways involved in the production of 
the precursor for sesquiterpene, FPP, where this precursor is normally consumed by 
competing pathways in Yeast (Figure 1.6, B). By specifically knocking out the genes 
involved in diverting the FPP from the intended pathway, the metabolic flux is then 
diverted to the production of sesquiterpene [118]. 
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Figure 1.6 Focused pathway engineering 
(A), reprogram the central metabolism to enhance the precursor supply of DXP pathway in E. coli 
[117]. (B), knockout the competing pathway utilizing FPP in Yeast for enhancement of sesquiterpene 
production [118]. The green or red blocks represent the knockout targets. (C), modulation of redox and 
ATP balancing for improved production of succinate in E. coli [119]. Red reactions are targets to be 
modified. (D), enhanced isoprenoids (carotenoids) secretion with the modulation of ABC transporters 
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The high conversion of glucose to certain major metabolites other than biomass will 
result in imbalanced cofactors inside the cell. As an example, to achieve a high 
production of succinate in E. coli, the major redox and ATP regeneration pathways 
were optimized [119] (Figure 1.6, C). Some molecules such as certain biofuels may 
not be efficiently efflux into the medium. This will cause stress and inhibit normal 
cellular functions [120] and so the export system can be enhanced in order to efflux 
these inhibitory molecules resulting in greater cell viability and increased productivity. 
One example of this type of manipulation is the overexpression of the enzyme, msbA, 
of the ABC transporter system where the increase in efflux of carotenoids further 
increased the overall production level [121] (Figure 1.6, D).  
Thus, the general aim of these approaches is to identify relevant target that increases 
the kinetics of the pathways involved by increasing the metabolic flux towards the 
product and yet maintaining cell viability. As discussed, except for the rate limiting 
steps in the pathways directly related to the production of the metabolites, unpredicted 
bottlenecks may exist in the system. Regardless, these bottom-up approaches provide 
more rational ways of optimizing and mitigating bottlenecks than the global level top-
down approaches. 
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1.2.3 Pathway tuning 
After identifying relevant genes to be overexpressed or knockout, the next step is to 
optimize the metabolic flux. As microbial fermentation is a dynamic process where 
cells are evolutionally optimized for growth and biomass production, any perturbation 
to the system (overexpression or knockout of genes) can have unpredictable 
consequences on productivity. Such perturbations may either cause a diversion of 
metabolic resources from the intended purposes or disrupt normal cellular functions 
secondarily which may then affect cell growth and productivity. The extent of 
overexpression of genes is known to affect cellular physiology by over commitment 
of transcriptional and translational resources [122, 123] and hence, it is certainly not 
advantageous to merely overexpress genes at high levels. It is thus not surprising that 
such perturbations on the intricate cellular networks must be carefully controlled and 
fine-tuned to achieve the optimal condition for high productivity.   
Recombinant protein overexpression faces significant challenges in controlling the 
quality, quantity and solubility of proteins [124, 125]. Similarly, the overexpression of 
heterologous enzymes for the production of exogenous metabolites often results in 
non-functional and insoluble inclusion bodies [126, 127]. The enzymes can be made 
more soluble by overexpressing chaperones in the cells [128, 129], fusion with 
partners [130] or the use of certain excipients. We discovered that some enzymes in 
either DXP or MVA pathway form inclusion bodies when overexpressed in E. coli 
and the flux through the pathway was enhanced when the solubility of the enzymes 
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were increased [115]. Besides enhancing solubility by the above strategies, the 
expression efficiency can also be improved by using the same proteins from other 
species or modified by protein engineering [131, 132]. Despite some successes in 
improving solubility, it remains a significant challenge for most heterologous or 
homologous proteins when overexpressed in E. coli [133]. 
Another way to enhance the flux efficiency is by co-localization of consecutive 
pathway enzymes where the local concentrations of metabolic intermediates can be 
greatly increased.  For example, two enzymes of MVA pathway, hmgS and hmgR, 
were co-localized by fusion with different small peptides that interacted with specific 
target protein domains. Multiple target domains were further held by a protein 
scaffold allowed the co-localization of these two enzymes by protein-protein 
interaction (Figure 1.7, A). By manipulating the composition of the scaffolds, the 
metabolic flux was improved and the production of mevalonic acid increased (Figure 
1.7, B) in E. coli [134]. Despite the initial success in producing pathway intermediates, 
the approach has not been successfully applied to the whole pathway, possibly due to 
toxicity of the overexpressed scaffold proteins. 
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Figure 1.7 Enhancing the metabolic flux by enzyme co-localization [134] 
(A), Co-localization of hmgS and hmgR with the aiding of protein scaffolds. (B), optimization of 
pathway flux by varying the scaffolds. 
To modulate the perturbation levels, besides enzyme engineering, the most efficient 
and commonly used approach is to regulate the gene expression levels directly. This 
can be achieved by exploiting the underlying mechanisms involved in transcription 
and translation.  
The expression of a gene is essentially controlled by regulatory elements called 
promoters, which are sequences recognized by RNA polymerase and trans-acting 
factors like transcription factors (σ factor). Inducible promoters are commonly used in 
metabolic engineering to regulate the expression levels of GOI by varying the 
exogenous concentration of inducers. Widely used natural inducible promoters 
A B 
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include the arabinose inducible pBAD promoter [135] and the inducible lac promoter 
[136]. Other kinds of inducible promoters responsive to chemical cues include the 
benzoate inducible Pm promoter [137], xylene inducible Pu promoter [138] and 
salicylate inducible Psal promoter [139].  As sugars can be metabolized, sugar analogs 
that can induce the promoter but not consumed are used instead and an example is 
isopropyl-β-D-thio-galactoside (IPTG) to replace the metabolizable sugar, lactose. In 
order to control the expression of GOI, the inducible promoter is usually inhibited by 
repressor protein binding to an operon sequences in the promoter. The inducer then 
interacts with the repressor causing conformational changes which destabilize the 
binding to the operon thus allowing the RNA polymerase to initiate transcription. 
Such basic mechanism has been exploited in plasmids carrying modified regulatory 
sequences controlling various inducible promoters. Such engineered promoters are 
widely used in metabolic engineering for transcriptional control and these include the 
IPTG inducible T7 promoter, pTrc promoter, pTac promoter and T5 promoter.   
A series of well characterized promoter libraries have been reported where the 
regulatory regions have been specifically engineered or even randomly mutated to 
produce various promoters with varying expression levels [140]. For example,  a T7 
library with varying  expression levels of GOI over a range of 50 fold has been 
generated by single base mutations of the regulatory sequences [141] (Figure 1.8, A). 
These promoter libraries are powerful tools for metabolic engineering and an example 
of the use was in the expression of recombinant genes (β-lactamase or 
phosphoglucomutase) where enhancement of production was observed using the Pm 
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promoter library in E. coli [142] (Figure 1.8, B). Another example is the use for the 
production of lycopene which was improved by replacing the native promoter with 
various mutant bacteriophage Pl promoters in the genome of E. coli [143] (Figure 1.8, 
B).   
 
Figure 1.8 Promoter engineering for metabolic engineering 
A 
B C 
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(A), T7 promoter library of all possible single mutations characterized by in vitro transcription [141]. 
(B), enhancement of β-lactamase (bla) and phosphoglucomutase (celb) expression with Pm promoter 
library [142] in E. coli. (C), enhancement of lycopene production with bacteriophage Pl promoter 
library [143] in E. coli. 
Other than regulating gene expression by manipulating promoters, protein expression 
can also be modulated at the translation levels. In E. coli, the initiation of translation 
is controlled by a short sequence (6 – 10 bases) in the mRNA upstream of the protein 
coding sequences which is recognizable by the ribosome (16 rRNA). This stretch of 
sequences is known as the Shine-Dalgarno sequence or the ribosome binding site 
(RBS) [144]. There is a spacer of about 8 bases between RBS and the start codon of 
protein (ATG). By changing the length and sequences of this spacer, the strength of 
RBS, the ratio of translation initiation, can be finely modulated without changing the 
RBS sequences [145] (Figure 1.9, A). Furthermore, it is known that the recognition by 
the ribosome is influenced by the secondary structure of the mRNA [146, 147].  With 
improved understanding of RNA secondary structure formation [148, 149], a 
mathematical model correlating the Gibbs free energy of the structure and RBS 
strength has been successfully established [150] (Figure 1.9, B). Free online software 
is now available for the prediction of RBS strength in translation and for the design of 
artificial RBS with the desired properties [151].  
Besides RBS, the mRNA stability can also affect protein expression and the stability 
can be influenced by secondary stem-loop structures [152-155]. 
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Figure 1.9 Engineering the ribosome binding site (RBS) 
(A), tuning the translation level by modulation of the length of spacer between RBS (Shine-Dalgamo 
region) and start codon (ATG) [145]. (B), Design artificial RBS with specified strength calculated by a 
mathematical model calculating the gibbs free energy of mRNA folding around the RBS region [150].  
Although various tools have been developed for enhancing protein production by 
modifying RBS or RNA stability, the consequences due to the changes are less 
predictable than promoter engineering.  
1.2.4 Multivariate-modular approach to pathway engineering 
To optimize a pathway where usually multiple bottlenecks exists, the tuning of the 
expression of a single gene is not enough. Based on the biochemical understanding of 
A B 
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metabolic mechanisms, it is now possible to consider a metabolic network as an 
assembly of various distinct modules made up of different enzymes with different 
biochemical constraints and that these modules can then be modulated empirically 
with the aid of computational tools so as to allow the rapid and systematic 
identification of optimal conditions for achieving the desired outcome  [156].  Various 
attempts have been made to tune the genes encoding the enzymes in multiple modules 
simultaneously using the transcriptional or translational controlling mechanisms [157].  
A comprehensive example is the engineering of DXP pathway for taxadiene (C20 
isoprenoid) production in E. coli [158] (Figure 1.10) where the pathway was divided 
into the upstream module consisting of four bottle neck enzymes in the DXP pathway 
(dxs, idi, ispD, ispF) and the downstream module consisting of heterologous enzymes 
(GGPPS and taxadiene synthase). Various promoters with different strength and 
various plasmids with different copy numbers were used together to modulate the 
expression of both modules and an optimum combination for isoprenoid production 
was identified. Similar method has also been applied to engineer the MVA pathway 
for amorphadiene (C15, isoprenoid) production, although less comprehensively [159]. 
In another example, the first three enzymes (atoB, hmgS and hmgR) of MVA pathway 
were placed as a polycistron where special sequences were introduced to the 
intergenic regions inducing a RNase E site and a stem-loop secondary structure [160] 
(Figure 1.11). After RNase E digestion, three pieces of coding sequences with 
different RBS binding efficiencies as wells as stabilities were generated and by 
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simultaneously tuning these intergenic regions, an optimum condition for mevalonate 
production was identified.  
 
Figure 1.10 Multivariate engineering of DXP pathway [156, 158] 
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These examples illustrated a useful framework for the engineering of an intricate 
metabolic network by controlling multiple enzymatic reactions in the pathway as 
distinct modules or cassettes to achieve the desired outcome. However, more rational 
and systematic ways of defining modules and searching for the optimal conditions for 
enhanced productivity are necessary to exploit the full capabilities of the pathways.  
1.2.5 Construction of genetic carrier  
In bacteria, GOI with regulatory elements can be either integrated into the genome or 
carried by a self-replicating genetic carrier called plasmid. Genomic integrated 
expression methods are well established for E. coli [15, 16]. There are some 
significant hurdles when using such methods which include the need to produce 
specific modified strains with the integrated GOI for each task, limited copy number 
(usually single-copy insertions) and low efficiency in integrating into the genome 
which makes it a labor and time consuming affair.  Although new technologies such 
as chemically inducible chromosomal evolution (CIChE) [161] where the copy 
number in the genome can be increased by selection using increasing amount of 
antibiotics have been developed, the difficulty here is to remove the antibiotic 
resistant genes as well as the unpredictable effects on cell physiology caused by the 
randomized insertions, making this approach inappropriate for rational engineering 
tasks.  Thus, plasmid-based systems are still favoured in laboratory as well as in 
industry simply because the autonomous replicating plasmids are easily constructed 
and are convenient to be transferred between strains. Thus, plasmids offer an efficient 
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and flexible way to build the genetically engineered host [162], especially for 
metabolic engineering where large combinations of pathway modules are manipulated 
simultaneously. 
As mentioned, a significant challenge of multivariate pathway optimization is the 
construction of strains with multiple desired perturbations. Regardless of whether a 
plasmid is required or the need to integrate GOI into the genome, the construction and 
assembly of multiple native and/or heterologous genes with the designed regulatory 
elements is still a significant rate limiting step in metabolic engineering.  
The commonly used restriction enzymes and in vitro ligation based sequential cloning 
methods are often limited by the availability of unique restriction sites and are time 
consuming. Furthermore, single stranded DNA (ssDNA) overhangs generated by 
restriction enzymes are typically 2-8 nucleotides which exhibit poor annealing 
efficiencies and have limited use in assembling multiple large DNA fragments in a 
single step. To address the challenges, several sequence independent methods such as 
exonuclease based method [21, 163-168], uracil-DNA glycosylase based method [169, 
170] and phosphorothioate based method [171, 172] were developed to generate long 
ssDNA overhangs (>10nt) from PCR products; whereas, double stranded PCR 
products with long homolog sequences were directly used for cloning in other 
methods like topoisomerase based method, Yeast in vivo homolog recombination 
based method [21, 173, 174] and denature & re-annealing based method [175].  
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Despite some enhancement in cloning efficiency, only a few of these approaches have 
succeeded in assembling multiple (>3) DNA fragments into a plasmid in a single step. 
The sequence and ligation-independent cloning (SLIC) method that uses T4 DNA 
polymerase with 3’ to 5’ exonuclease activity to generate ssDNA for in vitro 
homologous recombination has been used to construct a ~7.5kb plasmid from 11 
fragments of DNA [163]. With the phosphorothioate-based DNA recombination 
method, PLICing, a combinatorial assembly of 5 pieces of DNA components to form 
a plasmid library of about 6-8 kb has recently been reported [171]. These methods and 
some others [176-179] have only demonstrated the construction of plasmids of less 
than 8 kb which carry only one recombinant gene for the purpose of generating a 
combinatorial enzymatic library.  
A metabolic pathway module often contains multiple genes each of which is about 1-
3 kb in size. Various attempts have been made to meet the increasing demand to 
assemble several large fragments of DNA inserts into plasmids of > 10 kb [156, 157, 
180]. A two-step isothermal in vitro assembling method called Gibson Assembly [181] 
(Figure 1.12, A), modified from the exonuclease based method by introducing an 
additional DNA repair step with DNA polymerase and ligase, was used to assemble a 
16.3 kb construct from 75 pieces of DNAs and the assembly of a 24kb plasmids from 
4 fragments [21, 182, 183]. In addition, using Gibson Assembly together with Yeast in 
vivo recombination system, a 582 kb mycoplasma genitalium genome was constructed 
from synthetic DNA oligonucleotides in several steps by the same group [21]. The 
Yeast in vivo recombination system has also been successfully utilized for one step 
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assembly of a 19 kb fragment into a plasmid or Yeast genome (DNA assembler 
method) [174] (Figure 1.12, B).  
With these examples, homologous overhang sequences with lengths of 100-500 base 
pairs were required to increase the assembling efficiency. This can be a significant 
challenge where suitable pre-existing sequences in the parental or chemically 
synthesized templates are required which can restrict the applicability and incur high-
cost of synthesis. Furthermore, these approaches are also time consuming and labor 
intensive, hence, are not suited for routine cloning projects. Besides, the requirement 
of multiple enzymes in vitro and/or in vivo for such construction will not only be cost 
prohibitive but will also require extensive labor, thus increasing the inconsistence of 
the performance by different users. 
 
Figure 1.12 Methods for assembly of large biological pathway 
(A), the Gibson Assembly method using exonucleae, DNA polymerase and DNA ligase to assembly 
DNA pieces with homolog overlaps in vitro [181]. (B), the DNA assembler method where multiple 
A B 
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DNA pieces with homolog overlaps were co-transformed together with a vector containing the 
necessary replication and selection elements for E. coli and Yeast into Yeast for assembly using its 
native recombination system [174]. 
1.2.6 Stable expression system 
Significant challenges exist when using plasmid-based engineered cells for the scale 
up production of desired metabolites by fermentation. These include plasmid 
maintenance and replication which can influence the productivity [184, 185]. 
Plasmids with similar replication mechanism are incompatible with each other thus 
cannot stably coexist inside the same cell [186, 187] as they share the same 
replication control elements like iterons, antisense RNAs, etc. After segregation, the 
daughter cells regulate the copy numbers of incompatible plasmids jointly and 
consequentially a stochastic distribution will occur which will eventually lead to 
plasmid loss (Figure 1.13, incompatible). On the other hand, the copy numbers of 
compatible plasmids are separately regulated so that the daughter cells will be 
identical (Figure 1.13, compatible). The incompatibility issue expectedly will limit the 
number of different plasmids carrying various genes of interest (GOI), provided the 
plasmids have origins of replication (Ori) in different incompatibility groups [19]. 
There are only limited numbers of such groups naturally (Table 1.2) and such 
plasmids from various groups with distinct replication mechanisms have different 
copy numbers and different responses to environment changes [188, 189], posing 
potential challenges in controlling the expressions of multiple GOI. 
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Figure 1.13 Plasmid incompatibility [186] 
 
 As an illustration, to engineer the DXP pathway by multivariate approach (Figure 
1.10), three plasmids – pSC101 (low copy number), p15A (medium copy number) 
and pBR322 (high copy number, derived from pMB1) are used to control the copy 
number of the pathway modules inside the cell where pSC101 and p15A are 
incompatible (Figure 1.10). The two pathway modules with incompatible Ori will not 
be maintained at the designated levels with prolonged cell growth thus cannot be used 
together (see section 1.2.4).  
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Mechanism of Action 
colE1, pMB1 RNAI controls processing of pre-RNAII into 
primer 
IncFII, pT181 RNA controls synthesis of RepA protein 
P1, F, R6K, 
pSC101, p15A 
interons sequesters RepA protein 
 
Furthermore, due to the asymmetry of plasmid distribution during cell division, the 
daughter cell may totally lose its plasmid during large-scale cultivation processes 
where cells undergo many rounds of replication. The result is that cells dispense the 
extra metabolic burden of synthesizing the plasmids giving rise to the survival of non-
plasmid harboring cells [162, 190]. This is particularly exaggerated with plasmids 
expressing recombinant proteins which impose high metabolic burden. As expected, 
this plasmid instability problem would be magnified on an industrial scale for which 
specific product yield over biomass are critical [185]. 
One common approach to overcome this is to supplement the growth medium with 
antibiotics for the selection of cells harboring the plasmid expressing the resistant 
gene. But the use of antibiotics is not industrially encouraged as it incurs cost, poses 
purification issues, has ecological constraints and faces regulatory challenges [191]. 
Furthermore, the use of antibiotics will also impose physiological burdens for the 
growth of cells expressing GOI [192] and the potential loss of selective pressure 
resulting from antibiotic degradation [193] will require constant supplementation. 
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Hence, to be industrially relevant, plasmids are required to be maintained under 
selection pressure without the use of antibiotics. The issue of antibiotic free 
fermentation at industrial scale has long been faced by recombinant pharmaceuticals 
industry [194]. To address this need, various antibiotic free selection plasmid/ host 
systems have been developed [162, 195] (Figure 1.14).  For example, with the 
toxin/antitoxin system, the host is engineered to produce certain lethal toxin so that 
plasmids carrying the antitoxin will be forced to be maintained as they are essential 
for cell survival (Figure 1.14, Toxin/Antitoxin (TA) systems). In other examples, the 
essential gene inside the genome was knocked out or knocked down to inhibit the 
growth of the cells where only those carrying plasmids expressing the rescues genes 
can grow (Figure 1.14, Metabolism-based systems and Operator repressor titration 
(ORT) systems). 
 
Figure 1.14 Antibiotic free plasmid selection systems [162] 
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Despite some success, these systems have only managed to maintain a single plasmid 
inside the cell for the production of plasmid DNAs or recombinant proteins. As yet 
there has not been any report of an attempt to maintain multiple plasmids in the 




This thesis attempts to address some unmet needs in metabolic engineering and 
synthetic biology by establishing novel tools and workflows for the multivariate 
combinatorial engineering of a focused system where limited number of highly 
relevant targets were systemically optimized (Figure 1.1). These tools and workflows 
will then be utilities to optimize the metabolic pathways enhanced isoprenoids 
production in E. coli. Furthermore, discoveries of the underlying mechanisms limiting 
the production of isoprenoids at high yield are also unanticipated in the course of the 
study. 
Firstly, in order to understand and characterize the contribution of various 
components inside a biochemical system to the production of a desired metabolite, 
merely modulating the expression of the gene (s) involved and observing the final 
C h a p t e r  1                                              P a g e  41 
 
yield is an incomplete approach. Transcriptional measurements of the levels of the 
expressed genes involved in the system provide a more detailed picture of the changes 
occurring. A direct transcriptional measurement method with minimized preanalytical 
viabilities, increased through-put and convenience is necessary to be developed to 
measure those changes accurately and efficiently (Figure 1.1, Part I).  
Secondly, a significant limitation of multivariate engineering is the absolute 
requirement to assemble multiple components of DNA rapidly. To address this need, 
a highly efficient, enzyme free cloning method needs to be developed for labor- and 
time-saving pathway assembly (Figure 1.1, Part II). With the method, the 
overexpression of endogenous DXP pathway enzymes can be combinatorially studied 
and novel bottlenecks can be revealed.   
Thirdly, after dividing the pathway into multiple modules, a versatile promoter-based 
control system that rapidly identified optimal expression levels for those gene 
cassettes will be developed (Figure 1.1, Part III). This method will allow the 
systematic optimization of the pathways (DXP or MVA) to produce various 
isoprenoids. Also the global boundary and properties of the pathways will be studied.  
Finally, to extend the workflow for more complicated systems as well as for industrial 
applications, a scalable compatible antibiotic-free multi-plasmid system will be 
developed. This system will enable the stable co-existence of large number of 
plasmids without the use of antibiotics (Figure 1.1, Part IV).  
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1.4 Organization of thesis 
In Chapter 1, the research background of metabolic engineering and a literature 
review of metabolic engineering methodologies were discussed. The objectives of this 
thesis addressing the challenges of multivariate pathway optimization were also 
described. 
In Chapter 2, a convenient and high throughput method was established for the 
quantification of transcription levels in E. coli. The mRNA levels of DXP pathway 
genes expressed in various strains and media were measured. This method was highly 
accurate in gene profiling by minimizing pre-analytical issues.  
In Chapter 3, a ligation independent cloning in vitro DNA assembly method was 
developed for the efficient one step assembly of multiple DNA fragments into a 
plasmid. The optimal combinatorial selections of overexpressed genes in the DXP 
were identified. 
In Chapter 4 described the use of the tools developed in Chapter 2 and Chapter 3 to 
facilitate the development of a novel multivariate-modular combinatorial engineering 
method.  Multiple DXP or MVA pathway modules were systematically optimized. 
Conditions and previously unknown limiting factors affecting the pathway for high 
productivity were also systematically identified. 
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In Chapter 5, a scalable compatible antibiotic-free multi-plasmid system was 
established which enabled the stable co-existence of unlimited number of artificially 
engineered compatible plasmids in a genetically modified host. 
In Chapter 6, the summary and the conclusion of the thesis were described. 
Suggestions for future works were made.  
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Chapter 2 A direct reverse transcription 
quantitative PCR method for transcriptional 
analysis in E. coli 
2.1 Background and motivation 
Transcriptional control of gene expressions is widely used in synthetic biology and 
metabolic engineering to finely optimize biological systems for the generation of 
desired phenotypes [196].  To better understand the transcription changes in 
engineered pathways, it is often desirable to measure the expressions of a selected 
number of desired genes that may contribute to the acquired phenotypes. In E. coli, 
transcription and translation are tightly coupled processes and there is a good 
correlation between the amount of protein biosynthesized and the amount of 
transcripts produced in vivo [197-199].  
Quantitative PCR (qPCR) has gained prominence over other detection platforms for 
transcriptional measurements due to its higher assay sensitivity, wider dynamic range 
and greater precision [200, 201]. With the recent availability of low sample 
consumption and high-throughput qPCR arrays, large numbers of studies can now be 
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conducted [202]. Thus, qPCR is debatably the most reliable, sensitive and flexible 
technology for quantification of nucleic acids.  
Reverse transcription qPCR (RT-qPCR) requires the use of total RNA typically 
prepared from cells lyzed by vigorous agitation or homogenization in the presence of 
lysis buffer that protect the RNA from ribonuclease degradation. Following lysis, the 
RNA is purified by either phase partition-based method like phenol/chloroform 
method [203], precipitation using catrimide/LiCl method [204] or spin column-based 
method such as RiboPure™-Bacteria method (Invitrogen) and RNAprotect® Bacteria 
method (QIAGEN). These multi-step approaches are labor intensive and cost 
prohibitive for high-throughput studies. Therefore, a rapid and robust pre-analytical 
method that allows direct quantification of transcripts, without the need to isolated 
RNA is highly desirable. 
Some enzyme based methods [205, 206] or multistep boiling methods that heat the 
sample in the presence of detergent containing buffer [207, 208] have been reported 
for cell lysis. However, with these methods, RNA precipitation is a critical step to 
obtain quality samples suitable for RT-qPCR. In this chapter, a rapid, cost-effective, 
high-throughput and time-saving thermal based method for the extraction of E. coli 
RNA was developed. In this approach, the cells were lysed, ribonucleases inactivated 
and RNAs extracted in a single heating step. The extraction was completed in <10 
minutes with low cost reagents and minimal labor. Importantly, the extracted RNA 
was directly used for downstream applications such as DNAse treatment and RT-
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qPCR. The overall process involving RNA extraction to quantification by qPCR, a so-
called “cells to CT (cycle threshold)” method, was completed in less than 2 hours in a 
high-throughput (96-well) format. As a proof-of-concept, the method was used to 
measure transcriptional changes of genes in the DXP pathway of engineered E. coli 
strains grown in different medium. 
 
2.2 Results 
2.2.1 Design and optimization of the novel method 
E. coli Bl21 DE3 strain was engineered and the strains were further used in process 
optimization studies. Two endogenous genes, the cysG (siroheme synthase) gene 
expressed at ~ 106 copy/ µL of cell (OD600 = 3.33) and idi (isopentenyl diphosphate 
isomerase) gene expressed at ~104 copy/ µL of cell (OD600 = 3.33), were measured 
by qPCR. The expression levels of these two genes were used as indicators for the 
quantity and quality of extracted RNA. Besides, the in vitro synthesized heterologous 
eGFP (enhanced green fluorescence protein) transcript was spiked into some of the 
samples to investigate the efficiency of RNA recovery. 
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E. coli is known to lyse when heated. With the aim to develop a RT-qPCR compatible 
RNA extraction method, various thermal lysis conditions were explored. As a start, 
cells were suspended in DEPC treated water and heated at a range of temperatures for 
varying amounts of time (70 to 95 °C, 5s to 5 min). The cysG mRNA levels were 
found to be efficiently extracted at high temperature (950C) for 5 min (Figure 2.1, A).  
 
Figure 2.1 The effects of heating conditions on the performance of the novel 
transcripton measuremet mehotd  
The standard errors from triplicates were displayed. Cells were heated at density of OD600 = 3.33. (A) 
Transcription level of endogenous cysG gene in E. coli BL21 DE3. The whole cell suspension in 
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processes. (B) The ribonuclease activities of RNA samples prepared by different method; the in vitro 
synthesized eGFP mRNA was spiked into the isolated RNA solution and quantified after 3h incubation 
at 37°C. In the control set, w/o cell means incubation of eGFP mRNA without any cell lysate and 
vortex means the cell was lysed by vortexing in the presence of glass beads at room temperature. 
Student t-test: * : p-value < 0.05, ** : p-value < 0.01, *** : p-value < 0.001. 
As compared to eukaryotes where mRNA exhibit half-live in the range of hours with 
few exceptions, bacteria has a much faster mRNA decay with half-live in minutes 
[209]. To protect the mRNA, the ribonucleases from E. coli cells need to be 
inactivated. Other than cell lysis, the heating may also disrupt protein secondary 
structure and promote protein precipitation. Thus, heating the samples followed by a 
spinning step to remove aggregated insoluble proteins and cellular debris may remove 
inactivated ribonucleases. In order to test the RNAse activity in these samples, the 
degradation of exogenously spiked in heterologous eGFP mRNA was measured. 
Samples were spiked with 5 pg/μL of eGFP mRNA and subsequently incubated at 
37 °C for 3 h and then measured by RT-qPCR (Figure 2.1, B). The results 
demonstrated that the amount of eGFP transcript measured after heating at 70 °C for a 
short period of time or just incubating the supernatant were significantly lower as 
compared to samples heated at higher temperature (95 or 98 °C; Figure 2.1). At 95 or 
98 °C, heating for 3 min resulted in samples with slightly lower RNA recovery as 
compared to the control (w/o cell). However, the amount of spiked RNA was identical 
to control with samples heated for 6 or 12 min indicating that RNAse activity was 
inactivated when heated sufficiently. Thus, heating at 95 °C for 6 min was chosen as 
the thermal lysis condition. 
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High temperature is known to accelerate RNA hydrolysis and the process can be 
further catalyzed by divalent ions such as Mg2+ by stabilizing the cyclic phosphate 
intermediates [210, 211]. Knowing that the cell lysates contains endogenous divalent 
ions such as Mg2+ or Ca2+, in order to minimize RNA degradation during heating, 
various concentrations of the chelating reagent, EDTA (Ethylenediaminetetraacetic 
acid) at pH ~ 7, were added to the suspension solution.  By measuring endogenous 
cysG and idi mRNA levels, the addition of EDTA significantly increased the yields 
(Figure 2.2, A).  The levels of exogenously added eGFP mRNA in samples heated at 
high temperature for 5 min in solutions containing 0.8 mM or higher concentrations of 
EDTA were found to be similar to controls while only about half were recovered in 
pure DEPC treated water (Figure 2.2, B). DNAse treatment was included as part of 
the workflow as genomic DNA contaminations would confound measurements of the 
transcripts. As Ca2+ is an essential cofactor of DNAse, the inclusion of this cation may 
affect the chelation properties of EDTA. As expected, with increasing amount of 
EDTA, the activity of DNAse was affected (Figure 2.2, C). This explained the slight 
increase in the measured level of idi mRNA when higher concentrations of EDTA 
(2.7 mM or more) were used (Figure 2.2, A). Although the DNase activity could be 
increased with the additional supplement of Ca2+ after heating (data not shown), 1.2 
mM EDTA was chosen as the optimal buffer condition where RNAse activity was 
effectively inactivated and yet did not adversely affect the downstream DNAse 
activity. 
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Figure 2.2 The effects of EDTA concentrations in the lysis buffer on the 
performance of the novel transcription measuremet method 
The standard errors from triplicates were displayed. All the samples with OD600 = 3.33 were heated 
for 6 min at 95°C followed by a spinning step to remove the insluble fractions. (A) Transcription level 
of endogenous cysG/ idi gene in E. coli BL21 DE3 strain. (B) The recovery of spiked eGFP mRNA; 
the in vitro synthesized eGFP mRNA was either spiked into the lysis buffer or measured directly 
(control w/o cell). (C) The DNAse activities at various lysis buffer compositions measured by qPCR 
quantificaiton of genomic or plasmid DNAs in the various cell lysates with or without DNAse 
treatment.  The activities were presented by the persentage of DNA left after 1h DNAse treatment at 
37°C. Student t-test: * : p-value < 0.05, ** : p-value < 0.01, *** : p-value < 0.001. 
The result of the above study provided a workflow which used a balanced 
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95 °C for 6 min. Exogenously added eGFP mRNA in this lysis solution showed ~ 
100 % recovery when heated at 95 °C for 6 or 12 min (Figure 2.3, A) while heating 
for lesser time (3 min) or at higher temperature (98 °C) resulted in a slight decreased 
in exogenously added eGFP mRNA level as well as for endogenous genes, idi and 
cysG (Figure 2.3, B).  
 
Figure 2.3 Optimization of the heating conditions with optimum buffer  
1.2mM EDTA was supplied into the lysis buffer. The standard errors from triplicates were displayed. 
All the samples with OD600 = 3.33 were heated in the presence of 1.2mM EDTA and followed by a 
spinning step to remove the insluble fractions. (A) Transcription level of endogenous cysG/ idi gene in 
E. coli BL21 DE3. (B) The recovery of spiked eGFP mRNA; the in vitro synthesized eGFP mRNA was 
either spiked into the lysis buffer or measured directly (control w/o cell). Student t-test: * : p-value < 
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2.2.2 Comparison with phenol/chloroform extraction method 
The expression levels of the heterologous terpene synthase, ADS (amorphadiene 
synthase) in cells harboring a plasmid encoding AD under the control of the T7 
promoter was used as the model to compare the performance of the newly developed 
method and the commonly used phenol/chloroform extraction method (TRI reagent 
TM). At various inductions, 100 μLxOD600 of cells were collected and RNAs were 
extracted with 0.15 ng eGFP mRNA spiked into the lysis solution. The recoveries 
(expressed as copy numbers) of endogenous cysG (Fig. 4a), idi (Figure 2.4, B) and 
recombinant ADS (Figure 2.4, C) transcripts extracted using the method developed in 
this study were consistently higher than by TRI reagent TM. Similarly, exogenously 
spiked eGFP mRNA was recovered at higher levels than with TRI reagent TM (Figure 
2.4, D). This apparent difference in recovery using the newly developed method and 
the TRI reagent TM may simply be due to loss of RNA in the precipitation step used in 
the latter method. In order to test this hypothesis, comparisons of the amounts of 
endogenously expressed transcripts were normalized to a reference gene.  
As cysG is a reliable reference gene for overexpression studies [212], the expression 
levels of idi and ADS in these engineered cells were normalized to that of cysG. At 
various levels of IPTG inductions, ADS but not idi expression changed (Figure 2.4, E) 
and there was a positive correlation of ADS amounts with the inducer concentrations 
used (Figure 2.4, F). It is important to note that after normalization to the reference 
gene the ADS expression levels were identical between the two methods used (Figure 
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2.4, E, F). However, the distinct advantages of the method developed in this study 
were that it was not as labor, time and cost intensive than the phase partition method 
using phenol/chloroform. 
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The Bl21 DE3 cells huboring pET-ADS plasmid were  induced with various IPTG concentrations (0.3, 
0.1, 0.033, 0.011 mM). The cells after 3h induction were collected. The RNA was prepared by both 
methods and measured by RT-qPCR. Same amount of cells (100 μLxOD600) were used for both 
method. The standard errors from triplicates were displayed. Transcription level of endogenous cysG 
(A), idi (B) gene and recombinant ADS (C) gene were measured. (D) The recovery of spiked eGFP 
mRNA; same amount (0.15 ng) of the in vitro synthesized eGFP mRNA was spiked into the lysis 
buffer for both method. The normalzied transcription levels of idi and ADS gene by cysG gene were 
presented in (E)(idi) and (F)(ADS). Based on the student t-test, the p-values between two methods in A, 
B, C, D were lower than 0.001 while there was no difference between two methods in E, F. 
 
2.2.3 RNA quality after extraction 
To further investigate the RNA quality by various extraction conditions, the RNA 
samples were analyzed on a denaturing gel (Figure 2.5). The 16s and 18s ribosome 
RNA bands were clearly visible with the phenol/chloroform extraction method and 
with the method developed in this study (95 °C, 6 min, 1.2 mM EDTA). In 
accordance with the previous results, a higher RNA yield was obtained with the 
heating method while lower temperature heating (70 °C) showed poor RNA integrity. 
Without EDTA, less distinct ribosomal RNA bands with visible smearing was 
observed, possibly due to the hydrolysis of RNAs during heating. 
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Figure 2.5 RNA quality after extraction 
Same amount of Bl21 DE3 cells with OD600 = 3.33 were used for RNA extraction with various above 
described methods where the precipitated RNA from phenol/chloroform method was re-suspend in the 
same volume of DEPC treated water comparing the rest. 20 μL of RNA samples together with 5 μL 5x 
RNA running dye were heated at 65 °C for 5 min before loaded into the denaturing gel. 
2.2.4 The utility of the new method for extracting RNA from high density of 
cells 
The performance of the new method for the isolation of total bacterial RNA from high 
density cell cultures was investigated next. The cells overexpressing ADS were 
collected and suspended with lysis solution at various cell densities. The levels of idi, 
cysG and ADS were then measured and a linear correlation of the expressions with 
cell density was observed of up to OD600 of ~11 (Figure 2.6, A). The relative 
expressions of the three genes normalized to the original growth condition (OD600 = 
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not efficient as the measured levels of all these genes were lower than expected. 
Similarly, exogenously spiked eGFP mRNA were recovered at levels similar to the 
controls only from cells at densities below OD600~ 11, indicative that this method 
was not suitable for efficient RNA extraction from cells at high density (Figure 2.6, 
B). As this method was specifically designed for extraction of RNA from cells grown 
in small scale (OD600 << 11) which allowed for the rapid assessment of optimal 
conditions for high productivity and the effect of gene expressions, it was more than 
sufficient for this purpose.  
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The Bl21 DE3 cells huboring pET-ADS plasmid were induced with 0.1mM IPTG for 3 hours before 
the cells were collected. The standard errors from triplicates were displayed.  (A) The relative copy of 
endogenous cysG, idi gene and recombinant ADS gene; the copy numbers of each gene were 
normalzied to the condition: OD600 = 3.33. (B) The recovery of spiked eGFP mRNA; the in vitro 
synthesized eGFP mRNA was either spiked into the lysis buffer or measured directly (control w/o cell). 
 
2.2.5 Measurement of DXP pathway in various engineered E. coli strains 
To demonstrate the application of this new method, a study was carried out to 
measure some of the transcripts in six different bacteria strains when cultured in rich 
medium (2xPY) or in defined medium (DM).  The transcription levels of the genes 
encoding enzymes in the pathway (dxs, dxr, ispD, ispE, ispF, ispG, ispH, idi, ispA) 
were determined by RT-qPCR to investigate the differences between the pathways in 
various strains and their responses to different growth mediums. In addition, four 
other genes encoding the sigma factors in E. coli (rpoE, rpoD, rpoS, rpoH) and three 
reference genes (cysG, idnT, hacT [212]) were also measured. Six different strains, 
Bl21-Gold DE3 (BL21), DH10B, DH5a, JM109, MG1655 and Xl10-Gold (XL10), 
were harvested at the early exponential growth phase and calibrated to a defined 
OD600 of 6. The samples were then extracted using the lysis solution and the 
expression levels of various genes determined.  All extractions were carried in 96-
well plates. All the genes were reliably detected with excellent data from three 
biological replicates (Figure 2.8) proving the robustness of the the method. The 
average expression levels of these 16 genes  in cells grown in 2XPY and DM were 
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combined and found to spread more than 1000 folds as showed in the box plot (Figure 
2.7, A). This indicated that the method is suitable for measurement of gene 
expressions with a wide dynamic range. Interestingly, the rpoS gene endoding σ32, the 
regulator of stationary phase genes, was more highly expressed than the other genes 
under this growth conditions (Figure 2.7, A). To compare different growth conditions, 
the transcription levels of the DXP pathway genes and sigma factor genes were firstly 
normalized to the geometric mean of three reference genes (cysG, idnT, hacT). The 
variation of the expression of each gene at different conditions were then calculated as 
the fold changes relative to the respective mean expression levels across all conditions 
and these were then presented as a heatmap (Figure 2.7, B). The expression levels of 
DXP pathway genes were highly similar except for idi which was found to be lower 
in BL21 strain when grown in defined medium and higher with DH10B or JM109 
strain grown in 2xPY medium. Intriguingly, in growth medium, the expressions of 
rpoD and rpoE were suppressed in MG1655 strain but enhanced in Bl21 strain. There 
was no change for rpoE and significant decrease of rpoS could be observed in JM109 
strain in defined medium. Generally, cells tended to show more variations in gene 
expressions when cultured in defined medium. 
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Figure 2.7 Transcription levels of DXP pathway genes in various E. coli strains 
The transcription level of cysG, idnT, hcaT, dxs, dxr, ispD, ispE, ispF, ispG, ispH, idi, ispA rpoE, rpoD, 
rpoS, rpoH in  Bl21-Gold DE3 (BL21), DH10B, DH5a, JM109, MG1655 and Xl10-Gold (XL10) 
strains when grown in 2xPY medium or growth medium (DM). The cells were harvest at early 
exponential phase and same amount of cells at each condition (300 μL x OD600) were used for 
transcription measurement. (A) The box plot of the expression levels of 16 measured genes (in both 
2xpy and DM). (B) Varianation of DXP pathway genes and sigma factor genes in different strains and 
meidums. All the genes were normalzied to three normalziers: cysG, idnT, hcaT and the fold changes 
rellative to the each gene’s mean expression levels at various conditions were presented in different 
colors. The fold changes were calculated from the mean of three replicates and changes less than 1.5 
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Figure 2.8 The copy numbers of measured DXP pathway genes 
The transcription level of cysG, idnT, hcaT, dxs, dxr, ispD, ispE, ispF, ispG, ispH, idi, ispA rpoE, rpoD, 
rpoS, rpoH in  Bl21-Gold DE3 (BL21), DH10B, DH5a, JM109, MG1655 and Xl10-Gold (XL10) 
strains when grown in 2xPY medium or growth medium (DM). The cells were harvest at early 
exponential phase and same amount of cells at each condition 300 μLxOD600) were used for 
transcription measurement with the novel method. The standard errors from triplicates were displayed. 
The copy numbers were calculated with a standard curve prepared using linear double strand DNA. 
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2.3 Discussion 
E. coli has been extensively used in biotechnology for the production of human 
insulin and other high-value compounds [74]. It is usual to control the transcription of 
desired genes to finely optimize various cellular processes for the generation of 
desired phenotypes [196]. In order to aid in the design of better expression systems, a 
better understanding of the transcription changes in the GOI and the effects on the 
pathways as well as on the global cellular response to genetic manipulations is highly 
desirable.  
To measure gene expression, RNA is extracted and purified from cells and this 
involved multiple pre-analytical steps which is often labor and cost intensive. 
Furthermore, these multi-step methods, introducing high variability, are not suitable 
for high-throughput studies. To develop a high-throughput method, a convenient way 
for cell lysis other than using mechanical force is necessary. For mammalian cells, 
various reagents with mild detergents are able to lyse the cells at room temperature 
[213-215] where RNA can then be directly used for RT-qPCR. These reagents are not 
suitable for the lysis of bacterial cell due to the presence of the cell wall. Instead, the 
addition of lytic enzyme [205] and proteinase K [206] or boiling the cell at high 
temperature is critical for efficient bacteria cell lysis. These methods require the use 
of enzymes and also require an extra step of purification by precipitation.  
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Various boiling methods have been developed for high-throughput bacteria cell lysis 
such as Triton X-100 boiling method [207], hot SDS heating method and RNAsnap 
method [208]. Besides cell lysis, another critical step is the removal of ribonuclease 
activity. In order to do so, the ribonuclease inside the cell lysate can either be 
removed by precipitation such as with chloroform extraction in the Triton X-100 
boiling method or inactivated by protein denaturing reagents like sodium dodecyl 
sulfate (SDS) or phenol in the SDS heating method or the RNAsnap method. All these 
chemcialls are not compatible with downstream RT-qPCR so that additional 
purification step is again necessary. As it is difficult to perform the RNA purification 
conveniently, these methods are limited to small scale studies.  
To our knowledge, there is yet to be a method that lyse bacteria and inactivate 
ribonuclease activity in a single step. In view of this unmet need, a lysis reagent and 
protocol were developed that yielded high quality total RNA for RT-qPCR 
measurement in one step. This “cell to CT (cycle threshold)” workflow is rapid and 
can be completed in less than 2 hours and is high throughput. Furthermore, extensive 
studies were carried out to rationally design, optimize and characterize the method by 
measuring endogenous as well as heterologous spiked RNAs with RT-qPCR. 
By heating the E. coli cells in a simple reagent consisting of EDTA, RNA was 
extracted effectively without the use of detergents and the RNA was compatible with 
downstream enzymatic reactions. The lysis solution and isolation conditions were 
systematically optimized to prevent loss of RNA and at the same time minimizing the 
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interference with downstream applications. This new method has significantly higher 
mRNA yield as compared to the classical phenol/ chloroform extraction method while 
perseveres the relative representations with RNA expressed at various abundances.  
One interesting observation in the study was that the ribonuclease activity was 
sufficiently inactivated after heating at 95 °C or higher temperature for 6 min or more. 
Ribonucleases are generally thought to be highly stable in solution and hence, for 
RNA isolation, complex chemicals found in specialized lysis buffers are required. 
After extraction, the lysate spiked with eGFP mRNA was not degraded when exposed 
for as long as 3 h at 37 °C and the quality of RNA sample was as good as the one 
obtained with phenol/ chloroform extraction method. It was likely that ribonucleases 
may have co-precipitated with other proteins and along with cellular debris were 
removed by centrifugation. Further studies are required to validate this propose in the 
future.  
In our protocol, total RNA could be extracted from low numbers of cells. Typically, 
30 μL of early exponential phase cells were sufficient for the quantification of all the 
genes in the study. The current protocol was also suitable for measuring gene 
expressions from cell densities as high as OD600 ~ 11. Extractions from higher cell 
densities were slightly less efficient, possibly due to a limitation of the volume of 
lysis solution used.  
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The 1-deoxy-D-xylulose-5-phosphate (DXP) pathway synthesizes the building blocks 
for isoprenoids – isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate 
(DMAPP) in bacteria. The endogenous pathway can be engineered to increase the 
production of heterologous isoprenoids including valuable pharmaceuticals such as 
Taxol [216] and Artemisinin [217]. The pathway is also a perfect target for antibiotics 
development as eukaryotes produce IPP and DMAPP via another pathway, the 
mevalonate pathway. As a demonstration, the transcription levels of the genes 
encoding enzymes in the pathway in six widely used laboratory E. coli strains grown 
in either rich medium or defined medium were measured with the cell-to-Ct method 
described herein and the whole workflow was carried in 96-well format. Most of the 
pathway genes were expressed at comparable levels except idi where decrease in 
expressions were observed in three strains after switching the growth in rich medium 
to defined medium. Some of the sigma factors including the primary sigma factor (σ70, 
RpoD), the heat shock sigma factor (σ32, RpoH) and the starvation/stationary phase 
sigma factor (σ38, RpoS), were also differentially expressed in various growth 
conditions. These changes may have important implications when using this pathway 
for the production of metabolites.  
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2.4 Conclusion  
The measurement of gene expression provides another layer of understanding 
between the genetic perturbations and metabolism responses which is often 
overlooked in most of the metabolic engineering studies, partly due to the 
unavailability of a convenient method for RNA extraction. The “cell-to-Ct” method 
developed in this study produced better RNA yield and minimized pre-analytical 
variations. The representation of the expression levels of various genes remain 
identical to the more commonly used method of phenol/ chloroform extraction. The 
low sample requirement as well as the fast and simple protocol makes this method 
ideal for high throughput studies. The response of genes encoding enzymes in the 
DXP pathway to different growth mediums (the rich medium and the defined medium) 
was measured and no significant change in the expression levels were observed in six 
different strains while there were some differences in the expression of transcription 
factors suggesting that the DXP pathway is relatively unaffected by growth in these 
two environments.  
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2.5 Methods 
2.5.1 Chemical, growth medium and bacteria strain 
Unless stated otherwise, all chemicals were purchased from either Sigma or Merck. 
The yeast extract and peptone were purchased from BD. The defined medium was 
prepared following previous paper [218] supplying 20g/L glucose as carbon source. 
The 2xPY medium contained: peptone (20 g/L), yeast extract (10 g/L) and NaCl (10 
g/L). Bl21-Gold DE3 strain (Stratagene) was used in the studies for optimization of 
the novelT method. The pET-ADS plasmid expressing heterologous terpene synthase 
– ADS (amorphadiene synthase) was constructed by placing the ADS gene between 
NdeI and BamHI sites of pET-11a vector (Stratagene). Bl21-Gold DE3 strain and 
other strains: DH10B (Invitrogen), DH5a (Invitrogen), JM109 (Stratagene), Xl10-
Gold (Stratagene) and MG1655 (ATCC) were then used to measure the transcription 
levels of endogenous genes by the optimized method. Cell density (absorbance at 600 
nm) was measured by SpectraMax 190 microplate reader. 
2.5.2 eGFP mRNA preparation 
SuperScript RNA Amplification System (Invitrogen) was used to produce eGFP 
mRNA following the manufacturer’s instructions. A pET-eGFP vector was used as 
the template for mRNA synthesis. The vector was constructed by placing the eGFP 
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gene from pIRES-EGFP vector (Clontech) between NdeI and BamHI sites of pET-
11a vector (Stratagene). The produced mRNAs were purified by ethanol precipitation. 
2.5.3 RNA extraction 
TRI Reagent TM RNA Isolation Reagent (Sigma-Aldrich) was used to perform the 
RNA extraction by phenol/chloroform method. 100 μLxOD600 of cells were 
collected by centrifugation and lysed with homogenizer in TRI Reagent added with 
0.15 ng eGFP mRNA. The RNA isolation was carried out following the 
manufacturer’s instructions. The RNA samples were finally re-suspended in 30 μL of 
DEPC treated water. For the novel method, unless stated otherwise, 100 μLxOD600 
of cells were collected by centrifugation and re-suspended in 30 μL of DEPC treated 
water (final OD600 = 3.33) together with 0.15 ng eGFP mRNA (5 pg/μL) and 
different concentrations of EDTA. The mixtures were heated at various temperatures 
and durations as stated. The insluble fractions were removed by centrifugation and the 
soluble fractions were used for further applications.  
2.5.4 DNAse treatment 
All RNA samples were treated with DNAse before proceeded to do reverse 
transcription. RQ1 RNase-Free DNase (Promega) was used following the 
manufactory’s protocol. Typically, 4 μL of RNA samples were mixed with 0.8 μL of 
10x Reaction Buffer, 0.8 μL RQ1 RNase-Free DNase and top up to 8 μL with DEPC 
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treated water. The reaction was incubated at 37 °C for 1h. Then, 0.8 μL of Stop 
Solution and 2 μL of 10mM random hexamer were supplied and the mixtures were 
heated at 65 °C for 10 min. After heating, the mixtures were chilled on ice 
immediately. 
2.5.5 Reverse transcription - quantitative polymerase chain reaction 
The ImProm-II™ Reverse Transcription System (Promega) was used for cDNA 
synthesis following the manufactory’s protocol. Typically, 3.5 μL of DNAse treated 
samples were used in a 10 μL reaction. After the reaction, 150 μL of water was added 
to dilute the samples. The real-time quantitative PCR reactions were carried out in 25 
µl final volume containing 5 µl diluted cDNA samples, 1x Xtensa Buffer (Bioworks), 
200 nM of each primer, 2.5 mM MgCl2 and 0.75 U of iTaq DNA polymerase (iDNA). 
The reactions were analyzed using a BioRad iCycler 4TM Real-Time PCR Detection 
System (Bio-Rad) with SYBR Green I detection and the following  protocol: an initial 
denaturation of 1 min at 95 °C, followed by 40 cycles of 20 s at 95 °C, 20s at 60 °C, 
and 20s min at 72 °C. A melt curve was then carried out to check the melting 
temperature of the amplicon. Primers were listed in Table 2.1. For all the studies, 
technical duplicates or triplicates were carried out for RT-qPCR reactions. The 
standard curve prepared using linearized plasmid DNA or PCR product (1-3 kb) 
containing the amplicon (80-120 bps) was measured together with the samples. The 
genes’ copy number concentrations (copy/ μL) in the diluted cDNA samples were 
calculated based on the stand curves. 
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 Table 2.1 The primers used for qPCR 
Gene Sence primer Antisence primer 
cysG TTGTCGGCGGTGGTGATGTC ATGCGGTGAACTGTGGAATAAACG 
ldnT CTGTTTAGCGAAGAGGAGATGC ACAAACGGCGGCGATAGC 
hcaT GCTGCTCGGCTTTCTCATCC CCAACCACGCTGACCAACC 
dxs AAGGCCCGCAGTTCCTGCAT GGCAAACCGCCGCTACTTTTC 
dxr AAGGTCTGGAATACATTGAAGC CACTGCCGTCCTGATAGC 
ispD GCAACCACTCATTTGGATGTTTGC CACCGAGTGTTCAAGAATGGTTTG 
ispE GGAAGCGGTGCGAATATC ATTGCCAGAGATGATTTAATGC 
ispF CGAATTGGACACGGTTTTGACG CATCGGTCAACGCATGGAGC 
ispH CTCCAACTCCAACCGTCTG CCTCTTTCACCCACTCTTCC 
ispG CGCTGGTGGCTGACATCC ACGCTCTTCATTACCGATATTGC 
idi AATCTATCTATCCTGACT ATAATCCATCACTTCATC 
ispA GCATTATTAGGTGGTAAGC ATGAGTAAGCGTGGATAC 
ADS CCGTATCGTAGAATGCTATT CCGCTTTGGTGAAGAATA 
rpoS GGTGGTAAAAATTGCCCGCCG CGTTCCGGGTCAAACTTCTCTACC 
rpoD CGAAAGGTCGCAGTCACGCT CCAGGTAGTCAAACTGCTTCGG 
rpoE CGAGTCTGGTTTCCCGCTATG TCTCCCCGGAACGAATCCAG 
ropH TTATGCGGGCTATGGCCTG TGAACGGCGAAGGAGACCAG 
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Chapter 3 Combinatorial Engineering of 1-deoxy-
D-xylulose 5-phosphate Pathway using Cross-
lapping In Vitro Assembly (CLIVA) Method  
3.1 Background and motivation 
In order to optimize an endogenous metabolic pathway, only selected pathway genes 
should be overexpressed to minimize the perturbation to the intricate biological 
system.  A few empirically selected enzymes (dxs, idi, ispD, ispF) are thought to be 
the limiting steps in the DXP pathway and increasing the expression levels of these 
enzymes have been shown to improve isoprenoid production to a certain extent [219-
222].  Without a detail and global understanding of the biochemical mechanisms in a 
system, it will be challenging to identify and define the bottlenecks of a pathway 
when combinatorial sets of enzymes are overexpressed. Therefore, it is more practical 
to identify these key limiting enzymes and the combinations by overexpression of the 
genes empirically. To carry out a combinatorial study, high through-put generation of 
recombinant plasmid libraries with multiple desired genes is necessary. The one 
inconvenient and sometime insurmountable hurdle is the lack of robust cloning 
methods to allow the rapid construction of such libraries. 
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Synthetic biology and metabolic engineering require convenient, robust and universal 
tools to manipulate genetic materials [156, 157]. As such, a demand is to assemble 
multiple genetic components including sequences encoding enzymes, functional 
fusion tags and control elements (promoters, terminators and ribosome binding sites). 
This is especially true for the multivariate engineering of a pathway. The commonly 
used restriction enzymes and in vitro ligation based sequential cloning methods are 
often limited by the availability of unique restriction sites and are time consuming. 
Furthermore, single stranded DNA (ssDNA) overhangs generated by restriction 
enzymes are typically 2-8 nucleotides which exhibit poor annealing efficiencies and 
have limited use in assembling multiple large DNA fragments in a single step. 
To address these challenges, several sequence independent methods, generating long 
ssDNA overhangs [21, 163-172] or using double stranded PCR products with long 
homologous sequences [21, 173, 174], have been developed for the assembly of large 
DNA inserts into vectors. Only a few of these approaches have reported the assembly 
of multiple (>3) DNA fragments in a single step. Methods such as the T4 DNA 
polymerase based sequence and ligation-independent cloning (SLIC) [163], 
phosphorothioate-based ligase-independent gene cloning (PLICing) [172] and others 
[176-179] have only demonstrated the construction of plasmids of less than 8 kb. 
Various attempts have been made to meet the increasing demand to assemble several 
large fragments of DNA inserts into plasmids of > 10 kb [156, 157, 180]. An 
isothermal in vitro assembling method with synthetic oligonucleotides was used to 
assemble a 16.3 kb construct from seventy-five fragments of DNAs and the assembly 
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of a 24kb plasmids from four separate fragments [21, 182, 183]. In addition, using 
yeast in vivo recombination system, a 582 kb Mycoplasma genitalium genome was 
constructed from synthetic DNA oligonucleotides in several steps [21]. The yeast 
system has also been successfully used for the one step assembly of a 19kb fragments 
into a plasmid or yeast chromosome [174]. With these examples, homologous 
overhang sequences with lengths of 100-500 base pairs were required to increase the 
assembly efficiency. This can be a significant challenge where suitable pre-existing 
sequences in the parental or chemically synthesized templates are required which can 
restrict the applicability and incur high-cost of synthesis. Furthermore, these 
approaches are also time consuming and labor intensive, hence, are not suited for 
routine cloning projects.  
Here, the development of a reliable, scalable and robust cloning method (cross-
lapping in vitro assembly, CLIVA) for the rapid construction of large recombinant 
DNA from multiple fragments in a single step is described. This approach exploits the 
unique properties of phosphorothioate modified nucleotides where highly efficient 
and site specific cleavage is achieved using iodine in an ethanolic solution [223, 224]. 
Recently, Milan Blanusa et al [171] demonstrated the use of such phosphorothioate 
chemistry for the assembly of multiple small protein domains [172]. Unique to the 
CLIVA method is a novel cross-lapping design which allows the generation of long 
homologous overhang sequences (36-38 bases) by cleavage of optimally positioned 
phosphorothioate modified nucleotides and the use of selective cations resulting in a 
highly efficient assembling process. To demonstrate the utility of this method, 16 
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plasmids of 7.8 kb to 21.6 kb in size, encoding various combinations of genes in the 
1-Deoxy-D-xylulose 5-phosphate (DXP) pathway in E. coli were constructed. To our 
knowledge, this is the first report of the successful assembly of large constructs 
containing multiple genes using an enzyme independent in vitro method to engineer 
multi-enzyme pathways in a short duration. 
In this study, the effects of various combinations of the enzymes in the DXP pathway 
in providing precursors to downstream production of amorphadiene, the precursor for 
antimalarial drug artemisinin [217], was systematically investigated for the first time. 
The CLIVA method enabled the assembly of multiple plasmids containing various 
combinations of genes rapidly. Metabolic profiling using ultra-performance liquid 
chromatography mass spectrometry (UPLC-MS) [225] identified the accumulation of 
intracellular MEC (one of the DXP pathway intermediate) as a limiting factor for 
isoprenoid production. The overexpression of iron sulfur cluster (Isc) operon, which 
supplied the cofactors for the function of two succeeding enzymes downstream of 
MEC (ispG and ispH), was found to be beneficial for the production of amorphadiene. 
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3.2 Results 
3.2.1 Design of CLIVA 
PCR has been used to produce overlapping homologous sequences by adding 
extraneous tag sequences to the gene specific primers [163, 171, 174]. With such a 
design, the homologous sequences are limited to the length of the tags. In order to 
increase the assembly efficiency, tags to be homologous to the gene specific 
sequences were designed (Figure 3.1, A). This cross-lapping design allowed us to 
increase the length of the homologous sequences at each junction as compared to 
conventional strategies. Besides, other than modifying all the bases in the homologous 
sequences which increased the cost of primer synthesis, the possibility of decreasing 
the modification frequency (number of phosphothiodate modification per 
oligonucleotide) while maintaining a high efficiency of assembly was explored 
(Figure 3.1, B). Critically, by the use of certain cations, the efficiency of the assembly 
process was substantially increased and this has enabled the construction of large 
plasmids from multiple fragments in one step.  
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Figure 3.1 The cross-lapping in vitro assembly (CLIVA) method.  
(A) Illustration of the design at one junction between two modules (blue and red). The cross-lapping 
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GSS. The phosphorothioate modifications were indicated as cycles. An “Ox/y” designation was used to 
define the primers, where O denoted overlap; x was the length of overlap which had one modification 
at each y base pairs of the sequence. (B) Illustration of assembling of multiple DNA modules into one 
plasmid.  
In order to demonstrate the utility of this method, a series of plasmids carrying 
multiple genes of a metabolic pathway was constructed. As shown in “Figure 3.1, B”, 
all the pathway modules as well as a vector module containing the origin of 
replication and antibiotic resistant gene were first amplified from the parental 
plasmids using a pair of cross-lapping primers and subsequently treated with a 
solution of ethanolic iodine as described in “3.5 Methods”. The assembly was then 
carried out in the optimal condition with equal molar of each DNA module fragment 
(see below).  
3.2.2 Optimization of CLIVA  
The construction of a 7.1 kb PAC-SIDF plasmid was initially used as a model for 
identifying suitable designs and optimal conditions for CLIVA. The PAC-SIDF 
plasmid was generated by combining two modules amplified from different sources: 
the PAC vector (2.8 kb) consisting of P15A origin of replication and chloramphenicol 
resistant gene (Figure 3B) from a pre-existing pAC-lyc plasmid [226] and SIDF 
module (4.3 kb) containing four 1-Deoxy-D-xylulose 5-phosphate (DXP) pathway 
enzymes (dxs, idi, ispD, ispF, Figure 3A) from a pre-existing pET-dxs-idi-ispDF 
plasmid [161]. All the primers used in the optimization process were listed in Table 
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3.3 where the PAC-F/PAC-R and SIDF-F/SIDF-R were the gene specific sequences 
targeting at pAC-lyc plasmid and pET-dxs-idi-ispDF plasmid.  
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(A) Optimization of cations using the assembly of PAC-SIDF plasmid with O12-13/4-5 design (12-13 
bases overlap with modification at every 4-5 bases). (B) The transformation efficiency of PAC-SIDF 
plasmid in the presence of MgCl2. (C) The effect of the phosphorothioate modification frequency on 
the assembly efficiency. O12-13/4-5, O12-13/6-7, O12-13/12-13 designs: 12-13 bases overlap with 
modification at every 4-5 bases, 6-7 bases or 12-13 bases. (D) The effect of overlap length on the 
assembly efficiency. O12-13/4-5, O24-25/4-5, O36-38/4-5 designs:  12-13 bases, 24-25 bases, 36-38 
bases overlap with modification at every 4-5 bases. (E), Different cations’ effects on the assembly 
efficiency. The assembling efficiencies of PAC-SIDF plasmid with O36-38/4-5 design (36-38 bases 
overlap with phosphorothioate modification at each 4-5 bases) at 2.5 mM or 12.5 mM of MgCl2, CaCl2, 
CoCl2 or CuCl2 were presented. (F), The assembly efficiency of overlap designs with single 
phosphorothioate modification. O12-13/12-13, O24-25/24-25, O36-38/36-38: 12-13 bases, 24-25 bases, 
36-38 bases homologous sequences with one phosphorothioate modification. All the experiments were 
done at triplicates and the standard errors were shown in the figure. 
 
The construction of a 7.1 kb PAC-SIDF plasmid was initially used as a model for 
identifying suitable designs and optimal conditions for CLIVA. The PAC-SIDF 
plasmid was generated by combining two modules amplified from different sources: 
the PAC vector (2.8 kb) consisting of P15A origin of replication and chloramphenicol 
resistant gene (Figure 3.1, B) from a pre-existing pAC-lyc plasmid [226] and SIDF 
module (4.3 kb) containing four 1-Deoxy-D-xylulose 5-phosphate (DXP) pathway 
enzymes (dxs, idi, ispD, ispF) (Figure 3.3, A) from a pre-existing pET-dxs-idi-ispDF 
plasmid [161]. All the primers used in the optimization process were listed in “Table 
3.3” where the PAC-F/PAC-R and SIDF-F/SIDF-R were the gene specific sequences 
targeting at pAC-lyc plasmid and pET-dxs-idi-ispDF plasmid (3.5 Methods) Ionic 
strength is known to affect DNA hybridization [227]. As cations can reduce charge 
repulsion between the negatively charged phosphodiester backbones of double 
stranded DNA, I sought to investigate the assembly efficiency in relation to the 
concentrations of MgCl2 or NaCl. The assembly efficiency increased dramatically 
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with the addition of salts and the divalent cation (Mg2+) resulted in much higher 
enhancement (Figure 3.2, A), consistent with the findings of others [228]. With 
respect to Na+, there was a positive correlation between the ionic concentration and 
the assembly efficiency. With Mg2+, a decrease in the assembly efficiency was 
observed at high concentrations. A limitation in using high concentrations of salts 
(NaCl or MgCl2) was that these reaction mixtures were incompatible with the use of 
electroporation for transformation. This proposal was consistent with the observation 
of the severe suppression of transformation efficiency at high MgCl2 concentration 
(62.5 mM) (Figure 3.2, B). Thus, the optimum MgCl2 concentration was identified as 
2.5mM. I also tested other divalent ions (CuCl2, CaCl2, and CoCl2) and found that 
Ca2+ acted similarly to Mg2+, while Co2+ and Cu2+ were found to be significantly 
poorer (Figure 3.2, E). This was possibly due to the toxicity of Co2+ and Cu2+ ions at 
high concentrations [229, 230].  
Existing methods that generate ssDNA with phosphorothioate chemistry have every 
base of the overlap sequence chemically modified, which is cost prohibitive for long 
overlapping sequences [171, 172]. It was hypothesized that it was unnecessary to 
cleave the overlapping sequence into single bases; instead, by cleaving the nucleotide 
at several discrete sites into smaller fragments, the assembly should work equally well. 
This was then tested using four types of 12-13 bases overlap designs: O12-13/1, O12-
13/4-5, O12-13/6-7 and O12-13/12-13 with different positions of the sequences 
modified with phosphorothioate where the modifications at positions were 1 base 
apart, 4-5 bases apart, 6-7 bases apart or 12-13 bases apart, respectively ( 
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Table 3.3). Unexpectedly, amplification using O12-13/1 primer pairs (modification 
inserted at every base) yielded extremely low amount of amplicon and was not used 
for further studies. The exact reason for this poor amplification is currently unknown. 
Nonetheless, the O12-13/4-5 design was successfully amplified showed high 
assembly efficiency. Slightly lower assembly efficiency was observed when using the 
O12-13/6-7 design and even lesser still with the O12-13/12-13 design (Figure 3.2, C). 
It is worthy to note that with the O12-13/12-13 design where a single modification 
was incorporated, the cleavage resulted in a fragment of the DNA which was identical 
to the overlap sequence and hence, may have competed for annealing.  So this 
arrangement would result in a lower efficiency in assembly, consistent with the 
observation in “Figure 3.2, C”. Increasing the modification frequency greater than one 
in 4-5 bases apart did not substantially improve the efficiency of assembly as 
compared to one in 6-7 bases.  
Another critical parameter for the assembly of multiple DNA fragments is the length 
of the overlaps that determines the specificity as well as the efficiency of the 
annealing. As predicted, when compared to short overlaps (12-13 bases), the assembly 
efficiency increased with longer overlapping segments (36-38 bases) by as much as 3 
fold (Figure 3.2, D). With the increasing number of pathway modules to assemble, it 
is critical to have high assembly efficiency at each junction. 
Extending the study, the assembling efficiencies of designs with single 
phosphorothioate modification (O12-13/12-13, O24-25/24-25 and O36-38/36-38) 
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were examined (Figure 3.2, F). With this arrangement, the design with longer overlap 
sequences after cleavage (O24-25/24-25 where the overlap was 24-25 bases) showed 
lower efficiency of assembly than a shorter one (O12-13/12-13 where the overlap was 
12-13 bases).  In addition, an even longer overlap (the O36-38/36-38 design where the 
overlap was 36-38 bases) was even poorer.  Thus, with single phosphorothioate 
modification, the efficiency of assembly was related to the length of the cleaved 
product whereby the fragmented pieces of DNA should be short so as not to interact 
with the overlap sequences. Thus, the O36-38/4-5 design was suitable for the 
assembly of multi-components with high efficiency, while the O12-13/12-13 design 
was sufficiently efficient and cost effective, replacing the use of restriction enzyme 
and ligation based method for routine tasks. 
3.2.3 Constructions of plasmids for combinatorial study of DXP pathway 
Next, the CLIVA method was used to assemble a series of plasmids consisting of 
various combinations of modules containing the genes of the 1-Deoxy-D-xylulose 5-
phosphate (DXP) pathway [231] and for amorphadiene production (Figure 3.3, A). In 
addition, two operons, ISC (iron-sulfur cluster (Isc) operon) and SUF (sulfur 
mobilization (Suf) operon), containing the proteins necessary for Fe–S cluster [232] 
assembly in E. coli were also constructed (Figure 3.3, A). Details of the modules and 
their abbreviations were presented in “Figure 3.3, B”.  
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Figure 3.3 Combinatorial assembly of DXP pathway  
(A) The dxp pathway and Fe-S cluster assembling pathway. GA3P: glyceraldehyde 3-phosphate, DXP: 
1-deoxy-D-xylulose 5-phosphate, MEP: 2C-methyl-D-erythritol 4-phosphate, CDP-ME: 4-
diphosphocytidyl-2C-methyl D-erythritol, CDP-MEP: 4-diphosphocytidyl-2C-methyl D-erythritol 2-
phosphate, MEC: 2C-methyl-D-erythritol 2,4-diphosphate, HMBPP: hydroxylmethylbutenyl 
diphosphate, IPP: Isopentenyl pyrophosphate, DMAPP: Dimethylallyl pyrophosphate, GPP: Geranyl 
diphosphate, FPP: Farnesyl diphosphate, GGPP: Geranylgeranyl diphosphate. (B) Illustration of 
various modules assembled in the project (correlated to Table 3.5). CAM: chloramphenicol resistance 
gene, p15A-ori: p15A original of replication. 
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Fragments of treated DNAs were mixed and transformed into E. coli for the one step 
assembly of these genes (Figure 3.1, B) and the correct clones were identified by 
quantitative colony PCR as described in “3.5 Methods”. With each construct, two 
randomly selected positive clones were further confirmed by restriction mapping and 
at least one of these was verified by sequencing. The sequencing results covered all 
the sequences encoding the junctions (the overlap sequence between the modules) as 
well as more than 50% of the sequences in the plasmid. No change in the sequences 
was observed, indicative of the high fidelity of amplification and high specificity of 
cleavage. As expected, the efficiency decreased with increasing number of fragments 
(Table 3.1). However, even with the largest plasmid (21.6kb, S-R-DEF-GH-ISC-IAA-
PAC plasmid from 6 modules) assembled, the efficiency was reliably high (~2.0 x 103 
cfu/μg input DNA). The false positive colonies resulting in lower accuracy of 
assembly were largely due to the existence of plasmids with incomplete pathway 
modules (demonstrated by quantitative colony PCR and restriction mapping, data not 
shown). 












IAA-PAC 6.2 2 3612.8 100.0 
S-IAA-PAC 8.7 2 1052.8 100.0 
S-R-IAA-PAC 10.5 3 78.8 93.5 
S-DEF-IAA-PAC 11.3 3 61.3 96.8 
S-GH-IAA-PAC 11.3 3 46.6 83.9 
S-R-DEF-IAA-PAC 13.1 4 13.2 42.6 
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S-R-GH-IAA-PAC 13.1 4 15.6 38.3 
S-DEF-GH-IAA-PAC 13.9 4 9.0 27.7 
S-R-DEF-GH-IAA-PAC 15.6 5 5.1 12.7 
S-ISC-IAA-PAC 14.2 3 15.4 25.5 
S-SUR-IAA-PAC 14.7 3 17.4 21.3 
S-GH-ISC-IAA-PAC 16.8 4 4.9 14.1 
S-GH-SUR-IAA-PAC 17.2 4 4.5 11.3 
S-R-GH-ISC-IAA-PAC 18.5 5 3.1 9.9 
S-R-GH-SUR-IAA-PAC 19.0 5 2.6 7.0 
S-R-DEF-GH-ISC-IAA-PAC 21.6 6 2.0 8.5 
*: More than 30 colonies for each construct were analyzed by quantitative colony PCR for the 
3.2.4 Overexpression of GH and R-DEF inhibited amorphadiene production 
Next, the various combinations of pathway genes with the essential module (IAA) 
containing the heterologous amorphadiene synthase were tested for amorphadiene 
production. Consistent with previous reports [220, 225, 233], high induction resulted 
in lower production of isoprenoids (Figure 3.4, A, different IPTG inductions). 
Comparing constructs at their optimal induction levels, as expected, the expression of 
the first committed step (dxs – module S) enhanced the amorphadiene production. 
However, the overexpression of the rest of the pathway genes in conjunction with the 
S and IAA modules had variable negative effects on productivity. Notably, the 
expression of GH module (ispG and ispH) as well as R (dxr) -DEF (ispD, ispE and 
ispF) modules led to a significant inhibition on the production (Figure 3.4, A). 
Consistent with the observations, a simple linear model correlating the pathway 
modules and amorphadiene yields at their optimal inductions revealed that the 
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expression of GH module or the co-expression of R-DEF modules had negative 
impacts (Figure 3.4, B).  
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(A) 48h amorphadiene yield. Different concentrations of IPTG were represented by bars with different 
colors. The experiment was repeated four times and the standard errors were shown. (B) The 
correlation of pathway modules with amorphadiene yield at optimal IPTG inductions. (C) Early 
response of intracellular metabolites at 3h after induction. The gray areas indicated the overexpressed 
section of DXP pathway. The experiment was repeated twice and the averages were shown. 
Accumulation of intracellular MEC was inversely correlated to amorphadiene productivity. 
 
In order to investigate the changes in the levels of intracellular metabolic 
intermediates with the overexpression of the various modules, cells were harvested 
after 3 h of induction and the metabolites were quantified by UPLC-MS (Figure 3.4, 
C). The induction of the expression of the genes in any of the modules resulted in 
significant accumulation of intracellular MEC, indicative of a limitation in metabolite 
conversion with genes downstream, an observation in congruence with our previous 
report [225]. Interestingly, the overexpression of GH module did not fully convert 
MEC to the downstream metabolite IPP/DMAPP. Instead the metabolite HMBPP 
accumulated in all strains where the GH module was overexpressed (Figure 3.4, C, 
the second row). Other than that, the genes in the pathway upstream of MEC were 
functionally expressed as the accumulations of the metabolites were positively 
correlated with the expressed genes. Hence, the overexpression of dxs, the first and 
committed step in the DXP pathway, resulted in the accumulation of DXP (Figure 3.4, 
C, S-IAA). Similarly, the overexpression of dxs and dxr resulted in the accumulation 
of MEP (Figure 3.4, C, S-R-IAA) and the co-expression of S-R-DEF resulted in the 
high accumulation of MEC (Figure 3.4, C, S-R-DEF-IAA). Besides, higher 
expressions of these genes resulted in the parallel increases in activities (higher 
concentrations of accumulated intermediates).  
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In order to further investigate the pathway, a kinetic study measuring the 
concentrations of intracellular, extracellular DXP metabolites and amorphadiene was 
carried out with strains harboring different modules. As expected, the induction of dxs 
resulted in a significant increase in the level of intracellular DXP in the strain with S-
IAA modules (Figure 3.5, A, S-IAA|DXP). Curiously, extracellular level of DXP was 
also increased substantially albeit with different kinetics (Figure 3.5, B, S-IAA|DXP). 
Similarly, the expression of the S-R-IAA modules resulted in the accumulation of 
both intracellular and extracellular MEP (Figure 3.5, A, B, S-R-IAA|MEP). With all 
three modules, MEC accumulated intracellularly and significantly more with the S-R-
DEF-IAA modules. Intriguingly, the extracellular levels of MEC accumulated to 
similar levels and were inversely correlated to the inducer concentrations in strains 
carrying any of the three modules (Figure 3.5, B, MEC). The inverse correlation of 
metabolite levels with the inducer concentration used was also observed with the 
production of amorphodiene. The S-R-DEF-IAA-PAC strain accumulated large 
quantities of intracellular MEC and yielded much less amorphodiene as compared to 
strains harboring the S-IAA or S-R-DEF-IAA modules (Figure 3.5, B, MEC). 
Although high IPTG inductions yielded higher concentrations of intracellular 
intermediates initially (Figure 3.5, B, first 10 h), the relationship was reversed at later 
time points, especially with the highest induction (0.1mM IPTG) (Figure 3.5, A, 
highly accumulated intermediates). Other metabolites (CDP-ME, IPP/DMAPP, GPP, 
FPP) were found to be accumulated at insignificant levels.  
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Figure 3.5 The kinetic behavior of S-IAA-PAC, S-R-IAA-PAC and S-R-DEF-
IAA-PAC strains 
(A) The specific concentration (μM/OD) of intracellular metabolites: DXP, MEP and MEC. The rest of 
the metabolites were accumulated at concentrations lesser than 2µM/OD and were neglected. (B) The 
concentration of extracellular metabolites: DXP, MEP, MEC and amorphadiene. The rest of the 
metabolites were accumulated at concentrations lesser than 50µM and were neglected. (C) The cell 
density. 
 
3.2.5 Overexpression of either ispG, ispH or both was inhibitory 
Noticing that high MEC accumulated inside the cells when S-R-DEF modules were 
overexpressed and was inversely correlated with amorphadiene production, a valid 
hypothesis to test was whether MEC will be fluxed towards IPP and DMAPP by 
overexpressing downstream enzymes. Previously the additional co-expression of ispG 
and ispH (GH module) was inhibitory to the system and resulted in the accumulation 
of HMBPP – the intermediate between these two enzymes (Figure 3.4). To dissect the 
effects of ispG and ispH, the overexpression of either one of the enzymes in GH 
module together with S-R-DEF modules was carried out to test if the amorphadiene 
could be enhanced. The results showed that ispG, ispH or both caused the decreased 
production of amorphadiene indicating that common factor/s necessary for the 
activities of these two enzymes may be limiting (Figure 3.6).   
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Figure 3.6 Overexpression of ispG and/or ispH in high MEC production strain  
 
3.2.6 Overexpression of Fe–S operons modestly increased amorphodiene 
productivity 
An attempt was made to increase the activities of ispG and ispH (GH module) in 
converting MEC to the downstream metabolite IPP/DMAPP so as to increase 
amorphodiene production. As the essential cofactor for these two enzymes, the genes 
in the iron-sulfur (Fe-S) cluster pathways (iron-sulfur cluster (Isc) operon– iscS, isCU, 
iscA, hscB, hscA, fdx) and/or sulphur mobilization (Suf) operon (SUF module (surA, 
surB, surC, surD, surS, surE) [232, 234] were assembled using CLIVA and 
transformed into E. coli. Disappointingly, the overexpression of either operon 
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production of amorphodiene (Figure 3.6, 1-3 columns). However, the overexpression 
of Isc operon in other constructs together with GH module showed modest 
enhancements (Figure 3.6, 4-8 columns). 
 
Figure 6 Overexpression of Fe-S operons in the plasmid 
Different concentrations of IPTG were represented by bars with different colors. The experiment was 
repeated four times and the standard errors of four replicates were presented as error bars. The two 
tailed p-values of student’s t-test were carried out to compare certain conditions and presented as P in 
the figure. 
A possible reason for the limited amorphadiene enhancement by overexpressing Fe-S 
operons is that high expression of these operons containing of five or six enzymes 
with a multiple copy plasmid may create extra metabolic burden and consume the 
resources for the expression of DXP pathway enzymes. New systems were then 
created for the overexpression of Fe-S operons at lower level by replacing their 
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promoters in the genome with T7 promoters. MG1655 DE3 (MG) strain was used as 
the parental strain to generate MG-ISC and MG-SUF strains with either Isc or Suf 
operon overexpressed. Both strains showed a higher production of amorphadiene 
comparing to the original strain when carrying S-R-DEF-GH-IAA or S-R-DEF-IAA 
plasmid (Figure 3.7) where high MEC is expected to be accumulated confirming the 
usefulness of Fe-S operon overexpressing on the production of isoprenoids. However, 
the productivity was still low than strains with only S-IAA module overexpression. 
Further fine tuning the expression levels of various pathway modules including these 
operons is important to optimize isoprenoids production. 
 
Figure 3.7 Overexpression of Fe-S operons by changing genomic promoters  
MG1655 DE3 (MG) strain was modified by replacing the promoter for Isc operon (MG-ISC) or Suf 
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3.3 Discussion 
This chapter demonstrated the rapid assembly of large plasmids with an array of 
metabolic genes (21.6 kb plasmid with 16 genes) using a novel ligation independent 
cloning (CLIVA) method. These recombinant plasmids were then used to 
systematically investigate the effects of the various combinations of the enzymes in 
the DXP pathway in producing amorphadiene, the precursor for antimalarial drug 
artemisinin [217]. Metabolic profiling using ultra-performance liquid chromatography 
mass spectrometry (UPLC-MS) [225] identified the accumulation of intracellular 
MEC (one of the DXP pathway intermediate) as a potential negative contributor to 
isoprenoid production. The overexpression of the Isc operon, which supplied the 
cofactor for the function of two succeeding enzymes downstream of MEC (ispG and 
ispH) (Figure 3A), was found to modestly increased the production of amorphadiene. 
The manipulation of genetic material is a fundamental and routine requirement for 
engineering of biological systems where multiple genes are assembled and used to 
produce downstream products [156, 157]. The traditional in vitro ligation based 
cloning methods are sequence-dependent and are often not efficient in assembling 
multiple fragments of DNAs. Consequently, these limitations have been addressed 
with methods that assemble multiple DNA fragments with overlapping homologous 
sequences in a single step. Such in vitro assembling method [21, 182, 183] or the 
Yeast in vivo homolog recombination based DNA assembler method [174] uses 
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enzymes with exonuclease activities to generate ssDNA and other enzymes to repair 
the over-treated non-homologous ssDNA gaps. The use of multiple enzymes does not 
only incur cost but is also inefficient and time consuming. Based on the 
phosphorothioate chemistry that allows cleavage of DNA at specific sites, the 
enzyme-free CLIVA method provides robust performance for the one-step assembly 
of multiple DNA modules. Typically, the construction can be completed within 1-2 
days, as compared to the more involved method of Yeast recombination (1-2 weeks).  
The novel design of the cross-lapping PCR primer pair (~40 bases) enabled high 
efficiency of amplification by PCR and efficient assembly of multiple DNA 
fragments. Unlike other studies [171, 172], phosphothioate modifications of every 4-5 
bases intervals in the homologous sequences was sufficient to enable efficient cleave 
and assembly of the sequences. The use of cations at optimal concentration was found 
to significantly enhance the assembly efficiency while maintaining high 
transformation efficiency. Even with a single phosphothioate modification, the 
assembly of two pieces of DNA fragments (~3-4 kb each) was highly efficient (~ 
2.0x106 cfu/ μg input DNA). This was far superior to the use of restriction enzymes 
and ligase (< 104 cfu/ μg input DNA for the same construct) in parallel studies. Hence, 
the CLIVA method can replace all routine recombinant DNA constructions with the 
use of just a single phosphothioate modification in each primer. The assembly of the 
21.6kb plasmid (S-R-DEF-GH-ISC-IAA-PAC) from 6 fragments of DNAs was 
sufficiently efficient (~2.0 x 103 cfu/μg input DNA) and was completed in less than 2 
days.    
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With constructs encoding multiple genes under the control of the same regulatory 
elements (T7 promoters and terminators), there were large amount of repeated 
sequences (200-300 bps) in regions between modules. As those perfect repeats may 
randomly anneal with each other during assembly, it was not surprising that the 
assembly of such multiple identical sequences resulted in numerous false positive 
clones which contained partially assembled sequences, an observation confirmed by 
quantitative colony PCR and restriction analysis. The use of the same regulatory 
elements to control multiple modules is predictably to be even more challenging for 
recombination based methods which are known to selectively rearrange repeated 
sequences in vivo [174].  
The S-R-DEF-IAA-PAC strain resulted in lesser yield of amorphadiene as compared 
to the other strains (S-IAA-PAC or S-R-IAA-PAC) which encode fewer numbers of 
genes in the pathway. The overexpressions of this poor performing construct resulted 
in transient accumulations of high levels of intracellular MEC but yet showed similar 
extracellular levels with the other modules. The inverse relationship of the levels of 
intracellular MEC and the downstream metabolite productivity suggests an inhibitory 
role of MEC in regulating isoprenoid production, possibly due to the increase in 
oxidative stress in the cell [235-237]. Recently, MEC was also identified as a 
signaling molecule that induces stress-responsive genes in plant [238], consistent with 
an involvement in stress response. Whether such stress response mechanism occurs in 
these strains remains to be determined. 
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The overexpression of module (GH) containing ispG and ispH resulted in the 
accumulation of HMBPP and yet did not increase amorphodiene production as would 
have been anticipated. Future testing the overexpression of either enzyme of GH 
module (ispG or ispH) yielded similar result. A possibility is the limitation in the co-
factor system [232, 234] which involved the iron-sulfur cluster an observation 
consistent with a recent report in S. cerevisiae [239]. The co-expression of Isc or Suf 
operon did enhance the production of amorphadiene production but the yield was 
significantly lower than in strain overexpressing the S-IAA modules. Only modest 
enhancement was observed when the GH module was co-expressed with ISC module. 
Fine tuning of the expression level of operons by replacing their promoters in the 
genome confirmed their beneficial effects for isoprenoids production. Fine tuning of 
the expression level of various pathway modules need to be further explored. 
3.4 Conclusion  
Given the need to construct multiple vectors, the CLIVA method described herein 
provides a rapid, effective and efficient approach to identify combinations of genes 
useful for the production of metabolites. With a combinatorial selection of 
overexpression targets for DXP pathway, the overexpression of related pathway genes 
may not simply enhance but may unpredictably inhibit downstream metabolite 
production.  Given the complexity of cellular regulatory pathways and experimental 
conditions, a systematic and multivariate approach to identifying optimal 
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combinations of genes for high yield production is in high demand and will 
necessitate the construction of arrays of recombinant plasmids using the CLIVA 
method described herein.   
The accumulation of intracellular MEC was found to inhibit production of isoprenoids 
and the overexpression of downstream enzymes, ispG, ispH, did not resolve the 
problem while the co-expression with the cofactor supply system (Fe-S operons) 
showed some limited benefits. It was further discovered that by lowering the 
overexpressed level of the cofactor supply system greater benefits were achieved. 




3.5.1 Reagents, growth medium and bacteria strain 
Restriction enzymes were purchased from NEB. The high fidelity DNA polymerase 
(iProofTM) from Bio-Rad was used to amplify the DNA fragments for assembly and 
the iTaqTM DNA polymerase from iDNA was used for quantitative colony PCR. 
Unless stated otherwise, all chemicals were purchased from either Sigma or Merck. 
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Peptone and yeast extract were purchased from BD. Oligonucleotides were purchased 
from AITbiotech. Unmodified oligonucleotides were purified by desalting and the 
phosphorothioate modified oligonucleotides were purified with cartridge. All the cells 
for plasmid construction were grown in 2xPY medium or 2xPY agar plates containing: 
peptone (20 g/L), yeast extract (10 g/L) and NaCl (10 g/L) with or without agar (7.5 
g/L). The E. coli XL10-Gold strain (Invitrogen) was used for plasmid construction. 
The electroporation competent cells were prepared: 1 L of XL10-Gold cells at 
OD600~= 0.4, washed for three time with equal volume of 10% cold glycerol, 
suspended in 10 ml of cold 10% glycerol and stored at -80 °C. For amorphadiene 
production, the E. coli Bl21-Gold DE3 strain (Stratagene) harboring different kinds of 
DXP pathway plasmid together with the pRepressor plasmid carrying the lac 
repressor gene was cultured in production medium: peptone 20 g/L, yeast extract 10 
g/L, NaCl 10 g/L, glycerol 20 g/L, HEPES 50 mM and Tween 80 5 g/L. The 
pRepressor plasmid was constructed by removing the T7 promoter, RBS and T7 
terminator of pET-11a (Stratagene) plasmid and replacing the antibiotic resistant 
(ampicillin) with kanamycin. All the culture contained 34 mg/L chloramphenicol and 
100 mg/L kanamycin to maintain the DXP pathway plasmid and pRepressor plasmid 
respectively. The cell density was defined by absorbance at 600 nm (OD600) and 
measured by SpectraMax 190 microplate reader. For amorphadiene production, 1% 
(v/v) cell culture of overnight grown cell culture was inoculated into 0.8ml production 
medium together with another 0.2 ml organic dodecane phase to extract amorphadiene 
in 14mL BD FalconTM tube. The dodecane phase contained 1 g/L trans-caryophyllene 
as internal standard for amorphadiene. Cells were grown at 37 °C with 300 rpm 
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shaking for 2 h when OD600 reached the range of 0.5 - 0.8 and induced by different 
concentrations of isopropyl β-D-1-thiogalactopyranoside (IPTG). After induction, the 
cell was incubated at 28 °C with 300 rpm shaking for the rest of the experiment. The 
induction time was considered as the zeros time point in the study.  
3.5.2 Quantitative colony PCR 
The quantitative colony PCR was carried out to test the presence of successful 
ligations at all the junctions of constructed plasmids using the primer listed in “Table 
3.2”. For example, to confirm the S-GH-IAA-PAC plasmid, the junctions of PAC-S, 
S-GH and GH-IAA were verified by quantitative colony PCR respectively. For each 
junction, the sense primer in the upstream module and antisense primer in the 
downstream module were used as a pair to perform the real-time quantitative PCR, 
which were dxs-1609F/ispG-329R, ispH-693F/ADS-941R and PAC-seqF/dxs-122R 
pairs respectively. For quantitative colony PCR, the overnight cultured colonies were 
suspended in 100 µl of water. The real-time quantitative PCR reactions were carried 
out in 25 µl final volume containing 5 µl of cell suspension, 1x Xtensa Buffer 
(Bioworks), 200 nM of each primer, 2.5 mM MgCl2 and 0.75 U of iTaq DNA 
polymerase (iDNA). The reactions were analyzed using a BioRad iCycler 4TM Real-
Time PCR Detection System (Bio-Rad) with SYBR Green I detection and the 
following  protocol: an initial denaturation of 10 min at 95 °C to lyse the cells, 
followed by 40 cycles of 30 s at 95 °C, 30 s at 60 °C, and 1 min at 72 °C. A melt 
curve was then carried out to check the melting temperature of the amplicon. Various 
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primer pairs were selected from Table 3.2 to measure different module linkages in all 
the selected colonies. The results with a Ct number earlier than 18 and correct melting 
temperature were recognized as positive.  
Table 3.2 Primers used to check the constructions with quantitative colony PCR 
Name Position Sequence 
dxs-1609F S, sense CCGCTTGATGAAGCGTTAATTCTGG 
dxs-122R S, antisense GGAACGGCTCACGCTGT 
dxr-704F R, sense AAGGTCTGGAATACATTGAAGC 
dxr-782R R, antisense CACTGCCGTCCTGATAGC 
ispF-220F DEF, sense TTAAAGGTGCCGATAGCC 
ispE-349R DEF, antisense ATTGCCAGAGATGATTTAATGC 
ispH-693F GH, sense CTCCAACTCCAACCGTCTG 
ispG-329R GH, antisense ACGCTCTTCATTACCGATATTGC 
idi-462F IAA, sense TGTATTACACGGTATTGATGCCACG 
ADS-941R IAA, antisense GCTTTGGTGAAGAATACGCGAGCA 
PAC-seqF PAC, sense CCTGCTCGCTTCGCTACT 
PAC-seqR PAC, antisense GCGGTGCGGACTGTTG 
FDX-89F ISC, sense CTCTGCGTAACGGTATCG 
iscS-601R ISC, antisense ACATCAGGTCAACTTTCAACT 
surfA-334R SUF, sense TCTGGGCTTTAGGGTTGT 
surfE-273F SUF, antisense GATGACGCCGCAGGATAT 
3.5.3 Plasmid assembling by CLIVA method 
The primers for CLIVA optimization studies are listed in “Table 3.3” and for DXP 
pathway assembling are listed in “Table 3.4”. The design details for all the 16 
constructed plasmids are listed in “Table 3.5”. The modules containing various 
DXP pathway genes (dxs, dxr, ispD, ispE, ispF, ispG, ispG, idi, ispA or iron-sulfur 
(Fe-S) biosynthesis pathway (Isc operon, Suf operon), Figure 3B) were amplified 
from the source plasmids constructed by placing those genes between T7 promoter 
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and T7 terminator in pET-11a plasmid from Stratagene. The genomic DNA purified 
from MG1655 DE3 (ATCC) strain was used as original source for E. coli genes. The 
ADS from Artemisia annua was codon optimized for bacteria expression (Table 3.5). 
All the genes inside each module have their own ribosome binging sites (RBS). The 
PAC vector was amplified from pAC-Lyc plasmid from previous study [226]. The 
amplified DNA fragments were purified and treated with 20 U DpnI at 37 °C for one 
hour. After that, 100 mM Tris-HCL at pH 9, 0.3% (v/v) iodine and 10% (v/v) ethanol 
were supplied to the reactions and the mixtures were heated at 70 °C for 5 min. If the 
mixture turned out to be colorless, additional 0.3% (v/v) iodine and 10% (v/v) ethanol 
would be supplied and the mixture would be heated at 70 °C for another 5 min. The 
DNA fragments treated with iodine and ethanol were then purified by ethanol 
precipitation. For CLIVA optimization experiments, 0.15 pmol of every pieces 
together with different kinds and concentrations of salts were heated at 80 °C for 1 
min, cooled down to the temperature which was 3 degree lower than the melting 
temperature of the overlapped sequences, kept for 10 min and then cooled down to 
20 °C at 0.1 °C/s. 0.5 µl of the assembling mixture was mixed with 50 µl of XL10-
Gold competent cell for electroporation. For DXP pathway assembling experiments, 
all the DNA fragments were prepared at 0.25 µM and equal amount of every pieces 
were mixed with MgCl2 at 2.5 mM. The mixture were heated at 80 °C for 1 min, 
cooled down to 68 °C, kept for 10min and then cooled down to 20 °C at 0.1 °C/s. 0.5 
µl of the assembling mixture was mixed with 50 µl of XL10-Gold competent cell for 
electroporation. 
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Table 3.3 Primers used for CLIVA optimization 
Part I: the primers used for various designs 
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The PAC-F, PAC-R, siDF-F and siDF-R were the gene specific sequences.  An “Ox/y” designation 
was used to define the primers, where O denoted overlap; x was the length of overlap which had one 
modification at each y base pairs of the sequence. For example, O13/1 was a primer with 13 bases of 
overlap and phosphorothioate modifications at every base-pair. Similarly, O13/4 denoted a primer with 
13 overlaps and phosphorothioate modifications at every 4th base-pair. 
Part II: the sequences of the primers 










































O38/38-siDF-R TTGGTTCCACTCTCTGTCCTCCCCGAAAAGTGCCAC*CTG  
The phosphorothioate modifications were presented as *.  























CL-pET-aR CL-pET-2F GGCC*TCAAC*CTACT*ACTGC*GGGC*CTCTT*GCGG*GATA 
CL-pET-bR CL-pET-3F CCTTG*CGGC*GGCG*GTGG*CTTG*GTTAT*GCCG*GTAC*TGC 
CL-pET-cR CL-pET-4F TGGG*TATGG*TGGC*AGGG*TCACC*CTGGA*TGCT*GTAG*GC
A 
CL-pET-dR CL-pET-5F CGCC*ACTTC*GGGC*TCACG*CTCA*TCGT*CATC*CTCG*GCA 
CL-pET-eR CL-pET-6F ACAGG*TGCG*GTTGC*TGTTA*AATTG*CTAAC*GCAG*TCAG*
GCA 
CL-pET-fR CL-pET-7F TCTACG*CCGG*ACGCA*TCCG*AGGC*CCTTT*CGTCT*TCA 
CL-pET-gR CL-pAC-F TTGGTT*CCAC*TCTCT*GTCC*TCCC*CGAAA*AGTG*CCAC*CT
G 
The phosphorothioate modifications were presented as *. And the underlined sequences were the gene 
specific sequences of the primers. 
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Table 3.5 Design details for DXP pathway construction  
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3.5.4 Metabolite measurement 
Amorphadiene was trapped in the dodecane phase and quantified as previously 
described [240]. The dodecane phase was diluted 100 times in ethyl acetate and the 
amorphadiene was quantified by Agilent 7890 gas chromatography/mass 
spectrometry (GC/MS) by scanning 189 and 204 m/z ions, using trans-caryophyllene 
as standard. The amorphadiene concentrations were adjusted to the volume of cell 
suspension (0.8 ml) for report. 
The DXP pathway intermediates (DXP, MEP, CPD-ME, CDP-MEP, MEC, HMBPP, 
IPP, DMAPP, GPP, FPP, Figure 3A) were quantified by UPLC-MS as described 
[225]. For extracellular metabolites, the growth medium was diluted 30 times in 
methanol, shaken at room temperature for 2 min and centrifuged at 20,000 g for 5 min 
to yield the supernatant as the sample for injection. For intracellular metabolites, 1 ml 
x OD600 cell was collected and the medium was removed with centrifugation. The 
cell pellet was then suspended in 30 µl of water, 120 µl of methanol was added 
afterwards and the mixture was shaken at room temperature for 10 min to lyse the 
cells and release the intermediates [241]. The cell debris was removed by 
centrifugation at 20,000 g for 5 min. 5 µl of either extracellular or intracellular sample 
was injected. Aqueous solution containing 15 mM acetic acid and 10 mM 
tributylamine and methanol were used as mobile phase with a UPLC C18 column 
(Waters CSH C18 1.7 μm 2.1x 50 mm). The elution was done at 0.15 mL/min with 
gradient. A standard curve following the same treatment was used to quantify the 
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extracellular or intracellular metabolites. The detection limit was at least 5 µM in the 
final sample for FPP, CDP-MEP and at least 1 µM in the final sample for the rest of 
the metabolites.  
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Chapter 4 UNivariant Extrinsic Initiator Control 
System for microbes (µ-UNeICS): a tool to 
modulate and optimize multiple recombinant gene 
expression levels in microbes for synthetic biology 
and metabolic engineering 
4.1 Background and motivation 
It is now known that most metabolic pathways are not restricted by a single rate-
limiting step. The exploitation of the pathway for the production of metabolites will 
require the optimal expression of several native and/or heterologous enzymes in 
tightly coordinated manner [156, 157, 242]. Failure to do so will invariably result in 
undue metabolic burden where metabolic imbalance can lead to the accumulation of 
intermediate metabolites or gene products with potential cytotoxicity or, in some 
cases, may affect normal cell growth [159, 222]. Besides, the stress caused by the the 
overexpression of enzymes (proteins) [243] which can be insoluble [115, 116] will 
induce the selection of low producers during fermentations [190]. Thus, a significant 
challenge of using microbial cells as biofactories is to optimally balance the 
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expressions of number of enzymes in a pathway where multivariate optimization is 
necessary. 
A number of tools are currently available to allow the fine modulation of gene 
expression in a pathway. This include methods for generating randomized genetic 
knockouts and overexpression libraries, synthetic promoter libraries, tunable 
intergenic regions, and global techniques (e.g., artificial transcription factor 
engineering, ribosome engineering, global transcription machinery engineering, and 
genome shuffling) [242, 244].  
Promoters, both constitutive and inducible, have long been used to control gene 
expressions. The genetic engineering of promoters of various strengths has produced 
large libraries which have been used predominately to precisely control the expression 
of a single or small number of genes [245].  
To differentially control a large number of genes, it is common to use multiple 
promoters with different strengths combined with various genetic carriers such as 
plasmids of different copy numbers. A distinct disadvantage of this approach is that 
there are a restricted number of such regulatory elements where the ability to tune the 
expression of the GOI is limited. Furthermore, when differential expressions of 
multiple genes are required, the search for an optimal condition is often extensively 
time and resource consuming due to the permutation of the regulatory elements to be 
used [157]. In addition, the multiple control elements use divergent mechanisms 
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which are subjected to different global cellular controls. Because of these constraints, 
it will be difficult to predict the response of the system when engineered, thus 
reducing the chance of finding the optimal condition rapidly. Hence, simultaneously 
optimization of the expression of a number of genes in a pathway is still highly 
empirical, unpredictable and time consuming. Currently, there is no way of knowing 
if an optimal is achieved by tuning with the existing tools and methods, making these 
highly unsatisfactory. Hence, a tacit demand, yet to be met, is a systematic method to 
enable the optimization of the expression of multiple gene cassettes with predictable 
and well-controlled manner to enable the identification of an optimal set of 
parameters in a multidimensional space [156, 157].  
All isoprenoids are synthesized from two building blocks (IPP and DMAPP) by 
various synthase of the DXP or the MVA pathway and these can be heterologously 
expressed in E. coli (Figure 4.1, green pathways). To produce these two precursors 
through MVA pathway in E. coli, the whole heterologous pathway (hmgS, hmgR, 
MVK, PMVK, MVD) including a native upstream enzyme atoB is required to be 
overexpressed (Figure 4.1, MVA pathway) while several rate limiting steps have been 
identified for the native DXP pathway including the committed step, dxs, and three 
intermediate enzymes (ispD, ispF, idi (Figure 4.1, DXP pathway). These rate limiting 
steps for isoprenoids production through either pathway have been divided into two or 
three pathway modules where expression levels were altered and optimized by 
varying their promoter types or recombinant plasmid copy numbers [159, 222]. An 
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additional bottleneck of the DXP pathway has been described in “0” where the co-
expression of Fe-S operons resulted in enhanced production of isoprenoids.  
 
Figure 4.1 Isoprenoid production pathways 
Pathways for the production of isoprenoid (Amorphadiene or Lycopene): the DXP pathway in red, 
MVA pathway in blue, terpenoid synthesis pathway in green and other E. coli native genes in black. A 
solid arrow represents a single enzymatic step, while a dashed arrow represents multiple enzymatic 
steps. The overexpressed pathway modules are listed in either red box while using DXP pathway or in 
blue box while using MVA pathway. Key metabolites are with white boxes. Abbreviations for 
metabolites: GA3P: glyceraldehyde 3-phosphate, IPP: Isopentenyl pyrophosphate, DMAPP: 
Dimethylallyl pyrophosphate, GPP: Geranyl diphosphate, FPP: Farnesyl diphosphate, GGPP: 
Geranylgeranyl diphosphate. 
In this chapter, the overexpression of some genes in the DXP pathway (dxs, ispD, 
ispF, idi) and heterologous MVA pathway were used as the focused modules for the 
development of tools. A series of novel methods and tools for simultaneously tuning 
of multiple pathway modules were systematically developed to optimize the 
production of isoprenoids (Figure 4.1). A decomposition method was first explored to 




dxs dxr ispD ispE ispF ispG ispH 












dxs idi-ispD-ispF (IDF) ADS 
ADS-ispA (AA) 
crtE-crtB-crtI (crtEBI) 
hmgS-aroB-hmgR (SBR) MVK-PMVK-MVD-idi (KKDI) 
ispA 
GGPP 
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(Figure 4.2, A). These independent promoters (uses different cellular resources to 
control each promoter) allowed each component in the module to be simultaneously 
altered by varying the concentrations of their inducers. The ease of continuously 
altering the expression of GOI by modulating the promoter using exogenously added 
inducers makes it a convenient method. This decomposition approach was 
successfully utilized to optimize lycopene – a C40 isoprenoid production with DXP 
pathway by tuning the upstream pathway module (SIDF) [246] together with the 
downstream module (crtEBI) [226] (Figure 4.1). A global optimum could consistently 
be observed while excessive overexpression of the components in the modules 
resulted in inhibitory effects revealing the importance of pathway balancing. As this 
method is purely trial-and-error, the utility is severely limited by the enormous 
possible number of conditions to be tested with increasing permutation of modules. 
Instead of decomposition, another systematic method was developed by treating the 
expression of multiple modules as an integrated process. The optimal condition for 
productivity is modulating at two orthogonal dimensions - the ratio between pathway 
modules and the overall expression levels of each component (Figure 4.2, B). Based 
on the strong original T7 promoter, mutant promoters with different strengths were 
generated and combinatorially controlling various modules to produce different ratios 
of genes expressed. On another dimension, the extrinsic transcriber, acting as a master 
regulator, alters the overall expression level by uniformly tuning all the promoters 
independent of their strength as a whole system. This univariant controlling method 
was initially demonstrated by optimization the production of lycopene and then 
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extended to engineer a three module (S, ISF and ADS) synthetic pathway for 
amorphadiene – a C15 isoprenoid production (Figure 4.1). According to the results, 
the system was mainly restricted by a single global boundary making it possible to 
carry out a rational optimization with the univariant controlling method, minimizing 
the number of strains to construct. The method was further successfully applied to 
identify the optimum condition for amorphadiene synthesis through MVA pathway by 
simultaneously tuning three pathway modules (SBR, KKDI and AA, Figure 4.1). In 
addition, the properties and robustness of the invented tools were characterized at 
transcription and translation levels. The robustness of the system was also 
characterized by proving that two dimensions of control had no interaction and the 
engineered promoters would keep their relative strength at various conditions.  
 
Figure 4.2 Illustration of methods used for control of multiple pathway modules 
(A) Decomposition method. Each module of the pathway was individually controlled by an 
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Univariant controlling method. The system was regulated at two dimensions: the ratios of the pathway 
modules were modulated by applying different engineered promoters with various strengths and the 
overall expression were controlled by the master regulator that simultaneously and equally tunes the 
level of all promoters. 
 
4.2 Results 
4.2.1 Gene overexpression reduces lycopene production 
Lycopene (C40 isoprenoid), an effective antioxidant [81], was initially synthesized in 
E. coli with the overexpression of four bottleneck enzymes dxs, idi, ispD, ispF [246] 
in DXP pathway as well as three plant genes crtE, crtB, crtI separating into upstream 
(SIDF) and downstream (crtEBI) modules (Figure 4.1). It is well known that the 
excessive overexpression of enzymes can inhibit isoprenoid production [220, 233, 
247]. In order to investigate this issue, the SIDF module was expressed under control 
of inducible T7 promoter (pET-T7-SIDF plasmid) together with a constitutively 
expressed crtEBI module (pAC-LYC plasmid) in E. coli BL21-Gold DE3 strain. As 
predicted, the yield of lycopene increased initially but decreased at higher inductions 
(Figure 4.3, A). Initially, the hypothesis was that strong overexpression of upstream 
enzymes might interfere with the expression of downstream isoprenoid synthetic 
genes but it was later found to be incorrect [212]. Further studies were carried out to 
test if the inhibition was caused by the function of expressed enzymes or the 
expression process itself. An enhanced green fluorescence protein (eGFP) without 
C h a p t e r  4                                              P a g e  117 
 
enzymatic activity and noncoding version of the dxs and idi genes (t-dxs and t-idi), 
respectively, serving as translation and transcription controls were overexpressed at 
various levels together with a constitutive expression of crtEBI for lycopene 
production (Figure 4.3, B). The t-dxs and t-idi genes encoded dxs and idi, respectively, 
and were modified by deleting the ribosome binding sites as well as the start codons 
(ATG), thus disabling translation into proteins in E. coli (data not shown). Based on 
the results, it was likely that the overexpression process, mainly due to synthesis of 
proteins, posed a global biochemical limitation that burdened the cells and inhibited 
the isoprenoid production.  
 
Figure 4.3, Production inhibition caused by high gene expression 
Lycopene yields responding to gene expression controlled by IPTG inductive T7 promoter in BL21-
Gold (DE3) strain were measured. (A) Cell harboring pAC-LYC (continuously expression of crtE, crtB 
and crtI genes) and PETK-T7-SIDF plasmids; (B) Cell harboring pAC-LYC plasmid together with 
pETK-T7-eGFP(●) or pETK-T7-t-dxs (■) or pETK-T7-t-idi (▲) plasmid. pETK-T7-t-dxs (■) or 
pETK-T7-t-idi (▲) were engineered to be untranslatable into proteins. Presented data was average of 
triplicates with standard deviation.  
A 






































C h a p t e r  4                                              P a g e  118 
 
4.2.2 Optimization of lycopene production with two independent tunable 
promoters 
In order to minimize the burden caused by overexpression, limited amounts of the 
bottleneck enzymes should be expressed. Hence, it was necessary to distribute the 
quota of resources to distinct pathway modules in a balanced manner to maximize the 
overall flux towards the product. Tunable promoters, where expression levels are 
conveniently and continuously modulated by the cognate transcribers, are highly 
desirable for rapid identification of the optimal condition (Figure 4.2, A). To 
demonstrate, the SIDF and the crtEBI modules were driven by two distinct 
independent tunable promoters: IPTG inducible T7 promoter and arabinose inducible 
pBAD promoter. A two-dimensional search was carried out by varying both inducers 
simultaneously (Figure 4.4, A). The expression of either module, where genes were 
expressed as a polycistron, was monitored by the transcription level of the first 
enzyme in each of the module (dxs for SIDF module and crtE for crtEBI module). 
Shown in the transcription result (Figure 4.4, D), both promoters can be 
independently and consecutively regulated. In the search space, a smooth lycopene 
response surface with only one optimum at high arabinose (3.3 mM) and low IPTG 
(0.011 mM) inductions was observed. A minimum induction was require for SIDF 
module indicating that the strong T7 promoter creating superfluous stress may not be 
suitable for usage here. 
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Figure 4.4 Optimization of two modules for lycopene production with two 
independent tunable promoters 
(A-C): Lycopene production response to simultaneously tuning of pBAD promoter for crtEBI module 
and T7, TM2 or TM3 promoter for SIDF module in BL21-Gold (DE3) strain harboring pAC-BAD-
crtEBI plasmid together with pETK-T7-SIDF(A) or pETK-TM2-SIDF(B) or pETK-TM3-SIDF (C) 
plasmid. The dots indicate the lycopene yields and the surfaces were interpolated based on triangle-
based cubic interpolation. The numbers in the figures indicate the highest yields achieved 
experimentally; (D-F): Transcription levels of SIDF module (represented by dxs mRNA level) and 
crtEBI module (represented crtE mRNA level) at various induction conditions in (A), (B) and (C). All 
the transcription levels were normalized to level of cysG. The circled points indicate the highest 
lycopene production conditions in the surface and the squares indicate the covered expression range; 
(G): the combination of the highest production points and expression ranges in (D)(blue), (E)(red) and 
(F)(green).  
 
4.2.3 Design and construct mutant T7 promoters 
To alter the expression range, the T7 promoter was modified by site directed 
mutagenesis to create a mutant library with varying promoter strengths. The rate-
determining steps of transcription with T7 RNA polymerase are the binding of 
polymerase to specific T7 promoter sequence followed by the melting of the double 
strand DNA and initiation of transcription with small transcripts [248-250]. These 
actions can be mapped to the different regions of the conserved promoter sequence in 
“Figure 4.5”. With the system in this study, IPTG functions by inducing T7 RNA 
polymerase synthesis and relieving the inhibition of the T7 based promoters by 
binding to the repressor from the lac operator. To maintain the tunability, the native 
T7 promoter was selectively disabled at the melting/initiation region as it is an 
inherent property of the promoter unlike the binding process that can be affected by 
C h a p t e r  4                                              P a g e  121 
 
parameters such as polymerase and DNA concentrations. Based on the strengths 
measured by in vitro transcription [141], selected mutant promoters covering various 
expression levels were constructed (Table 4.1) and their strengths were determined by 
quantifying eGFP protein expression. Strikingly, the strengths characterized in vivo 
were different from the published in vitro measurement ([141], Table 4.1). According 
to the in vivo strengths, three low leaky T7 mutant promoters, herein named as TM1, 
TM2 and TM3, were chosen for further studies.  
 
Figure 4.5 Sequences of T7 promoter 
The numbers indicate the position relative to the transcription starting point (+1). The conserved 
sequence (black arrow), polymerase binding (blue arrow) and melting/initiation (red arrow) regions are 
indicated. 
The differences between mutant promoters are solely defined by the rate of 
melting/initiation which is a first order reaction independent of other factors. As a 
result, all mutant promoters (TM1, TM2 and TM3) should have a similar response to 
IPTG induction. This was validated by expressing the eGFP as the reporter in pAC 
vector (Figure 4.6, A). According to the normalized expression levels, these mutant 
promoters responded to various doses of IPTG equally (Figure 4.6, B) and retain their 
relative strength upon various inductions (Figure 4.6, C).  
C G A A A T T A A T A C G A C T C A C T A T A G G G G A A T T G T G A G  
-15 -10 -5 -1 +1 +5 +10 -20 
conserved sequence 
polymerase binding  melting/initiation 
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Strength in  
literature 
1 T7 N.A. 6.4% 100% 100% 
2  -2 to A, -3 to T 3.6% 104% 42% 
3 TM1 -1 to T, -2 to A 2.3% 92% 75% 
4  2 to T, -1 to T 1.5% 85% 65% 
5  -1 to T, -2 to G <1% 74% 58% 
6  -2 to A, -4 to G <1% 42% 41% 
7 TM2 -2 to G, -3 to C <1% 37% 56% 
8  -3 to G, -2 to C <1% 26% 46% 
9 TM3 +2 to A, +1 to A <1% 16% 13% 
10  +2 to C, +1 to C <1% 12% 33% 
11  +2 to A, +1 to C <1% 10% 19% 
12  +1 to T, -1 to G <1% 6.1% 24% 
All the mutation positions were labeled according to the sequence in Figure 4. The leaky and induced 
(0.3mM IPTG) expression levels were measured by expression of eGFP under control of various 
promoters in pET vector and normalized to the induced expression level of native T7 promoter. 
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BL21-Gold (DE3) strains harboring eGFP expression plasmids: pAC-TM1-eGFP, pAC-TM2-eGFP or 
pAC-TM3-eGFP and pRepressor plasmid expressing lacI gene were grown in the presence of different 
IPTG concentrations. EGFP was extracted at 48hrs after induction and measured with fluorescence 
reader (excitation wavelength: 588nm, emission wavelength: 610nm). (A), the fluorescence of all the 
conditions (IPTG, mutant promoters) were normalized to the strongest expression condition (pAC-
TM1-eGFP with 0.3mM IPTG); (B), the fluorescence of each plasmid with various IPTG inductions 
were separately normalized to the level of strongest induction (0.3mM IPTG); (C), the fluorescence 
each IPTG induction for different mutant promoters were separately normalized to the level of 
strongest promoter (TM1 promoter);  The error bars represented the standard deviation of three 
biological replicates.  
4.2.4 Optimization of lycopene production with mutant promoters  
The T7 promoter for SIDF module was replaced with two significantly weaker 
promoters TM2 and TM3 to extend the search space. The transcriptional result 
(Figure 4.4, E, F) showed that the mutant promoters have comparatively low 
expression in accordance to their strengths (Figure 4.4, G) and no interaction with 
pBAD promoter was observed. The lycopene response surface switched accordingly 
but kept with one optimum on the smooth surface (Figure 4.4, B, C). The predicted 
optimum conditions identified with different promoters (T7, TM2, TM3) were closely 
located (Figure 4.4, G) which proved that reaching a balance between pathway 
modules was a major task for pathway optimization. Evidently, the mutant promoters 
extended the coverage of the expression range while the optimum yield for T7 
promoter (56.4mg/L) was not as high as that of TM2 (74.5mg/L) or TM3 (80.0mg/L) 
promoters. A possibility was that to achieve the same expression level, the native 
promoter expressed the transcripts faster than the mutant ones which may impose 
excessive cellular burdens. However, regardless of the strength of the promoters, the 
expression rates showed similar kinetics in response to induction (Figure 4.7). 
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Another issue related to the use of native promoter is the high leaky expression that 
may burden the cells even before induction. Consistent with this suggestion was the 
significant reduction in isoprenoid production through either DXP or MVA pathway 
in strains with the Repressor plasmid (providing lacI protein that suppresses the 
expression before IPTG induction) removed so as to enable a constitutive activation 
of the native promoter [251] (Figure 4.8).  
The library provided promoters with variety of tunable ranges was then used in 
conjunction with other independent promoter to optimize metabolite production in a 
multivariate manner.  
 
Figure 4.7 The kinetic of eGFP expression driven by different promoters 
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BL21-Gold (DE3) strains harboring eGFP expression plasmids: pAC-T7-eGFP, pAC-TM1-eGFP, 
pAC-TM2-eGFP or pAC-TM3-eGFP and pRepressor plasmid expressing lacI gene were grown in the 
presence of different IPTG concentrations. Cells were incubated with 2xPY medium at 37 °C in 
Thermo Scientific Varioskan Flash Multimode Reader with shaking and eGFP was continuously 
monitored by measuring fluorescence (excitation wavelength: 580nm, emission wavelength: 610nm). 




Figure 4.8 Unregulated promoters result decreased isoprenoid production 
BL21-Gold (DE3) strains with or without pRepressor plasmid expressing the lacI repressor that 
inhibited the transcription from T7 based promoters before IPTG induction were introduced with 
amorphadiene synthetic pathways. The productions of amorphadiene were measured after various 
IPTG inductions. (A), the amorphadiene synthesis was carried out through DXP pathway: pAC-TM2-
dxs-TM/3-IDF-TM2-ADS plasmid. (B), the amorphadiene synthesis was carried out through MVA 
pathway: pAC-TM3-SBR-TM2-KKDI-TM3-AA plasmid. The error bars represented the standard 
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4.2.5 Development of a univariant controlling approach 
Because of the limited types and tunable range of independent promoters that are 
natural availability, a combinatorial multivariant-modular controlling approach is 
impractical with more than two modules where the experimental conditions will 
increase exponentially as well. In an attempt to develop a simplified, robust and 
rational engineering approach, the optimization challenge was dissected into two 
distinct parts: balance various pathway modules and reduce overexpression burdens. 
In order to maximize the flux efficiency and avoid toxic or inhibitory intermediates, a 
balanced pathway is always critically independent of the overall flux. On the other 
hand, the overall expression needs to be optimized to balance flux and burden - a 
general limitation caused by high expression regardless of the function of the module. 
To address these two distinct yet related challenges (flux and burden), selected 
promoters from the T7 promoter library was used to alter the relative ratios between 
various pathway modules by their strength. At the same time, the concentration of 
IPTG, serving as a global factor, was used to regulate the expressions of all the 
modules simultaneously while maintaining the ratios of promoter strengths (Figure 
4.2, B). By tuning these two orthogonal dimensions, this univariant controlling 
approach was able to overcome the limitations of the combinatorial multivariant 
controlling with other approaches. 
In order to test the hypothesis that the relative strengths or ratios of the strengths of 
these mutant promoters are indeed evenly distributed when they were competing for a 
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limited pool of resource, an in vitro transcription system was established to mimic the 
circumstances encountered in vivo. The modules were standardized by expressing 
eGFP gene with short sequence tags which could be differentiated by specific qPCR 
primers (Figure 4.9, A). All combinations of two or three tagged modules were mixed 
with equal amounts in the reactions and the results showed that the modules with the 
same promoter but different tags behaved similarly, indicative that these sequences 
were expressed equally (P1-TM1/P2-TM1, P1-TM2/P2-TM2, P1-TM3/P2-TM3) 
(Figure 4.9, B, D). Next, it was obvious that the expression levels of the gene from a 
weaker promoter (e.g., P2-TM2 in Figure 4.9, B), was expectedly lower in the 
presence of a strong promoter (P2-TM2/P1-TM1 in Figure 4.9, B) than when co-
transcribed with a comparable promoter (P2-TM2/P1-TM2 in Figure 4.9, B) proving 
the occurrence of competition at the reaction conditions (high template concentration 
to T7 polymerase availability) (Figure 4.9, B, D). Re-plotting the data (Figure 4.9, C, 
E) it was clear that the relative strengths of the mutant promoters were fixed, even 
under competitive, resource limiting conditions. With such constant ratios, depending 
on mutant promoters, the modules will always have the same occupancies of the 
transcription resource regardless of the experimental conditions. While on the other 
independent orthogonal dimension, IPTG should still regulate the overall resource 
independent of other parameters.  
C h a p t e r  4                                              P a g e  128 
 
 


























































































































































































copy/ copy template 


























































































C h a p t e r  4                                              P a g e  129 
 
(A), illustration of in vitro transcription experiment. The systems of two or three modules controlled by 
different promoters were combinatorially mixed together in equal amount for the reaction. The 
modules were standardized using eGFP genes with various short tags that were differentially measured 
by qPCR. To ensure the competition, the template concentration was adjusted to a high amount, as 
much as half of the concentration of T7 polymerase used; (B), (D): the transcription result of two(B) or 
three(C) module systems were presented as the copy of mRNA transcribed from per copy of template 
DNA. P1, P2 and P3 represented different modules where promoters were indicated at X axis; (C), (E): 
the ratio of the transcription levels between modules where promoters were indicated at the X axis. The 
error bars represented the standard deviation of four replicates.  
 
4.2.6 Optimization of lycopene production with the univariant controlling 
approach 
To further demonstrate, three promoters with varying strengths (TM1, TM2 and TM3, 
Table 4.1) were selected to control the expressions of the SIDF and crtEBI modules in 
a combinatorial way. Firstly, the transcription levels of the modules were measured so 
as to exam the behavior of the co-existing promoter in vivo. The inducer IPTG (0.3 – 
0.011 mM) was added to the cells with various combinations of the mutant promoters 
(e.g, pETK-TM-SIDF TM1 with pAC-TM-crtEBI TM1) in pAC and pET vectors 
(Figure 4.10, A). All mutant promoters expressing SIDF (pET vector) responded to 
IPTG similarly regardless of their strengths and the type of co-expression promoters. 
When the strongest promoter (TM1) is expressed in a high copy number plasmid 
(pET, ~ 100 copies), the expressions of the genes (crtEBI in pAC, ~30 copies) were 
found to be lower than expected when compared to the other combinations (Figure 
4.10, B) indicative of the limitation of transcription resource. Importantly, even in this 
situation, the relative strengths of mutant promoters remained constant (first 3 sets of 
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TM combinations). A common (univariant) resource is distributed at fixed ratios over 
mutant promoters with pre-set transcriptional strengths. Hence, any change in the 
global supply of resource will influence the transcription from each mutant promoter 
in a pre-set manner.  
 
Figure 4.10 Transcription levels of two modules for lycopene production 
optimized with univariant controlling approach 
BL21-Gold (DE3) strains harboring the combination of plasmids for two modules with different mutant 
promoters were grown in the presence of different IPTG concentrations for lycopene production. Two 
modules used in this study were the SIDF module (pETK-TM1-SIDF or pETK-TM2-SIDF or pETK-
TM2-SIDF plasmid) and the crtEBI module (pAC-TM1-crtEBI or pAC-TM2-crtEBI or pAC-TM3-
crtEBI plasmid). Note that both vectors were inducible by IPTG. The copy numbers of the vectors, pET 
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crtEBI module (crtE) (B) were measured with the protocol described in experimental method and 
normalized to the level of cysG. 
Next, the lycopene response using the univariant controlling approach was 
investigated. As expected, for any of the strains with various ratios between two 
modules, a compromising IPTG concentration for maximum lycopene by balancing of 
burden and flux could always be identified (Figure 4.11, A). On the other dimension, 
with optimal IPTG induction, lycopene production response to different promoter 
pairs differed (Figure 4.11, C). In general, crtEBI module required a stronger (TM1 or 
TM2) promoter than SIDF module (TM3) and the yield would be extremely low in 
contrary situations. These observations demonstrated the importance of both 
dimensions for optimal tuning. Putting the two dimensions together, the tested 
conditions dispersed well in the whole search space (Figure 4.11, B) the one that was 
wider than using pBAD promoter (Figure 4.4, D-F) for crtEBI module. Consequently, 
a slightly higher lycopene yield (102 mg/L) was achieved. Again, a global optimum 
was be identified and condition located adjacent it would have higher production than 
those distant ones. The existence of single global boundary allowed employing a 
rational optimization approach that stepwise zoomed into the optimum conditions 
which would then allow an accelerated optimization process by reducing the number 
of strains to be constructed (Figure 4.12).  
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Figure 4.11 Optimization of two modules for amorphadiene production with 
univariant controlling approach 
BL21-Gold (DE3) strains harboring the combination of plasmids for two modules with different mutant 
promoters were grown in the presence of different IPTG concentrations for lycopene production. Two 
modules used in this study were the SIDF module (pETK-TM1-SIDF or pETK-TM2-SIDF or pETK-
TM2-SIDF plasmid) and the crtEBI module (pAC-TM1-crtEBI or pAC-TM2-crtEBI or pAC-TM3-
crtEBI plasmid. (A): lycopene production at all conditions. The combination of pathway modules 
(SIDF: blue; crtEBI: red) were presented at X axis and the IPTG concentrations were presented as 
different bars; (B): lycopene production response to the expression levels of two modules; (C): 
lycopene production response to the combination of mutant promoters for two modules. Only the 
optimum lycopene yields at various IPTG concentrations were presented. The color of the dots 
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Figure 4.12 Rational optimization of lycopene production 
A simple rational workflow can be used to guide strain development. Firstly, a screening experiment 
can be conducted using only high (TM1) and low (TM3) strength promoters with various IPTG 
inductions to discretely cover the searching range (A). The response of the system to mutant promoters 
will reveal that applying stronger promoters for the expression of crtEBI module than SIDF module 
gives better yields (B). A second round of focused experiment around the optimum conditions deduced 
from the screening experiment can be then carried out and the optimum condition (pETK-TM3-siDF, 
pAC-TM2-crtEBI, 0.1mM IPTG) will be attained (C, D). By such approach, an optimal condition can 
be easily identified without the need to search for more. (A)(B): Initial screening experiment. (C)(D): 
the focused experiment. The color dots indicated the experimental conditions and the gray dots 
indicated the conditions unnecessary to test further after initial screening study. The color of the dots 
indicated the lycopene yields. (A)(C): lycopene production response and the expression levels of the 
two modules; (B)(D): lycopene production response to the combination of two modules using mutant 
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4.2.7 Simultaneously optimization of three pathway modules with the 
univariant approach 
In previous studies, four bottle neck steps, scattered throughout the DXP pathway 
(Figure 4.1), was grouped into a single module. It is highly possible that the optimal 
expression level for the committed step, dxs, is different from the rest of the 
intermediate steps (idi-ispD-ispF, IDF). The fact that IDF are the three enzymes in 
DXP pathway found to be highly soluble upon overexpression [115] as compared to 
the rest of the enzymes in the pathway suggests that less expressions may be required 
of them. To investigate this issue, the upstream pathway was divided into dxs and IDF 
modules and another important isoprenoid - amorphadiene, the precursor for 
antimalaria drug artemisinin [217], was synthesized with DXP pathway by changing 
the crtEBI module to ADS gene encoding amorphadiene synthase. To eliminate the 
possible biases caused by the variation of plasmid copy numbers, a library (27 
recombinant plasmids) harboring the full combination of three promoters (TM1, TM2, 
TM3) with the three modules were constructed into a single pAC vector with the 
CLIVA method (0) and each of these plasmids was transformed into BL21-Gold DE3 
strain along with a pRepressor plasmid critical for the function of IPTG.  
Tuning of IPTG, as expected, allowed the identification of optimal overall expression 
for each engineered strain (Figure 4.13, A). To extend the findings, the system was 
transferred to another routinely used E. coli strain MG1655 DE3 (K12 strain family) 
differing from the former B strain derivative BL21-Gold DE3 (Figure 4.13, B). As 
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expected, the IPTG performed well on balancing the burden and overall expression 
for each condition while notable difference could be observed comparing two strains. 
For MG655 DE3 strain, the maximum yield was attained at two conditions: pAC-
TM2-dxs-TM3-iDF-TM1-ADS with 0.1mM IPTG (232mg/L) and pAC-TM3-dxs-
TM3-IDF-TM2-ADS with 0.3mM IPTG (232mg/L) indicative that, for an optimum 
production, more ADS than dxs is required while the expression of IDF should be 
kept as low as possible, which validated our previous hypothesis. On the other hand, 
the best conditions for BL21-Gold DE3 strain: pAC-TM2-dxs-TM3-IDF-TM2-ADS 
with 0.3mM IPTG (281mg/L) and pAC-TM2-dxs-TM2-IDF-TM2-ADS with 0.1mM 
IPTG (274mg/L) showed an equal expression for the dxs and ADS modules.  
The measurement of expression levels of the selected strains revealed that with a low 
copy pAC vector, the competition for transcriptional resource did not appear to occur 
(Figure 4.14). On basis of that, the relative expression level (a.u.) of modules 
controlled by the univariant controlling method can be calculated by “Equation 1” 
where parameters were fitted by least squares method from the data of “Figure 4.6”. 
The amorphadiene production corresponding to the relative expressions of the 3 
modules were then represented in a 3-D graph (Figure 4.15, A, C). According to the 
plot, the univariant controlling method systematically covered a large space within 
which neither too low nor too high expression was propitious to production. The 
deduced high production conditions (more than half of the maximum) for both strains 
(Figure 4.15, B, D) were located at a fairly focused space raising the possibility of the 
existence of a single optimum.  
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Figure 4.13 Optimization of three modules for amorphadiene production with 
univariant controlling approach 
DXP or MVA pathway was applied for amorphadiene synthesis in either BL21-Gold DE3 or MG1655 
DE3 strain. The combination of TM1, TM2, TM3 promoters were used to drive the expression of three 
modules for either DXP pathway approach (pAC-TM-dxs-TM-IDF-TM-ADS plasmid) or MVA 
pathway approach (pAC-TM-SBR-TM-KKID-TM-AA plasmid). Strains harboring the pathway and 
pRepressor plasmid expressing lacI gene were grown in the presence of different IPTG concentrations. 
Amorphadiene yields were presented in (A): BL21-Gold DE3 strain, DXP pathway, (B): MG1655 DE3 
strain, DXP pathway and (C) MG1655 DE3 strain, MVA pathway. The combination of pathway 
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Figure 4.14 Transcription level of selected strains with three modules on pAC 
vector  
BL21-Gold (DE3) strains harboring selected plasmids: pAC-TM1-dxs –TM2-IDF-TM1-ADS plasmid, 
pAC-TM2-dxs –TM1-IDF-TM3-ADS plasmid or pAC-TM3-dxs –TM3-IDF-TM2-ADS plasmid and 
pRepressor plasmid (expressing lacI gene) were grown in the presence of different IPTG 
concentrations. The combination of pathway modules (dxs: blue; ADS: red; IDF: green) were 
presented at X axis and the IPTG concentrations were presented as different colored bars; The 
transcription level of each module (dxs, IDF, ADS) was measured with the protocol described in 
experimental method and normalized to the level of cysG; The error bars represented the standard 
deviation of three biological replicates. 
Equation 1 Calculation of relative expression levels in arbitrary units (a.u.). 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 (𝑎.𝑢. )= 𝐼𝑃𝑇𝐺 𝑖𝑛𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑠𝑡𝑟𝑒𝑛𝑔𝑡ℎ × 𝑀𝑢𝑡𝑎𝑛𝑡 𝑝𝑟𝑜𝑚𝑜𝑡𝑒𝑟 𝑠𝑡𝑟𝑒𝑛𝑔𝑡ℎ 
𝐼𝑃𝑇𝐺 𝑖𝑛𝑑𝑢𝑐𝑡𝑖𝑜𝑛 𝑠𝑡𝑟𝑒𝑛𝑔𝑡ℎ = � 100, 0.3 mM       IPTG61.4, 0.1 mM       IPTG33.6, 0.033 mM  IPTG10.5, 0.011 mM  IPTG 
𝑀𝑢𝑡𝑎𝑛𝑡 𝑝𝑟𝑜𝑚𝑜𝑡𝑒𝑟 𝑠𝑡𝑟𝑒𝑛𝑔𝑡ℎ = � 100, TM1 promoter41.9, TM2 promoter7.9, TM3 promoter 
The pathway modules’ expression levels were calculated as the product of the mutant promoter 
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promoters and IPTG inductions (Figure 4.6), the value of both strengths was estimated with least 
square linear optimization. The maximum levels were arbitrarily assigned as one hundred. As IPTG 
induction has similar effects on different promoters, multiplication between the two values was used to 
obtain the relative expression levels.  
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Strains harboring different pAC-TM-dxs -TM-IDF-TM-ADS plasmids with the combination of TM1, 
TM2, TM3 promoters on three modules and pRepressor plasmid expressing lacI gene were grown in 
the presence of different IPTG concentrations for amorphadiene production. (A, C): amorphadiene 
production in BL21 Gold-DE3 (A) or MG1655 DE3 (C) strains response to the relative expression 
level (a.u.) of three modules calculated by “Equation 1”. The color of the dots indicated the lycopene 
yields. The high production conditions (more than 50% of the maximum yield) are presented in (B) for 
Bl21-Gold DE3 strain and (D) for MG1655 DE3 strain.  
 
In an attempt to investigate the global trend at the dimension of ratios, the percentage 
modules in each construct were calculated according to the strength of mutant 
promoters and ternary plots were employed to illustrate the results. In the plot, each 
vertex of the equilateral triangle represents a pathway modules and the percentage of 
a specific module decreases linearly with increasing distance from its corner (Figure 
4.17, A) where the color of the dots represented the optimized yield obtained at IPTG 
dimension (Figure 4.16, A, B). The plots showed that a global optimum existed in 
both strains but slightly shifted towards more ADS in MG165 DE3 strain (Figure 4.16, 
B) when compared to BL21-Gold DE3 strain (Figure 4.16, A). On the whole, the 
conditions surrounding the global optimum have a higher yield than the far away ones. 
This kind of general reverse correlation indicated that the system has hit a global 
boundary, possibly due to the metabolic burden caused by high expression. On the 
other hand, the presence of several local optima, especially in BL21-Gold strain, 
suggested that there were local minor boundaries encountered. The global boundary 
leading to a continuous change in the yield throughout the search space allowed the 
rapid optimization of the pathway through a rational approach (Figure 4.17, B-D).  
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Figure 4.16 Ternary plot representation of the amorphadiene production 
(A): BL21-Gold DE3 strain, DXP pathway, (B): MG1655 DE3 strain, DXP pathway and (C) MG1655 
DE3 strain, MVA pathway. The percentage of each module was calculated based on “Equation 1”. 
Only the optimum amorphadiene yields at various IPTG concentrations were presented at each point 
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Figure 4.17 Ternary plot of amorphadiene response to ratios of three modules 
(A), illustration of a ternary plot. Each species (A, B or C) is 100% at the corner of the equilateral 
triangle and every point represents a different composition of the three components. By drawing 
parallel lines along the borders, the percentage of each species is equal to the length of the line aiming 
at the opposite border; (B), illustration of the rational optimization process. The red cycled points 
indicated the initial screening experimental conditions which separated the space into six regions (I, II, 
III, IV, V, and VI). Based on the yields at various points, the follow-up focused experiments were then 
carried out at selected region or regions defined by dashed lines in (C), (D); (C, D): ternary plot of 
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calculated based on “Equation 1”. Only the optimum amorphadiene yields at various IPTG 
concentrations were presented at each point and the color of the dots indicate the yield. The regions 
defined by dashed lines indicate the focused conditions resulting from the initial screening study.  
 
4.2.8 Applying the univariant controlling approach for MVA pathway 
optimization 
Next, the same approach was utilized to optimize the MVA pathway for 
amorphadiene production. The pathway was separated in to three modules SBR 
(hmgS-aroB-hmgR), KKDI (MVK-PMVK-MVD-idi) and AA (ADS-ispA) according to 
the order of flux (Figure 4.1). The overexpression of ispA was necessary when using 
MVA pathway but not DXP pathway which provides lesser upstream flux so that the 
endogenously expressed ispA is enough for fluxing (data not shown). By tuning the 
overall expression, an optimum could be identified for each strain as usual (Figure 
4.13, C). Notably, the MVA pathway was more sensitive to the tuning of promoters 
(Figure 4.13, C) comparing to DXP pathway (Figure 4.13, A, B).  The clear optimal 
(pAC-TM3-SBR-TM2-KKDI-TM3-AA) and two suboptimal (pAC-TM2-SBR-TM1-
KKDI-TM3-AA and pAC-TM3-SBR-TM1-KKDI-TM3-AA) revealed that a higher 
expression of KKDI module than the SBR module as well as a minimum expression 
of AA module was critical for the high production of amorphadiene. The same 
conclusion could be drawn from the ternary plot (Figure 4.16, C) where the global 
optimum located at a small corner area. The yields in this focused optimum region 
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were distinctly higher than the rest of the conditions (the color representation for 
amorphadiene yield is in exponential scale). 
 
4.2.9 Extracellular accumulation of DXP pathway intermediates during 
optimization 
The efflux of DXP pathway intermediates when the pathway was overexpressed has 
been discussed (Chapter 3). To further investigate the optimization process, 
extracellular accumulated metabolites of DXP pathway were measured for the Bl21-
DE3 Gold strain in conditions for amorphadiene production optimization and DXP (1-
Deoxy-D-xylulose 5-phosphate, product of dxs), MEC ((E)-4-Hydroxy-3-methyl-but-
2-enyl pyrophosphate, product of ispF) were found to be significantly accumulated 
(Figure 4.18, A). Reasonably, more DXP were accumulated when a stronger promoter 
(TM1) was applied to the dxs module (Figure 4.19, B, TM-dxs = 1). Examining the 
responses of various modules to IPTG induction carefully, at conditions optimum for 
amorphadiene production, significantly lesser amounts of DXP accumulated in the 
medium (Figure 4.19, A, B compare amorphadiene and DXP). By tuning the overall 
expression level, an optimum could be identified with minimized leakage of pathway 
intermediates. With the rest of the conditions (Figure 4.19, B, TM-dxs = 2, 3), DXP 
accumulated occasionally without a clear trend indicating the complexity of the 
process.    
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MEC accumulated to a higher level than DXP. Surprisingly, a similar response of 
MEC and amorphadiene could be found (Figure 4.19, A, B, compare amorphadiene 
and DXP). As a secondary product of the pathway due to the limitation of 
downstream enzymes, the yield of MEC was well correlated with amorphadiene at all 
conditions (Figure 4.18, B) and the ternary plot only differed slightly (Figure 4.18, C). 
This meant that certain global parameter or the upstream part of the pathway (up to 
ispF) was the major limiting factor that was optimized for both products. However, 
the extra high local area (pAC-TM3-dxs-TM2-IDF-TM2-ADS) observed in ternary 
plot of MEC (Figure 4.18, C) did not exhibit low expression for ADS module which 
had no direct relationship with MEC accumulation indicating that the pathway 
optimization was a interrelated process.  
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Figure 4.18 Extracellular metabolites accumulation 
Extracellularly accumulated metabolites of DXP pathway were measured for BL21-Gold DE3 strain in 
conditions same as amorphadiene production optimization through DXP pathway. (A): efflux of DXP 
pathway intermediates into the growth medium. DXP (1-Deoxy-D-xylulose 5-phosphate) and MEC 
((E)-4-Hydroxy-3-methyl-but-2-enyl pyrophosphate) were found highly accumulated in the medium; 
(B): correlation between amorphadiene and extracellular MEC. All the conditions were presented; (C): 
ternary plot representation of the extracellular MEC concentrations responded to the ratios of pathway 
modules’. Only the optimum amorphadiene yields at various IPTG concentrations were presented at 
each point and the color of the dots indicate the response yield. 
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Figure 4.19 Accumulation of MEC and DXP in the medium  
BL21-Gold (DE3) strains harboring pAC-TM-dxs-TM-IDF-TM-ADS plasmid with combinations of 
TM1, TM2, TM3 promoters and pRepressor plasmid (expressing lacI gene) were grown in the presence 
of different IPTG concentrations. The combination of pathway modules were presented at X axis and 
the IPTG concentrations were presented as different colored bars. The concentrations of amorphadiene 
(A), MEC (B) and DXP(C) in the medium were measured at the end point. To note that one molecule 
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4.3 Discussion 
To engineer a biological process, the expressions of the related genes are the most 
commonly and useful method to increase productivity. For pathway optimization, 
combinations of different promoters (e.g, lac, T7, T5, BAD etc) and recombinant gene 
carriers (various plasmids or genome) are widely used in current practices, which is 
highly unsatisfactory due to lack of predictability. As a result, most of the studies only 
managed to vary and optimize one parameter at a time and those bottom-up 
approaches reflect no insight in the global status of the systems. To address this with a 
top-down approach, decomposed of the whole pathway into two modules where 
expressions were separately controlled by well characterized independent tunable 
promoters were initially carried out. The ease of control of individual inducers 
allowed the simultaneous and continuous alteration of the expressions of both 
modules and revealed a global optimum within the expression range. But this 
multivariate strategy is not ideal as most of the naturally tunable promoters in 
microbes used sugars as regulators. The sugar inducers may complicate the system as 
they are limited by the transportation system and may affect cellular metabolism [244] 
while any perturbation of the global system will have distinct effects on each 
promoter, raising the difficulty in using multiple of them simultaneously. Together 
with the limitation of their dynamic range in tuning and the irrational nature of this 
multivariate approach, it can be impractical for manipulating multiple modules.  
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Rather than treating each module separately, another rational univariant controlling 
method was then developed by decomposing the regulatory process into two 
orthogonal dimensions: the overall expression level and the ratios between modules. 
The modulation of two dimensions was realized using a dependent tunable promoter 
library where promoter members share the same transcription resource - T7 RNA 
polymerase and a common mechanism of action so that the former dimension could 
be conveniently achieved by varying the availability of the inducer – IPTG. At the 
same time, mutations were specifically introduced to the melting/initiation region of 
the promoter making their relative strengths constant so that the ratio of modules was 
solely defined by the cognate promoters. The independence of two dimensions was 
validated at conditions when the promoters were used separately or together. With a 
wide dynamic range on both dimensions, the method comprehensively and 
continuously covers a board space allowing a systematic search for the optimum 
condition of three pathway modules. In addition, a rational approach can be applied to 
accelerate the optimization process, especially with complicated multiple module 
systems. 
As kinetic events and confounded by multiple feedback controls and global factors, 
little is known about the mechanism of pathway optimization. The production of 
pathway enzymes has now been shown to act as burdens to the cell, possibly due to 
the synthesis of unnecessary proteins or the formation of inclusion bodies when they 
were profusely produced inside the cell [115]. As a result, an optimum overall 
expression level could not be consistently predicted by tuning the IPTG concentration. 
C h a p t e r  4                                              P a g e  149 
 
Examining the other dimension of tuning in a ternary plot, a clear global optimum 
existed in all tested systems indicating the existence of major bottle necks which were 
presumably different for various systems as the MVA pathway was found to be much 
more sensitive to tuning than the DXP pathway. The information gained can serve to 
guide the identification of novel bottle necks. Further optimization to the system will 
no longer involve tuning the expression of the genes but other factors, e.g. strains, 
growth medium etc. This is important because by knowing the limits, other potential 
directions can be explored with confidence. For example, when studies were carried 
out initially with BL21-Gold (DE3) strain and later to MG1655 DE3 strain, different 
locations of the global optimum were identified in the ternary plot where the optimal 
values were comparable.  
When optimizing DXP pathway for amorphadiene production, the amount of 
intermediates released extracellularly responded distinctly to pathway tuning – MEC 
had a similar profile as amorphadiene while DXP was inversely correlated when the 
dxs module was highly expressed. An obvious kinetic difference between these may 
possibly be due to DXP being re-consumed by the cell but not MEC, which further 
increase the complexity of the optimization task. Despite all these confounding 
mechanisms, the univariant control method described herein provides a systematic, 
rational and robust tool for the modulation of multiple genes for metabolic pathway 
optimization. 
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4.4 Conclusion 
A univariant control method was established for the multivariate engineering of 
pathway modules by tuning two dimensions: the ratios between the modules and the 
overall expression defined with biological principles. The tuning of the ratios 
balanced the activity of pathway enzymes so as to minimize the accumulation of 
unwanted intermediates. While the overall expression level is related to metabolic 
flux and metabolic burden, the fine tuning balanced these two competing parameters. 
A well characterized and designed T7 promoter library was established which enabled 
the orthogonal regulation at these two dimensions.  
Comparing to other less systematic methods which attempt to modulate different 
pathway modules separately, the method described in this chapter allowed searching 
of a broad gene expression space with minimal effort. Moreover, the optimize systems 
were more tolerant to global and environmental changes.  
Applying the tools, combinatorial engineering of DXP or MVA pathway for 
isoprenoids production were carried out. Global optima were identified and at these 
conditions, large enhancements on the yields (> 40 fold for DXP pathway and > 1000 
fold for MVA pathway) were observed.   
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4.5 Methods 
4.5.1 Bacteria strains and Plasmids construction 
All the plasmids used in this study were summarized in “Table 4.2”. The original 
vector pBAD-B was purchased from Invitrogen and pET-11a was purchased from 
Stratagene. RK2A vector (pJB864) [252] was required from National BioResource 
Project (NBRP). All the E. coli genes were cloned from cDNA of E coli. MG1655 
strain from ATCC and amorphadiene synthase was codon optimized and synthesized 
from Genscript. The CLIVA method was used to generate mutant promoters and to 
combine multiple modules for amorphadiene production in to one (pAC) vector. E. 
coli XL10-Gold strain (Invitrogen) or DH10B strain (NEB) was used for plasmid 
construction. E. coli K-12 MG1655 DE3 was from paper [222] and E. coli BL21-Gold 
(DE3) strain was from Stratagene. Both strains carrying T7 RNA polymerase were 
used for isoprenoid production. 
Table 4.2 Plasmids used in this study 
Part I: Plasmid composition 
Name Vector Promoter Genes 
pETK  pETK T7 non 
pETK-T7-SIDF pETK T7 dxs-idi-ispD-ispF 
pAC-LYC pAC Constitutive crtE-crtB-crtI 
pBAD-crtEBI pBAD pBAD crtE-crtB-crtI 
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pAC-BAD-crtEBI pAC pBAD crtE-crtB-crtI 
pAC-T7-crtEBI pAC T7 crtE-crtB-crtI 
pAC-T7-ADS pAC T7 ADS 
pAC-T7-AA pAC T7 ADS-ispA 
pETK-T7-eGFP pETK T7 eGFP 
pETK-T7-dxs pETK T7 dxs 
pETK-T7-idi pETK T7 idi 
pETK-T7-IDF pETK T7 idi-ispD-ispF 
pETK-T7-t-dxs pETK T7 N.dxs 
pETK-T7-t-idi pETK T7 N.idi 
pETK-TM1/2/3-SIDF pETK TM1/TM2/TM3 dxs-idi-ispD-ispF 
pAC-TM1/2/3-crtEBI pAC TM1/TM2/TM3 crtE-crtB-crtI 
pETK-TM1/2/3-dxs pETK TM1/TM2/TM3 dxs 
pAC-TM1/2/3-ADS pAC TM1/TM2/TM3 ADS 
pAC-TM1/2/3-AA pAC TM1/TM2/TM3 ADS-ispA 
pRepressor pETK Constitutive lacI 
RK2A-T7-IDF Rk2A T7 idi-ispD-ispF 









pETK-T7-SBR pETK T7 hmgS-aroB-hmgR 
pETK-TM1/2/3-SBR pETK TM1/TM2/TM3 hmgS-aroB-hmgR 
RK2A-T7-KKDI Rk2A T7 MVK-PMVK-MVD-idi 









pETK- T7-eGFP-tag1 pETK T7 eGFP-tag1 
pETK- T7-eGFP-tag2 pETK T7 eGFP-tag2 
pETK- T7-eGFP-tag3 pETK T7 eGFP-tag3 
pETK- TM1/2/3-eGFP-tag1 pETK TM1/TM2/TM3 eGFP-tag1 
pETK- TM1/2/3-eGFP-tag2 pETK TM1/TM2/TM3 eGFP-tag2 
pETK- TM1/2/3-eGFP-tag3 pETK TM1/TM2/TM3 eGFP-tag3 
 
Part II: Plasmid construction 
Name Construction 
pETK  Replace the Ampicillin resistance gene of pET-11a with 
kanamycin resistance gene by ligation 
pETK-T7-SIDF Inserted into pETK one by one by ligation 
pAC-LYC From paper [226] 
pBAD-crtEBI Amplified from pAC-Lyc and inserted into pBAD-B one by 
one by ligation 
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pAC-BAD-crtEBI Replace the vector of pBAD-crtEBI with pAC vector by 
CLIVA method 
pAC-T7-crtEBI Replace the promoter of pAC-BAD-crtEBI with T7 promoter 
by ligation 
pAC-T7-ADS Replace the gene of pAC-T7-crtEBI with ADS by ligation 
pAC-T7-AA Replace the gene of pAC-T7-crtEBI with ADS and ispA by 
ligation 
pETK-T7-eGFP Amplified from pIRES-eGFP and inserted into pETK by 
ligation 
pETK-T7-dxs Inserted into pETK by ligation 
pETK-T7-idi Inserted into pETK by ligation 
pETK-T7-IDF Inserted into pETK one by one by ligation  
pETK-T7-t-dxs Remove the RBS and start codon of pETK-T7-dxs 
pETK-T7-t-idi Remove the RBS and start codon of pETK-T7-idi 
pETK-TM1/2/3-SIDF Modify the promoter of pETK-T7-SIDF by CLIVA method 
pAC-TM1/2/3-crtEBI Modify the promoter of pAC-T7-crtEBI by CLIVA method 
pETK-TM1/2/3-dxs Modify the promoter of pETK-T7-dxs by CLIVA method 
pAC-TM1/2/3-ADS Modify the promoter of pAC-T7-ADS by CLIVA method 
pAC-TM1/2/3-AA Modify the promoter of pAC-T7-AA by CLIVA method 
pRepressor Remove the T7 promoter, RBS and T7 terminator of pETK 
RK2A-T7-IDF Replace the vector of pETK-T7-IDF with RK2A vector by 
CLIVA method 




Combine the modules amplified from: pETK-TM1/2/3-
dxs, pAC-TM1/2/3-ADS and RK2A-TM1/2/3-IDF into 
pAC vector by CLIVA method 
pETK-T7-SBR The Yeast genes (Saccharomyces cerevisiae) were inserted 
into pETK one by one by ligation 
pETK-TM1/2/3-SBR Modify the promoter of pETK-T7-SBR by CLIVA method 
RK2A-T7-KKDI The Yeast genes (Saccharomyces cerevisiae) were inserted 
into RK2A-T7 one by one by ligation 




Combine the modules amplified from: pETK-TM1/2/3-
SBR, pAC-TM1/2/3-AA and RK2A-TM1/2/3-KKDI 
into pAC vector by CLIVA method 
pETK- T7-eGFP-tag1 Inserted into pETK by ligation. Tag1 was amplified 
from crtE. 
pETK- T7-eGFP-tag2 Inserted into pETK by ligation. Tag2 was amplified from 
crtE. 












Modify the promoter of pETK- T7-eGFP-tag3 by CLIVA 
method 
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4.5.2 Culture medium and growth conditions 
2xPY medium was prepared: peptone 20 g/L, yeast extract 10 g/L and NaCl 10 g/L, 
adjust pH=7.0, autoclaved at 121 °C for 20 mins. An additional 10g/L glycerol (for 
DXP pathway) or glucose (for MVA pathway), 50mM HEPES buffer (pH=7.4) and 
0.5% Tween 80 was added to 2xPY medium for isoprenoid production. The 
antibiotics were added at various concentrations to maintain the selection: ampicillin 
(100 mg/L), chloramphenicol (34 mg/L) and kanamycin (50 mg/L). 1% (v/v) of 
overnight grown cell culture was inoculated and cells were grown at 28 °C with 300 
RPM shaking for isoprenoids production. The inducers (L-arabinose or IPTG) were 
added when the cells’ optical density at 600nm reached the range of 0.6~0.8. For 
lycopene production, 1ml of cells was grown for 48 hours in 14mL BD Falcon™ tube. 
For amorphadiene, 0.8ml of cells together with 0.2ml of dodecane were grown for 72 
hours in 14mL BD Falcon™ tube [253].  
4.5.3 Lycopene and amorphadiene assay 
Intracellular lycopene content was extracted from 20-100 μL (depending on the 
content of lycopene in cells) of bacterial culture. The cell pellet was washed for about 
30~40 min and completely resuspended in 100 μL D.D. H2O. 20 μL of suspension 
was then extracted in 180 μL of acetone at room temperature for about 15 min with 
continuous vortexing and centrifuged at 2,800 g for 3 mins. The lycopene content in 
the supernatant was quantified through absorbance at 472 nm by microplate reader 
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(Spectra Max 190, Molecular Devices) and concentrations were calculated through a 
standard curve. Amorphadiene was quantified by gas chromatography/mass 
spectrometry (GC/MS) by scanning of 189 and 204 m/z ion, using trans-
caryophyllene as internal control and in vitro synthesized amorphadiene as standard 
curve.  
4.5.4 RNA purification and cDNA synthesis 
Total RNA from E. coli was prepared using TRIzol® reagent (Invitrogen) according to 
the manufacturer’s instructions. Total RNA was collected from samples in 
quadruplicate at each treatment time point. RNA concentration was quantified using a 
NanoDrop ND-1000 spectrophotometer (Thermo Scientific), and the 260/280 and 
260/230 ratios were examined for protein and solvent contamination. The integrities 
of all RNA samples were confirmed by formaldehyde agarose gel. 200 ng of total 
RNA were treated with RQ1 RNAse-free DNAse (Promega) and reverse transcribed 
in a total volume of 10 μL containing ImpromII (Promega) for 60 min at 42°C 
according to the manufacturer’s instructions. The reaction was terminated by heating 
at 70°C for 10 min. 
4.5.5 Reverse Transcription and Quantitative PCR (RT-qPCR) 
The cDNA levels were then analyzed using a BioRad iCycler 4 Real-Time PCR 
Detection System (Bio-Rad) with SYBR Green I detection. Each sample was 
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measured in duplicate in a 96-well plate (Bio-Rad) in a reaction mixture (25 µL final 
volume) containing 1x Xtensa Buffer (bioworks), 200 nM primer mix, 2.5 mM MgCl2, 
0.75 U of iTaq DNA polymerase (iDNA). qPCR was performed with an initial 
denaturation of 3 min at 95 ºC, followed by 40 cycles of 20 s at 95 ºC, 20 s at 60 ºC, 
and 20s at 72 ºC. The primers used for real time PCR were given in “Table 4.3”. And 
the reference genes used for real time PCR were cysG. The copies of the genes in 
cDNA were calculated with a standard curve prepared from plasmid DNA and 
presented as copy per copy of cysG. 
  Table 4.3 qPCR primers used in this study 
Gene Forward primer Reverse primer 
dxs CGGCTATCACTATAACGATGG CACGACGCTTCACAATGC 







eGFP GACCACTACCAGCAGAACACC GACCATGTGATCGCGCTT 
tag1 CACGCATCGCAAGGCTGA TGGCTGGCCTGTTACCTGA 
tag2 GGTCAGCCCACTACCCACAA CCCAACGGAGGCAAGGAT 
tag3 CGTCCTTATTGCGATCTTTACCG CAGGCGTTTCAACTGCTGG 
 
4.5.6 In vitro transcription 
Different modules (TM1/TM2/TM3-eGFP-tag1/2/3) were amplified from plasmid. 
Their concentrations were quantified using a NanoDrop ND-1000 spectrophotometer 
(Thermo Scientific) and in the reactions, the modules were added in equal molar. In 
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total, 50 ng of DNA were added into a 5ul in vitro transcription reaction using T7 
RNA polymerase (12.5u) and rNTP (0.5mM each) from NEB according to the 
manufacturer’s instructions. The reactions were carried out at 37 ºC for 2 hours and 
terminated by adding 50ul of DEPC treated water with 0.5mM EDTA. 4 μL of the 
RNAs were then used for RT-qPCR according the described protocols. 
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Chapter 5 A scalable compatible antibiotic-free 
multi-plasmid system (CAMPS) for metabolic 
engineering and synthetic biology 
5.1 Background and motivation 
In modern biotechnology, the fermentation of genetically modified microbes has been 
industrialized for the production of large biomolecules such as protein or DNA. In 
these instances, only limited number of genetic modifications is introduced into the 
cells. With the recent developments in genomics, microbes are now used to produce 
valuable chemical compounds by metabolic engineering and to generate novel 
biological phenotypes by synthetic biology. These processes often involve the 
modifications of one or more intricate biological pathways which necessitate the 
manipulations of multiple genes. 
In bacteria, plasmids are routinely used in metabolic engineering and synthetic 
biology simply because these are easily manipulated and can have multiple copies in 
cells. There are however, significant limitations restricting the utility of multiple 
plasmids in large scale fermentation processes. Firstly, the co-existence of two or 
more incompatible plasmids will invariably be regulated resulting in unstable copy 
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numbers whereby some of these plasmids will be lost over prolong periods of 
fermentation. One approach to circumvent this is to use plasmids that are naturally 
compatible. However, there are only limited numbers of these plasmids with distinct 
copy numbers. These plasmids have different replication mechanisms which are 
known to respond differently to environmental cues making the simultaneous use of 
these plasmids a challenge. Secondly, because they are non-essential for growth, 
plasmids may be lost during the scaling-up process where cells are known to be 
metabolically stressed by the over-expression of genes carried by the plasmid. One 
approach to circumvent this is to use antibiotics to exert selection pressures. 
Unfortunately, the use of antibiotics is both costs prohibitive, unstable in long term 
growth and faces significant regulatory issues. 
Hence, to be industrially relevant, combinatorial panels of plasmids which can stably 
co-exist (compatible) in a cell and grow under selection pressure without the use of 
antibiotics are highly desirable. To address this unmet need, a novel multi-plasmid 
system (Compatible Antibiotic-free Multi-Plasmid System, CAMPS) for the 
expression of multiple GOI carried by a number of multi-compatible plasmids in 
specially engineered host cells and grown in antibiotic-free medium was developed. 
This was designed based on modifying a parental plasmid where the recognition sites 
controlling plasmid copy number were specifically engineered to produce a library of 
compatible plasmids. Thus, these plasmids share the same replication mechanism but 
vary in copy numbers. In order to maintain these multiple plasmids without using 
antibiotics, multiple conditional essential genes (CEG) from the host genome were 
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grafted into these plasmids. As a result, all of these co-existing plasmids carrying the 
CEG were maintained during fermentation. The combination of multiple engineered 
compatible plasmids using the same replication mechanism co-existing in an 
antibiotic free fermentation condition is novel and has broad utility in metabolic 
engineering and synthetic biology. 
 
5.2 Results 
5.2.1 Overview of CAMPS 
To develop this scalable system (CAMPS) for metabolic engineering and synthetic 
biology, an integrated: 1) compatible plasmids and 2) conditional host cell system was 
designed and engineered specifically. These two components functions as one to 
achieve the desired outcome of an antibiotic free multi-plasmid expression system for 
the scale-up production of valued compounds by controlling the expressions of 
multiple genes (Figure 5.1). 
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Figure 5.1 Illustration of CAMPS 
 
5.2.2 Engineering of compatible plasmids 
With the limited availability of natural plasmids that can co-exist in the same cell, the 
aim was to generate compatible plasmids with novel original of replication (Ori) sites. 
How this is engineered is described below. 
It is well known that the replication and copy number of a class of plasmid (such as 
P15A and ColE1) is tightly controlled by the trans-acting factor RNA I [254, 255] as 
∆Ori  - engineered origin of replication (compatible with each other) 
CEG   - conditional essential gene 
……. 
Chromosomal DNA Bacterial cell 
Knock out 
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illustrated in “Figure 5.2” (Original plasmid).  The replication of a plasmid starts with 
the synthesis of the RNA primer – RNA II through the recognition of its promoter by 
RNA polymerase. The synthesized RNA II (in blue) will hybridize with the template 
DNA (the plasmid, in black) except for sequences around its 3’ prime which will form 
stable stem-loop secondary structures.  The RNA II will then be cleaved by RNase H 
(green ellipse) to generate a hydroxyl group recognizable by DNA polymerase I (Pol I, 
purple ellipse) which can synthesize the DNA primer to initiate replication. On the 
other hand, a promoter on the opposite strand will produce RNA I (in blue) – a short 
RNA complementary to the 3’ prime sequences of RNA II. The RNA I and RNA II 
will form symmetrical stem-loop structures exposing complete complementary 
sequences at each loop. Those sequences promote the annealing of RNA I and RNA II 
with the aid of Rom protein (red ellipse) to form a RNA-RNA hybrid which blocks 
the cleavage site for RNase H and in turn stops the replication. Inside each cell, the 
concentration of the inhibitor – RNA I, will increase with the increasing number of 
plasmid which forms a dynamic feedback process controlling the plasmid copy 
number. Thus, by modulating the promoters and expression levels of these RNAs, it is 
possible to change the copy numbers of the plasmids [256].  Furthermore, if another 
plasmid with the same Ori site coexists, both plasmids will generate identical RNA I 
and RNA II sequences and these will compete for interactions and inhibit the 
replication of each other (Figure 5.2 – Incompatible plasmid). This phenomenon 
called ‘incompatibility’ will destabilize the copy numbers of both plasmids resulting 
in the loss of a less favorable one (due to size, sequences, GOI etc). 
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Illustration of the mechanisms involved in the regulation of plasmid replication; the detailed 
description can be found in the main text. Original Plasmid section (white): the mechanism of the 
replication of p15A plasmid. Incompatible Plasmid section (red): the mechanism of incompatibility 
caused by the coexisting of plasmid with the same origin of replication. Compatible Plasmid section 
(blue): the design of novel plasmids and the mechanism of their compatibility. 
 
Based on this known mechanism of replication, a set of novel plasmids (Figure 5.2 – 
Compatible plasmid) to avoid the incompatibility issue was redesigned and 
genetically engineered. The result was that an unlimited panel of plasmids that do not 
exist in nature and the sites of modifications are unique were generated. As the 
desired sites to be modified could not be predicted in silico with precision, all the 
designs were empirically validated.  
The key step in replication, which can result in plasmid incompatibility, is the 
annealing of RNA I and RNA II to the recognition sites.  A hypothesis was that by 
altering the loop sequences it should be possible to modify the recognition (Figure 5.2 
– Compatible plasmid, red sequences) step. These engineered plasmids could then be 
compatible with the original parental plasmid. Precisely which nucleotide and the 
number of nucleotides on the loop to be modified was determined empirically as the 
effect of loop sequence on complex stability did not appear to vary simply with the 
number of potential Watson–Crick base-pairs that can be formed. For example, 
sequences that produce inverted loops can result in extremely low copy numbers 
[257]. In addition, single nucleotide changes in the sequences of RNA I/RNA II 
overlap can alter the affinity of their interaction but can maintain the complementarity 
of the sequences. This built-in tolerance to point mutations is thought to facilitate the 
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mutational fine-tuning of the system to maintain the existence of compatible plasmids 
and exclude incompatible plasmids with only minor changes [256]. As a result, with 
single nucleotide changes, the incompatibility properties can only be altered to a 
limited extent [258, 259]. Thus, to modify the sequences to achieve compatibility of 
multiple plasmids for our use it required experimentation and was not obvious by in 
silico prediction. 
To date, other than using naturally occurring compatible plasmids, there is no 
example of multiple plasmids system engineered based on RNA I/II interaction. To 
create a large plasmid library whereby members are not only compatible with the 
parental plasmid but also with other members in the library, the engineered sites on 
the loops need to be sufficiently different between different plasmids. Targeting at the 
loop sequences, a number of modifications to enable these plasmids to be compatible 
were empirically identified. 
At the same time, because the synthesis of RNA I and RNA II of the same plasmid 
share the same DNA template, the copy number control mechanism will be retained 
for each member. Thus, by engineering the Ori sites, plasmids that shared the same 
replication mechanism as the parental which will be similarly regulated upon 
environmental changes were generated.  
To demonstrate the idea, the second loop in the stem-loop structures of the origin of 
replication of the vector pAC vector, p15A Ori was generated [260]. A series of new 
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plasmids with unique 2nd loop sequences were constructed by site-directed 
mutagenesis and the screened plasmids showed a range of copy numbers. Selected 
plasmids were then tested and confirmed to be compatibility with the original one and 
with each other. 
5.2.3 Construction of artificial multi-compatible plasmids 
In order to construct multiple compatible plasmids based on the designs described 
above, site-directed mutagenesis was carried out to mutate the 2nd loop of p15A Ori 
[260] (Figure 5.3, A). A pair of primers with 5 degenerate bases targeting the loop 
sequences (TGGTA) was used to amplify T7-ADS-ispA-Cam-p15A-PAC plasmid. 
Both primers were pre-modified with thiophosphate and the PCR products were 
specifically cleaved with iodine/ ethanol solution to generate single strand DNA 
overhangs. The mutated plasmids were formed by the annealing of two 
complementary overhangs and then transformed into E. coli. After overnight culture, 
twenty randomly selected colonies were amplified and the plasmids were sequenced. 
Only two plasmids had the same sequences at the 2nd loop: TTCCC (Figure 5.3, B, 
number 2 and 8) and one plasmid had 4 bps instead of 5 (Figure 5.3, B, number 10) 
possibly due to the impurity of the degenerate primer. Those new Ori sites were 
named p15AL2-1 to p15AL2-20. The plasmids were then separately transformed into 
MG1655 DE3 strain for copy number measurement. For each plasmid, two random 
colonies were picked and the copy numbers were measured by qPCR (Figure 5.3, B) 
by normalizing to genomic DNA. The concentrations of the extracted plasmids were 
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similar to the copy numbers measured by qPCR (Figure 5.3, C). Half of the panel of 
plasmids had similar copy numbers (16-20 copies per copy of genome) when 
compared to the original parental plasmid (Figure 5.3, C, control) while the other half 
had higher copy numbers from 20 to 110 copies per copy of genome. Thus, a library 
of newly engineered plasmids with varying copies was constructed. 
 
Figure 5.3 Construction of compatible plasmid library 
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(A), Illustration of the thiophosphate mediated site-directed mutagenesis used to engineer the 2nd loop 
of p15A Ori site; (B), the copy number of screened plasmids with artificial Ori sites in MG1655, DE3 
strain measured by qPCR; The mutants’ 2nd loop sequences were presented in X-axis and the original 
one was used as the control (sequence: TGGTA). Except the control, all the plasmids were ascendingly 
sorted according to their copy numbers. Two biological replicates were carried out for each condition 
and the standard errors were presented. (C), the concentrations of extracted plasmids; the same amount 
of cells were used for column based plasmid extraction and the same amount of water were used to 
elute the plasmid. 
 
5.2.4 Compatibility test of multi-compatible plasmids 
As a proof-of-concept, multiple plasmids with different engineered Ori sites were 
tested for compatibility. The original site (p15A) and two engineered sites (p15AL2-5 
and p15AL2-8) were inserted into different plasmids together with various antibiotic 
resistant genes (Figure 5.4, A; Figure 5.5, A). Plasmids with these engineered sites 
have similar copy numbers in cells. These plasmids carried antibiotic resistant genes 
simply to enable the ease of selecting for the multiple plasmids. 
Firstly, a kanamycin (Kan) resistant plasmid with the original Ori site (T7-dxs-Kan-
p15A) was co-transformed with each of the three Ori sites carrying the 
chloramphenicol (Cam) resistant plasmid (T7-ADS-ispA-Cam-p15A, T7-ADS-ispA-
Cam-p15AL2-5 or T7-ADS-ispA-Cam-p15AL2-8). Both Kan and Cam were used 
initially to maintain the plasmids. In subsequent constructions, these would be 
substituted with CEG and conditionally rescued with the appropriate products (see 
below section). A comparison of the copy numbers in cells carrying single plasmid or 
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dual-plasmid were carried out (Figure 5.4, B). As expected, cells with dual-plasmid of 
the same Ori sequences (Cam-p15A or Kan-p15A) showed significantly lower copy 
numbers as compared to cells carrying just a single plasmid (Kan-p15A) even when 
antibiotics were supplied to force the maintenance of both plasmids. The behaviors of 
these dual-plasmid systems were then further studied in conditions where Kan, Cam 
or both antibiotics were removed from the medium to release the selection pressure 
(Figure 5.4, C).  The dual-plasmid cells with different Ori sites (engineered as 
described above) had identical performances in all conditions proving the plasmid 
incompatibility problem and that there was no interaction between the engineered Ori 
with the original one. Instead, the plasmids with identical Ori (Kan-p15A and Camp-
p15A) showed variable copy numbers. For example, the removal of Cam (Kan or No 
antibiotics conditions) induced the loss of Cam-p15A plasmid (Figure 5.4, C, Cam 
plasmid, Kan-p15A/Cam-p15A group) and at the same time resulted in a higher copy 
number for the competing plasmid (Kan-p15A) comparing to the dual-antibiotic 
condition (Figure 5.4, C, Kan plasmid, Kan – p15A/Cam – p15A group). These 
evidences support the idea that plasmids with engineered novel Ori sites were 
compatible with the original parental plasmid, co-existing in the same cells. 
To further validate the compatibility between two artificial Ori sites where the loop 
sequences differed only by 2 bases, cells carrying two groups of plasmids differ only 
by the Ori sites were compared. Both groups had three plasmids with either 
kanamycin (Kan), chloramphenicol (Cam) or spectinomycin (Spec) resistant genes 
respectively. All the plasmids in the “Original group” (T7-ADS-ispA-Cam-p15A, T7-
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dxs-Kan-p15A and T7-ADS-ispA-Spec-p15A) had p15A as their Ori sites while the 
“Engineered group” (T7-ADS-ispA-Cam-p15AL2-5, T7-dxs-Kan-p15A and T7-ADS-
ispA-Spec-p15AL2-8) were consisted of plasmids with different Ori sites (Figure 5.5, 
A). As expected, in the presence of all three antibiotics, the copy numbers of the 
plasmid in the “Original group” were significantly lower than with cells harboring a 
single plasmid (control), consistent with the idea that the replication of these 3 
plasmids (with identical Ori sequence) were affected by the presence of each other 
(Figure 5.5, B) while the “Engineered Group” was unaffected.  Furthermore,  in the 
absence of an antibiotic, the copy numbers of the three plasmids varied in the 
“Original group” as compared to the “Engineered group” where the copy numbers 
were consistently high (Figure 5.5, C). The results of this triple-plasmid study 
confirmed that plasmids with engineered Ori sites were compatible and can co-exist in 
the cells. Based on this, a multi-compatible plasmid system containing large number 
of plasmids can be easily established by introducing other mutations to the stem-loop 
sequences to create artificial Ori sites, which will be invaluable for studies involving 
the manipulation of multiple genes or pathways. 
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Figure 5.4 Compatibility test for dual-plasmid system 
(A), the 2nd loop sequences of three selected Ori sites (p15A, p15AL2-5, p15AL2-8), the plasmids 
used in the study and their abbreviations; B,C, the copy numbers of the original (T7-ADS-ispA-Cam-
p15A, T7-dxs-Kan-p15A) and artificial (T7-ADS-ispA-Cam-p15AL2-5, T7-ADS-ispA-Cam-p15AL2-
8) plasmids at various standing along or coexisting conditions in MG1655, DE3 strain when all 
relevant antibiotics (B) or only selected antibiotics (C)  were supplied to the medium. The copy 
numbers were measured by qPCR. Kan-plasmid: the plasmids carrying kanamycin (Kan) resistant gene. 
Can-plasmid: the plasmids carrying chloramphenicol (Cam) resistant gene. Three biological replicates 
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Figure 5.5 Compatibility test for triple-plasmid system 
(A), the 2nd loop sequences of three selected Ori sites (p15A, p15AL2-5, p15AL2-8) and the two 
groups of plasmids used in the study (Original group and Engineered group); B,C, the copy numbers of 
the plasmids when all relevant antibiotics (B) or only selected antibiotics (C)  were supplied to the 
medium. The plasmids were introduced into MG1655, DE3 strain either by groups (Original, 
Engineered) or separately (control) and measured by qPCR. The Kan-plasmid: the plasmids carrying 
kanamycin (Kan) resistant gene. Cam-plasmid: the plasmids carrying chloramphenicol (Cam) resistant 
gene. Spec-plasmid: the plasmids carrying spectinomycin (Spec) resistant gene. Three biological 
replicates were carried out for each condition and the standard errors were presented. 
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5.2.5 Design of conditional host cell system 
As discussed above, a significant disadvantage of using plasmid is the potential loss 
during cell growth and this can be averted by selection pressure using antibiotics. 
Various approaches to maintaining single plasmids without the use of antibiotics in 
bacteria [261] include the manipulation of essential genes such as dnpD [262], glyA 
[263],  fabI [264], murA [265] acpP [266] or the use of antidote/poison system [184]. 
With multiple plasmids, however, the situation is more complex and will depend on 
the products to be manufactured. As yet, there has not been any demonstration of the 
use of these methods for the maintenance of multi-plasmid where multiple GOI are 
required to be simultaneously expressed and the plasmids stably maintained 
simultaneously.  
A universal workflow to construct a multiple-plasmid/ host system by generating 
auxotroph host and complementing with conditional essential genes (CEG) was 
developed. By knocking out multiple CEG in a host genome and at the same time 
placing them separately on various plasmids, only cells with all the essential 
components – the genome and all the plasmids with CEG will survive (Figure 5.6). A 
significant challenge was the construction of these multiple knockout strains as 
removing CEG will usually be non-viable in the minimal medium used [267]. With 
cost consideration, industrial fermentations usually are carried out in minimal medium 
with either glucose or glycerol as carbon source. Using genes that were essential in 
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minimal medium but were dispensable in rich medium allowed a way to conveniently 
generate multiple knockout strains by culturing the cells in rich medium (Figure 5.6).  
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Illustration of the workflow to construct a multi-plasmid system which can be stably maintained inside 
the engineered E. coli host without the usage of antibiotics; 
 
Not all metabolic enzymes are essential for growth. Hence, the knock-out of an 
enzyme in a pathway can be compensated by alternative biosynthetic pathways or the 
availability of isoenzymes, the existence of alternative enzymes and even broad 
specificity or multifunctional enzymes [268]. Whether certain isozymes and 
alternative enzymes can complement for the missing one depends also on the 
expression levels and active states of the enzymes in that particular condition of 
growth. It was then obvious that these redundancies and unpredictability will make 
selection of pathways and enzymes to knock-out for the purpose describe below a 
daunting task. 
Not all CEG are suited for our purpose of multi-plasmid systems (section A). 
Recently, an antibiotic-free plasmid selection system based on glycine auxotrophy 
(glyA inactivation) for overproduction of recombinant protein in bacteria displayed 
diauxic growth and the production of side products [263]. It is currently unknown if 
this is simply due to the perturbation of the auxotrophic metabolic pathway involved 
or other factors yet to be determined. Similarly, such antibiotic-free plasmid selection 
system based on leucine auxotrophy for the production of an enzyme showed lower 
productivity and growth profiles as compared to the control cells [269]. Another 
confounding issue is that reports in literature do not always concur, making selection 
C h a p t e r  5                                              P a g e  176 
 
of CEG even more challenging [270, 271]. Hence, it was necessary to empirically 
determine the best combinations for CEG for our multi-plasmid based system 
(CAMPS).  
The selection of CEG was not easily predicted from current knowledge and available 
resources [272-276]. These databases contained collections of single but not multiple 
genes acting as conditionally or totally essential for growth in certain conditions. 
However, with the CAMPS there was a requirement to knock-out multiple CEG and 
in the process allowed the insertions and rescue of growth by using multiple plasmids 
with complementing CEG. The selection of multiple CEG, essentially metabolic 
enzymes, to knock-out was critical to the performance of the strain in both growth and 
productivity.  
With multiple co-existing compatible plasmids, auxotrophy could be achieved by 
using multiple CEG in series or in parallel of metabolic pathways [277]. The criteria 
necessary for the selection of either of these two approaches may be guided by a 
priori knowledge but had to be empirically established to provide a flexible, 
convenient and robust plasmid based platform for metabolic engineering and synthetic 
biology.  
In order to conveniently introduce large numbers of CAMPS plasmids, sets of one to 
three CEG were distributed into subgroups based on their functionalities. For each 
subgroup, instead of using the complex rich medium, the auxotroph was rescued by 
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the supplementation of specific metabolite that is economic and accessible to the cell. 
As a result, multiple CAMPS plasmids were sequentially or separately introduced into 
corresponding complementary host as subgroups, increasing the flexibility of pathway 
engineering.  
To demonstrate the use of an enzyme in a serial biochemical pathway, three CEG 
from a pool of 94 genes that were thought to be essential in both glycerol and glucose 
minimum mediums but not in rich medium were selected [277] and separately placed 
into three plasmids. The plasmids with these CEG (ΔaroA, ΔaroB and ΔaroC) were 
then shown to be stably maintained in single-plasmid/ host, dual-plasmid/ host and 
triple-plasmid/ host systems. 
5.2.6 Construction of antibiotic-free multiple-plasmid/ host system 
To demonstrate the proposed work flow for the establishment of multiple-plasmid/ 
host system (Figure 5.6), three CEG – aroA (5-enolpyruvylshikimate-3-phosphate 
synthetase), aroB (3-Dehydroquinate synthase) and aroC (Chorismate synthase) in a 
sequential aromatic amino acid biosynthesis pathway [278], were selected and 
inserted into three independent plasmids with different Ori sites: T7-ADS-Cam-aroB-
p15A, T7-dxs-Kan-aroA-pET and T7-CYP450-CPR-Spec-aroC-pCL plasmid. Host 
strains with single or multiple CEG knockouts (Table 5.1) were constructed in 2xPY 
medium (rich medium).  
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Table 5.1 Strains used in the study 
Name Genotype 
MG1655 (DE3) F- λ- ilvG- rfb-50 rph-1 
MG1655 (DE3, ΔaroA) F- λ- ilvG- rfb-50 rph-1 ΔaroA 
MG1655 (DE3, ΔaroB) F- λ- ilvG- rfb-50 rph-1 ΔaroB 
MG1655 (DE3, ΔaroC) F- λ- ilvG- rfb-50 rph-1 ΔaroC 
MG1655 (DE3, ΔaroBC) F- λ- ilvG- rfb-50 rph-1 ΔaroB ΔaroC 
MG1655 (DE3, ΔaroABC) F- λ- ilvG- rfb-50 rph-1 ΔaroA ΔaroB ΔaroC 
MG1655 (DE3, ΔpdxH) F- λ- ilvG- rfb-50 rph-1 ΔpdxH 
MG1655 (DE3, ΔproC) F- λ- ilvG- rfb-50 rph-1 ΔproC 
MG1655 (DE3, ΔpyrF) F- λ- ilvG- rfb-50 rph-1 ΔpyrF 
MG1655 (DE3, ΔargBCH) F- λ- ilvG- rfb-50 rph-1 ΔargBCH 
MG1655 (DE3, ΔaroABC, ΔpdxH) F- λ- ilvG- rfb-50 rph-1 ΔaroA ΔaroB ΔaroC 
ΔpdxH 
MG1655 (DE3, ΔaroABC, ΔproC) F- λ- ilvG- rfb-50 rph-1 ΔaroA ΔaroB ΔaroC 
ΔproC 
MG1655 (DE3, ΔaroABC, ΔpyrF) F- λ- ilvG- rfb-50 rph-1 ΔaroA ΔaroB ΔaroC 
ΔpyrF 
MG1655 (DE3, ΔaroABC, ΔargBCH) F- λ- ilvG- rfb-50 rph-1 ΔaroA ΔaroB ΔaroC 
ΔargBCH 
 
The host and plasmid combinations were then processed for survival test. The strains 
harboring various plasmids were initially generated in rich medium with the addition 
of antibiotics. If there was no observation of growth after 90 hour incubation at 37°C 
with shaking in the specified medium without antibiotics, the strain was considered to 
be non-viable. Based on the survival test, all the single knockout strains (MG1655 
(DE3, ΔaroA); MG1655 (DE3, ΔaroB) and MG1655 (DE3, ΔaroC)) did not grow in 
minimum medium with either glycerol or glucose as carbon source confirming their 
essentialness in minimum medium (Table 5.2). On the other hand, the growth was 
only rescued by supplying the relevant plasmid such as inserting T7-ADS-Cam-aroB-
p15A plasmid expressing aroB into MG1655 (DE3, ΔaroB) strain. At the same time, 
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there was no growth of MG1655 (DE3, ΔaroB) strain with T7-ADS-Cam-p15A 
plasmid in minimum medium confirming that the rescue effects were due to the 
expressions of the CEG in the plasmid. No rescue activity was observed by the 
overexpression of irrelevant CEG by other plasmids confirming that the selected CEG 
could not serve as isoenzymes for each other. Similar observations were also observed 
in other multiple-plasmid systems (Table 5.3). In minimum medium, the MG1655, 
(DE3, ΔaroB) strain could only replicate when carrying both T7-ADS-Cam-aroB-
p15A and T7-CYP450-CPR-Spec-aroC-pCL plasmids while the MG1655 (DE3, 
ΔaroABC) strain needed to carry all three plasmids (T7-dxs-Kan-aroA-pET, T7-ADS-
Cam-aroB-p15A and T7-CYP450-CPR-Spec-aroC-pCL) for survival. Thus, these 
engineered hosts could only survive if they carried the relevant plasmids in minimum 
medium.  





















- Yes No No No 
T7-ADS-Cam-p15A Yes No No No 
T7-ADS-Cam-aroB-p15A Yes No Yes No 
T7-dxs-Kan-pET Yes No No No 
T7-dxs-Kan-aroA-pET Yes Yes No No 
T7-CYP450-CPR-Spec-pCL Yes No No No 
T7-CYP450-CPR-Spec-aroC-pCL Yes No No Yes 
Yes: Growth, No: No growth 
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- No No 
T7-dxs-Kan-aroA-pET 
T7-ADS-Cam-aroB-p15A 











Yes: Growth, No: No growth 
Extending the study, the plasmid copy numbers were measured after 2 day growth in 
minimum medium with no antibiotic selection. IPTG - the inducer for T7 promoter 
was supplied in some of the conditions to create selection pressure to cells harboring 
recombinant proteins expressed under the control of T7 promoter. For single-plasmid/ 
host system, the T7-dxs-Kan-aroA-pET plasmid expressing E. coli native enzyme 
(dxs – 1-deoxyxylulose-5-phosphate synthase) and T7-ADS-Cam-aroB-p15A plasmid 
expressing a plant gene (ADS – amorphadiene synthase) could be retained in both 
native strain (MG1655 (DE3)) and the modified strain (MG1655 (DE3, ΔaroA) or 
MG1655 (DE3, ΔaroB)), where induction of gene expression by IPTG were carried 
out. However, after induction (0.1mM IPTG) both plasmids were lost in the native 
strain but well retained in the modified strains (Figure 5.7, A).  
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Figure 5.7 Plasmid stability test for various plasmid/ host systems  
(A), the plasmid copy numbers of single-plasmid/ host systems measured by qPCR; The T7-dxs-Kan-
aroA-pET, T7-ADS-Cam-aroB-p15A and T7-CYP450-CPR-Spec-aroC-pCL plasmids carrying 
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engineered host with relevant gene knockout. (B), the plasmid copy numbers of dual-plasmid/ host 
system measured by qPCR; both T7-ADS-Cam-aroB-p15A and T7-CYP450-CPR-Spec-aroC-pCL 
plasmids were introduced to MG1655, DE3, ΔaroBC strain. (C), the plasmid copy numbers of triple-
plasmid/ host system measured by qPCR; T7-dxs-Kan-aroA-pET, T7-ADS-Cam-aroB-p15A and T7-
CYP450-CPR-Spec-aroC-pCL plasmids were introduced to MG1655, DE3, ΔaroABC strain together. 
0.1mM of Isopropyl β-D-1-thiogalactopyranoside (IPTG) was supplied in certain conditions to induce 
the genes carried by the plasmids to generate selection stress. Kan-plasmid: the plasmids carrying 
kanamycin (Kan) resistant gene. Cam-plasmid: the plasmids carrying chloramphenicol (Cam) resistant 
gene. Spec-plasmid: the plasmids carrying spectinomycin (Spec) resistant gene. Three biological 
replicates were carried out for each condition and the standard errors were presented. 
The T7-CYP450-CPR-Spec-aroC-pCL plasmid expressing cytochrome p450 enzymes 
from plant, a class of membrane binding enzymes known to cause stress to bacteria 
[279, 280], were lost in the native strain even without IPTG induction while the 
modified strain retained the plasmid under uninduced or induced conditions (Figure 
5.7, A). The dual-plasmid/ host (Figure 5.7, B) and triple-plasmid/ host (Figure 5.7, C) 
systems were also able to retain their plasmids in minimum medium without antibiotic. 
These results demonstrated the stable maintenance of multiple-plasmids in engineered 
host without the need of antibiotic. 
5.2.7 Demonstration of the use of CEG from other pathways 
Three CEG (aroA, aroB and aroC, Figure 5.8) were all selected from the aromatic 
compound synthesis pathway (Figure 5.8). In order to further demonstrate the 
effectiveness of antibiotic-free plasmid/ host system using CEG, genes from other 
pathways that synthesize conditional essential compounds including co-factors, amino 
acids and nuclear acids that could be rescued by growth in rich medium were grafted 
from the E. coli genome to various CAMPS plasmids (Figure 5.8). The pdxH gene 
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encoding the last step of PLP (pyridoxal 5'-phosphate) biosynthesis, the pyrF gene 
encoding the UMP synthase and proC gene encoding the last step of proline 
biosynthesis were placed into the following engineered vectors - p15AL2-9, p15AL2-
4 and p15AL2-4, respectively (Table 5.4). The viability test confirmed that the 
engineered host with CEG knockout could only grow in the minimum medium (with 
glucose as carbon source) in the presence of the appropriate CAMPS plasmid (Table 
5.4, strain 1-3). The plasmids stability were also validated by comparing the plasmid 
copy number of these three strains cultured in minimum medium with or without 
selection stress (induction of recombinant genes ADS and ispA expression with 0.1 
mM IPTG) where there was no difference observed in these two conditions (Figure 
5.9).  
Moreover, the multiple-knockout strains without aroA, aroB, aroC genes and pdxH, 
pyrF, or proC gene in the genome could only survive when all four plasmids carrying 
necessary CEG were present (Table 5.4, strain 5-6). And the strain where the argBCH 
operon encoding three CEG in the biosynthetic pathway of arginine was knocked out 
can only grow in the presence of all the three CAMPS plasmids – T7-ADS-ispA-
Cam-argB-p15AL2-10, T7-ADS-ispA-Cam-argC-p15AL2-6 and T7-ADS-ispA-Cam-
argH-p15AL2-11 (Table 5.4, strain 4). These results lend further evidence that the 
multiple antibiotic-free plasmids expressing the CEG complemented the host where 
these genes were deleted. 
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Figure 5.8 Conditional essential genes in various pathways 
A solid arrow represents a single enzymatic step while a dashed arrow represents multiple enzymatic 
steps. Abbreviation for CEG: pdxH: pyridoxine 5'-phosphate oxidase, aroA: 5-enolpyruvylshikimate-3-
phosphate synthetase, aroB: 3-dehydroquinate synthase, aroC: chorismate synthase, pyrF, orotidine-5'-
phosphate decarboxylase, proC: pyrroline-5-carboxylate reductase, argB: N-acetylglutamate kinase, 
argC: N-acetyl-gamma-glutamylphosphate reductase, argH: argininosuccinate lyase. Abbreviation for 
metabolites: TCA: tricarboxylic acid, G3P: Glyceraldehyde 3-phosphate, PEP: phosphoenolpyruvic 
acid, E4P: D-Erythrose 4-phosphate, α-KG: alpha-ketoglutaric acid, PPP: pentose phosphate pathway, 
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Table 5.4 Survival test of plasmid(s)/ host systems using novel CEG 
Plasmid Strain 1 
 MG1655, DE3 MG1655, DE3, ΔpdxH 
- Yes No 
T7-ADS-ispA-Cam-pdxH-p15AL2-9 Yes No 
Plasmid Strain 2 
 MG1655, DE3 MG1655, DE3, ΔproC 
- Yes No 
T7-ADS-ispA-Cam-proC-p15AL2-4 Yes No 
Plasmid Strain 3 
 MG1655, DE3 MG1655, DE3, ΔpyrF 
- Yes No 
T7-ADS-ispA-Cam-pyrF-p15AL2-1 Yes No 
Plasmid Strain 4 
 MG1655, DE3 MG1655, DE3, ΔargBCH 







Plasmid Strain 5 
 MG1655, DE3 MG1655, DE3, ΔaroABC, ΔpdxH 






Plasmid Strain 6 
 MG1655, DE3 MG1655, DE3, ΔaroABC, ΔproC 






Plasmid Strain 7 
 MG1655, DE3 MG1655, DE3, ΔaroABC, ΔpyrF 





Yes No  
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Yes: Growth, No: No growth. The growth test was carried out in minimum medium with glucose as 
carbon source.  
 
 
Figure 5.9 Plasmid stability test for CAMPS with pyrF, proC and pdxH  
The plasmid copy numbers of single-plasmid/ host systems with or without IPTG induction (0.1 mM) 
were measured by qPCR. The T7-ADS-ispA-Cam-pyrF-p15AL2-1, T7-ADS-ispA-Cam-proC-
p15AL2-4 and T7-ADS-ispA-Cam-pdxH-p15AL2-9 plasmids carrying conditional essential genes 
were introduced to engineered host with relevant gene knockout and cultured in minimum medium 
with glucose as carbon source. 
5.2.8 Introduction of multiple CEG carrying plasmids into engineered host 
The construction of multiple CEG knockout host for antibiotic-free system can be 
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CAMPS faced significant challenge where multiple CEG carrying plasmids were 
required to be transformed into the same host. The co-transformation of plasmids in to 
E. coli is technically difficult, especially for large plasmids encoding multiple 
pathway genes. Practically, at most two plasmids can be introduced into the host at 
once and this will not meet the requirement for CAMPS. One way to transform 
multiple plasmids into the host is to do it one plasmid at a time using different 
antibiotics for selection at each insertion. Unfortunately, there is only limited number 
of antibiotics available and having multiple antibiotic resistant genes will incur 
metabolic burden and hence, is not practical.  
To overcome this, an antibiotic-free approach was proposed for the assembly of 
CAMPS (Figure 5.10). As the rich medium contain essential metabolites for cell 
growth, all the CEG are non-essential when cultured with rich medium. By supplying 
all the specific metabolites used by CEG to the minimum medium, the cell should 
then be able to grow. The externally supplied metabolites can either be the direct 
product of the CEG or the intermediates in the linear metabolic pathway downstream 
of the CEG. With the supply of a combination of these key metabolites, a collection 
of modified minimum medium will allow the switch of CEG between its essential and 
non-essential statuses. By growing the strains with the multiple CEG knocked-out in 
the respective medium supplemented with the appropriate products iteratively, it 
should be possible to assemble strains harboring multiple plasmids with multiple CEG, 
which was performed as described below (Figure 5.10). 
C h a p t e r  5                                              P a g e  188 
 
 
Figure 5.10 Introduction of multiple CEG carrying plasmids into engineered 
host 
The illustration of the antibiotic-free method to introduce multiple CEG carrying plasmids into multiple 
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Firstly, the growth properties of CEG knockout strains in various modified minimum 
mediums were tested.  By supplying the direct product of CEG to the minimum 
medium with glucose as carbon source (MMG) (Figure 5.8), the growth of engineered 
strains was rescued. Examples of this approach were the growth of MG1655 (DE3, 
ΔpdxH) strain when the minimal medium when supplemented with pyridoxal 5'-
phosphate (PLP), the growth of MG1655 (DE3, ΔproC) strain when supplemented 
with proline (PRO), the growth of MG1655 (DE3, ΔpyrF) strain when supplemented 
with Uridine monophosphate (UMP) and the growth of MG1655 (DE3, ΔargBCH) 
strain when supplemented with arginine (ARG) (Table 5.5). Furthermore, the 
engineered strains can also be rescued by supplying metabolites at several steps 
downstream of the medium CEG (Figure 5.8) such as the growth of MG1655 (DE3, 
ΔaroB) strain when the medium was supplemented with shikimate (SK) and the 
growth of MG1655 (DE3, ΔargBCH) strain harboring T7-ADS-ispA-Cam-argH-
p15AL2-11 plasmid when supplemented with ornithine (OR) (Table 5.5). The 
survival test validated that every chosen supplement here was efficiently utilized by 
the cell and complemented the lack of specific CEG (Table 5.5).   
Next, the studies on the use of antibiotic-free procedures of introducing multiple CEG 
carrying plasmids were designed and tested (Table 5.6). For MG1655 (DE3, 
ΔaroABC) strain where all the selected CEG were in a linear pathway, the modified 
strains with T7-dxs-Kan-aroA-pET and T7-CYP450-CPR-Spec-aroC-pCL plasmids 
were firstly transformed into cells grown in the MMG+SK medium where aroB was 
non-essential. The cells were then further transformed with the T7-ADS-Cam-aroB-
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p15A plasmid and selected in MMG medium (Table 5.6, strain 1). Similarly, MG1655 
(DE3, ΔargBCH) strain was generated by introducing T7-ADS-ispA-Cam-argH-
p15AL2-11 plasmid in the first step in cells grown in the MMG+OR medium. Then 
the T7-ADS-ispA-Cam-argB-p15AL2-10 and T7-ADS-ispA-Cam-argC-p15AL2-6 
plasmids were introduced into cells grown in MMG medium (Table 5.6, strain 5). For 
quadruple CEG knockout strains: MG1655 (DE3, ΔaroABC, ΔproC) strain (Table 5.6, 
strain 2), MG1655 (DE3, ΔaroABC, ΔpdxH) strain (Table 5.6, strain 3), MG1655 
(DE3, ΔaroABC, ΔpyrF) strain (Table 5.6, strain 4), three plasmids carrying aroA, 
aroB or aroC genes were first introduced using protocols similar to the assembly of 
MG1655 (DE3, ΔaroABC) strain (strain 1) while additional product (PRO, PLP or 
UMP) was supplied to the relevant mediums for each of the strain. Using MMG 
medium for selection, the last plasmid (T7-ADS-ispA-Cam-proC-p15AL2-4, T7-
ADS-ispA-Cam-pdxH-p15AL2-9 or T7-ADS-ispA-Cam-pyrF-p15AL2-1) was then 
introduced into the corresponding strain in the third step. By combining the 
procedures of stain 1 and strain 5, the assembly protocol for sextuple CEG knockout 
strain: MG1655 (DE3, ΔaroABC, ΔargBCH) strain was similarly carried out (Table 
5.6, strain 6) where ARG was supplied to make argB, argC and argH genes non-
essential while transforming the aroA, aroB, aroC carrying plasmids. The results of 
these studies demonstrated the success in introducing multiple plasmids with a variety 
of CEG by using minimal medium supplemented with the appropriate chemicals 
which were products of the CEG activities.  
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Table 5.5 Survival test of mutant strains in modified minimum medium  
Strain and plasmid Medium 












MG1655, DE3 Yes Yes Yes Yes Yes Yes Yes 
MG1655, DE3, ΔpdxH No Yes No No N.A. No No 
MG1655, DE3, ΔproC No No No Yes N.A. No No 
MG1655, DE3, ΔpyrF No No Yes No N.A. No No 
MG1655, DE3, ΔargBCH No No No No N.A. Yes No 
MG1655, DE3, ΔargBCH 
T7-ADS-ispA-Cam-argH-
p15AL2-11 
No No No No Yes Yes No 
MG1655, DE3, ΔaroB No No No Yes No No No 
MG1655, DE3, ΔaroABC No No No No No No No 
Yes: Growth, No: No growth. N.A.: not aviable (the condition was not tested). The growth test was 
carried out in minimum medium with glucose as carbon source at 37 °C for 6 days with shaking (250 
RPM). MMG: minimum medium with glucose. Chemicals were supplied at 2g/L inside the modified 
minimum medium. Abbreviation for chemicals: PLP: pyridoxal 5'-phosphate, UMP: Uridine 
monophosphate, SK: Shikimate, PRO: Proline, OR: Ornithine, ARG: Arginine. 
Table 5.6 Procedures to introduce multiple CEG carrying plasmids 
Strain 1 Plasmid to transform Step Medium 
MG1655, DE3, ΔaroABC 
T7-dxs-Kan-aroA-pET 
T7-CYP450-CPR-Spec-aroC-pCL 1 MMG+SK 
T7-ADS-Cam-aroB-p15A 2 MMG 







T7-ADS-Cam-aroB-p15A 2 MMG+PRO 
T7-ADS-ispA-Cam-proC-p15AL2-4 3 MMG 







T7-ADS-Cam-aroB-p15A 2 MMG+PLP 
T7-ADS-ispA-Cam-pdxH-p15AL2-9 3 MMG 
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T7-ADS-Cam-aroB-p15A 2 MMG+UMP 
T7-ADS-ispA-Cam-pyrF-p15AL2-1 3 MMG 
Strain 5 Plasmid to transform Step Medium 
MG1655, DE3, ΔargBCH 
T7-ADS-ispA-Cam-argH-p15AL2-11 1 MMG+OR 
T7-ADS-ispA-Cam-argB-p15AL2-10 
T7-ADS-ispA-Cam-argC-p15AL2-6 2 MMG 







T7-ADS-Cam-aroB-p15A 2 MMG+ARG 
T7-ADS-ispA-Cam-argH-p15AL2-11 3 MMG+OR 
T7-ADS-ispA-Cam-argB-p15AL2-10 
T7-ADS-ispA-Cam-argC-p15AL2-6 4 MMG 
MMG: minimum medium with glucose. Chemicals were supplied at 2g/L inside the modified 
minimum medium. Abbreviation for chemicals: PLP: pyridoxal 5'-phosphate, UMP: Uridine 
monophosphate, SK: Shikimate, PRO: Proline, OR: Ornithine, ARG: Arginine. The construction 
procedures of strain 1-5 were experimentally validated and the construction procedure of strain 6 was 
proposed. 
5.2.9 CAMPS for metabolite production 
To demonstrate the utility of CAMPS, the production of amorphadiene through 
mevalonate (MVA) pathway was examined. The genes encoding the pathway 
enzymes were divided into three modules: the SAR module (hmgS, hmgR, atoB), the 
KKDI module (MVK, PMVK, MVD, idi) and the AA module (ADS, ispA). The 
modules were then separately placed into two sets of CAMPS plasmids: the MVA-
213 set (TM2-SAR-Spec-aroC-p15A-1, TM1-KKID-Cam-aroB-p15A-8, TM3-AA-
Kan-aroA-p15A) and the MVA-323 set (TM2-SAR-Spec-aroC-p15A-1, TM1-KKID-
Cam-aroB-p15A-8, TM3-AA-Kan-aroA-p15A) where they were under the control of 
T7 promoter mutants of different strengths of controlling transcription (Figure 5.12, 
A). The combinations of mutant T7 promoters which enable high amorphadiene 
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productivity selected as described in Chapter 4 were used to drive the expression of 
pathway modules. The plasmids in each set were then transformed into the MG1655 
(DE3, ΔaroABC) strain to assemble the CAMPS.  
Firstly, plasmid stability was tested for these strains when cultured in antibiotic-free 
minimum medium with glucose as the carbon source (Figure 5.12, A). From the result, 
all the engineered plasmids in both sets had stable copy numbers in varying induction 
conditions which resulted in selection pressure not only because of the synthesis of 
the recombinant enzymes but also due to the perturbation of the global cellular 
metabolism. All the plasmids were found to be stably retained under different 
induction conditions, an essential feature in industrial scale fermentation process. 
 












































Plasmids of CAMPS: 
A B 
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CAMPS were introduced into the mutant strain (MG1655, DE3, ΔaroABC) and cultured in minimum 
medium with glucose as carbon source. Various concentrations of IPTG (0.3 mM or 0.033 mM) were 
supplied to induce the genes carried by the plasmids to generate selection stress in certain conditions. 
(A), two CAMPS (MVA-213 and MVA-323) consist of three plasmids carrying the genes of MVA 
pathway and amorphadiene synthase: SAR: hmgS-hmgR-aroB, KKID: MVK-PMVK-MDV-idi, AA: 
ADS-ispA; (B), the plasmid copy numbers. Three biological replicates were carried out for each 
condition and the standard errors were presented. 
The production of amorphadiene were then compared when the two sets of plasmids 
were separately transformed into either the native strain (MG1655 (DE3)) or the 
engineered strain (MG1655 (DE3, ΔaroABC)). The strains were initially cultured in 
rich medium (2xPY++ medium) supplemented with three antibiotics (kanamycin, 
chloramphenicol and spectinomycin) to force the maintaining of all the plasmids. 
Although the MVA-213 set yielded less amorphadiene than the MVA-323 set which 
agreed with the results reported in “chapter 4”, there was no difference between two 
strains with or without CAMPS (Figure 5.12, B) when the same set of plasmids were 
used. Those observations confirmed that the knockout strain with several essential 
gene disabled have similar properties in amorphadiene production as compared to the 
native strain. 
Next, the productivity of the strains when cultured in antibiotic-free minimum 
medium with glucose or glycerol as the carbon source and various IPTG inductions 
were compared (Figure 5.12, C). The optimum yield of each strain with CAMPS was 
similar if not higher than when they were cultured in antibiotic conditions in rich 
medium. Clearly, the productivities using the native strain MG1655 (DE3) were 
significant lower at all conditions when compared to the strains engineered for 
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CAMPS. The results proved that the CAMPS, in the absence of antibiotics, not only 
was able to retain the plasmid copy number but also maintained the productivity of 
metabolites. 
 
Figure 5.12 Amorphadiene production with CAMPS  
(A), two CAMPS (MVA-213 and MVA-323) consist of three plasmids carrying the genes of MVA 
pathway and amorphadiene synthase: SAR: hmgS-hmgR-aroB, KKID: MVK-PMVK-MDV-idi, AA: 
ADS-ispA; Both systems were introduced into the native strain (MG1655, DE3) or the mutant strain 
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when cultured in 2xPY++ medium supplied with three antibiotics to maintain the plasmids. (C), 
various systems’ amorphadiene yields when cultured in minimum medium with either glucose or 
glycerol as carbon source without antibiotics. Four different IPTG concentrations were used to induce 
the expression of pathway genes. 
 
5.3 Discussion 
For metabolic engineering and synthetic biology, it is critical to have a stable 
multiple-plasmid system. As compatibility is an important issue when using multiple 
of plasmids simultaneously, the only option is to use plasmids from different 
compatibility groups which are limited in numbers and also highly variable in copy 
numbers. The mechanisms of plasmid replication were discovered decades ago [254, 
281, 282]. In p15A Ori, the regulation of plasmid copy number and the compatibility 
of different plasmids are high related. The key step in controlling plasmid copy 
number is the inhibition of plasmid replication by RNA I which recognizes a 
complementary stem-loop structure of RNA II – the RNA primer that initiates the 
plasmid replication. Based on the mechanism, various attempts had been made to 
engineer the copy number of a plasmid by manipulating the sequences in the stem-
loop structures with good success [283-286] while attention to the compatibility issue 
of these modified plasmids has yet to be determined. In nature, plasmids with slight 
different sequences in the stem-loop structures are known to be compatible and are 
thought to evolutionarily related. For example, the p15A like plasmids: p15A, Col E1, 
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RSF 1030 and CloDF13 are compatible with each other to a certain degree [260] 
(Figure 5.13). Some other evidences have also suggested that the recognition of RNA 
I and RNA II accounts for the compatibility between plasmids [258, 259].  
Based on existing knowledge, the loop sequences of RNA I/II were specifically 
engineered for the first time and the modified plasmids have now been proven to be 
compatible. Plasmids with loop sequences differing by as few as two bases were 
found to be compatible. From these observations, an unlimited number of compatible 
plasmids can be created. In addition, by engineering the sequences in the origin of 
replication, these plasmids have varying copy numbers when present in the host. To 
engineer metabolic pathways, other than selecting high copy number plasmids, 
plasmids with similar copy numbers to the parental plasmid (p15A Ori) can be 
selected for the ease of control. Another important differentiating factor in this study 
as compared to the use of different naturally compatible plasmids is that the modified 
plasmid library generated here share the same mechanisms of replication and 
resources. 
To expand the plasmid library, compatible plasmids can be generated by engineering 
the 2nd as well as the 1st and 3rd loop of p15A series Ori. Other series of plasmid 
family with replication mechanisms controlled by the recognition between RNA loops 
can be also engineered similarly. An example is the IncIα plasmid family whereas Inc 
RNA regulates the repZ translation and Inc18 plasmid family whereby RNA III 
inhibits the transcriptional of RepR protein [255]. 
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Figure 5.13 Stem-loop structure of RNA I in p15A like plasmids [260] 
 
Another challenge of using multiple plasmids is the maintenance of the plasmids 
inside the host during large scale fermentation processes. The use of antibiotics is not 
only limited by the lack of different antibiotics available but also challenges the 
purification, regulatory and cost issues. There are several antibiotic-free systems for 
the maintenance of a single plasmid usually for the purpose of recombinant 
production [184, 262-266]. However, there is yet to be an example of a robust 
antibiotic-free multiple-plasmid system.  
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This chapter described the development of a novel method to construct a versatile 
antibiotic-free multiple-plasmid system in which the plasmids carried genes that 
complemented the auxotroph host thereby stably maintaining the plasmids even under 
conditions of cellular stress. The first challenge was to construct strains with multiple 
essential gene knockouts, which could not survive in the absence of the appropriate 
plasmids. To overcome this, the choice of the conditional essential genes (CEG) 
allowed the strains to be conveniently created in rich medium where those genes are 
conditionally non-essential. Nine CEG from various biosynthetic pathways were 
experimentally demonstrated separately or in combinations. It was shown that the 
plasmids were stable even when the cells were subject to high selection pressure. 
After strain construction, another challenge was the lack of an antibiotic-free 
approach to introduce multiple plasmids into the strain because the limitation in the 
efficiency of co-transformation of plasmids to E. coli. This issue was surmounted with 
the use of modified growth medium where the strains lacking certain CEG could be 
grown by supplementing with the appropriate products. As a result, all the plasmids 
can be stepwise transformed in an iterative manner using respective modified growth 
medium at each step.  
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5.4 Conclusion 
With two key features: compatible plasmids using the same replication mechanism 
and culture in antibiotic-free medium, the novel multi-plasmid system established in 
the chapter will be beneficial to studies involving the simultaneous manipulation of 
large number of genes in industrial large scale production process.  
The multi-plasmids system is more flexible to manipulate and provided a more 
efficient way for pathway engineering compared to genomic integration.  
As a proof-of-concept, this was demonstrated by the production of amorphadiene 
where the native host yielded much less amorphadiene as compared to CAMPS 
strains in antibiotic free environment.  
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5.5 Methods 
5.5.1 Chemical, growth medium and bacteria strain 
Unless stated otherwise, all chemicals were purchased from either Sigma or Merck. 
The yeast extract and peptone were purchased from BD. The growth medium was 
prepared following previous paper [46] supplying 20g/L glucose or glycerol as carbon 
source. The 2xPY medium contained: peptone (20 g/L), yeast extract (10 g/L) and 
NaCl (10 g/L). The 2xPY++ medium contained: peptone (20 g/L), yeast extract (10 
g/L), NaCl (10 g/L), glucose (20g/L), Tween 80 (0.5%), HEPES (50mM) and was the 
rich medium used for amorphadiene production. Xl10-Gold (Stratagene) or DH5a 
(Invitrogen) strain was used for plasmid construction. Unless stated otherwise, all the 
cells were grown at 37°C with shaking (250 rpm). In certain conditions, various kinds 
of antibiotics were supplied as following: ampicillin – 100 mg/L, kanamycin – 50 
mg/L, chloramphenicol – 34 mg/L, spectinomycin – 100 mg/L. MG1655 (DE3) strain 
was the same as the one used in previous study [47] and was the strain used for 
studies involving the construction and characterization of novel compatible plasmids. 
Cell density (absorbance at 600 nm) was measured by SpectraMax 190 microplate 
reader.  
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5.5.2 Amorphadiene production 
For amorphadiene production experiment, 800 μL of cells were cultured together with 
200 μL of dodecane phase and cultured at 28 °C with shaking (250 RPM) in 15 ml 
FalconTM tube. The experiments were carried out for two days for rich medium 
(2xPY++ medium) and for four days for growth medium (growth medium with 
glycerol or glucose). Amorphadiene was trapped in the dodecane phase and quantified 
as previously described [240]. The dodecane phase was diluted 100 times in ethyl 
acetate and the amorphadiene was quantified by Agilent 7890 gas 
chromatography/mass spectrometry (GC/MS) by scanning 189 and 204 m/z ions, 
using trans-caryophyllene as standard. The amorphadiene concentrations were 
adjusted to the volume of cell suspension (0.8 ml) for report. 
5.5.3 Strain construction 
The strains used in the study were listed in “Table 5.1”. Based on the parental strain 
(MG1655 (DE3)), the knock-out strains were constructed using the method described 
in the paper [48]. The primer pairs KO-aroAF/ KO-aroAR, KO-aroBF/ KO-aroBR, 
KO-aroCF/ KO-aroCR, KO-pdxHF/ KO-pdxHR, KO-proCF/ KO-proCR and KO-
pyrFF/ KO-pyrFR were used to knock out the aroA, aroB, aroC, pdxH, proC, and 
pyrF genes receptively. The KO-argBCHF/ KO-argBCHR primer pairs were used to 
knockout the argBCH operon consisting of argB, argC and argH genes. The knock-
out strains were confirmed by PCR analysis with the primers listed in section 
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“Primers used to check the knockout strains”. The “in” primers were targeting at the 
sequences removed from the genome and “out” primers were targeting at the genome 
regions outside the removed sequences. 
5.5.4 Plasmid construction  
The strains used in the study were listed in “Table 5.7”. The T7-ADS-ispA-Cam-
p15A plasmid, T7-dxs-Kan-pET plasmid and T7-CYP450-CPR-Spec-pCL plasmid 
were from previous studies. All plasmid were constructed with CLIVA method and 
primers were listed in “Table 5.7”. The mutagenesis of 2nd loop of p15A Ori was 
carried by PCR amplification of T7-ADS-ispA-Cam-p15A plasmid with I-15ALoop2-
F/ I-15ALoop2-R degenerate primer pairs. The I-aroA-F/I-aroA-R, I-aroB-F/I-aroB-R 
and I-aroC-F/I-aroC-R primer pairs were used to amplify the aroA, aroB and aroC 
genes from the genome of MG1655 strain (ATCC) together with their RBS sequences. 
The genes were then inserted into plasmids at locations adjacent to the antibiotic 
resistant genes to form a polycistronic expression. The I-KAN(aroAr)f/ I-
KAN(aroAf)r, I-CAM(aroBr)f/ I-CAM(aroBf)r and I-SPE(aroCr)f/ I-SPE(aroCf)r 
primer pairs were used to amplify the vectors respectively. 
Table 5.7 Plasmids used in the study 
Name Promoter and 
gene 
Ori ARG CEG 
T7-ADS-ispA-Cam-p15A T7-ADS-ispA p15A Cam  - 
T7-dxs-Kan-p15A T7-dxs p15A Kan - 
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T7-ADS-ispA-Cam-p15AL2-5 T7-ADS-ispA p15AL2-5 Cam - 
T7-ADS-ispA-Cam-p15AL2-8 T7-ADS-ispA p15AL2-8 Cam - 
T7-ADS-ispA-Spec-p15AL2-8 T7-ADS-ispA p15AL2-8 Spec - 
T7-ADS-ispA-Spec-p15A T7-ADS-ispA p15A Spec - 
T7-ADS-Cam-p15A T7-ADS p15A Cam - 
T7-ADS-Cam-aroB-p15A T7-ADS p15A Cam aroB 
T7-dxs-Kan-pET T7-dxs pBR322 Kan - 
T7-dxs-Kan-aroA-pET T7-dxs pBR322 Kan aroA 
T7-CYP450-CPR-Spec-pCL T7-CYP450-CPR RSF1010 Spec - 
T7-CYP450-CPR-Spec-aroC-pCL T7-CYP450-CPR RSF1010 Spec aroC 
T7-ADS-ispA-Cam-pdxH-p15AL2-9 T7-ADS-ispA p15AL2-9 Cam pdxH 
T7-ADS-ispA-Cam-proC-p15AL2-4 T7-ADS-ispA p15AL2-4 Cam proC 
T7-ADS-ispA-Cam-pyrF-p15AL2-1 T7-ADS-ispA p15AL2-1 Cam pyrF 
T7-ADS-ispA-Cam-argB-p15AL2-10 T7-ADS-ispA p15AL2-10 Cam argB 
T7-ADS-ispA-Cam-argC-p15AL2-6 T7-ADS-ispA p15AL2-6 Cam argC 
T7-ADS-ispA-Cam-argH-p15AL2-11 T7-ADS-ispA p15AL2-11 Cam argH 
TM3-AA-Kan-aroA-p15A TM3-ADS-ispA-
Kan 
p15A Kan aroA 
TM3-SAR-Spec-aroC-p15A-1 TM3-hmgS-
hmgR-atoB 
p15AL2-1 Spec aroC 
TM2-SAR-Spec-aroC-p15A-1 TM2-hmgS-
hmgR-atoB 
p15AL2-1 Spec aroC 
TM2-KKID-Cam-aroB-p15A-8 TM2-MVK-
PMVK-MVD-idi 
p15AL2-8 Cam aroB 
TM1-KKID-Cam-aroB-p15A-8 TM1-MVK-
PMVK-MVD-idi 
p15AL2-8 Cam aroB 
Ori – original of replication, ARG – antibiotic resistant gene 
5.5.5 Plasmid copy number measurement  
The copy number of plasmid was defined as the ratio of the copy of plasmid DNA and 
to the copy of the genomic DNA. The copy numbers were measured by quantitative 
PCR (qPCR) with a standard curve prepared using linearized plasmid DNA or PCR 
product (1-3 kb) containing the amplicon (80-120 bps). Typically, 5 μL of cells whose 
medium were removed by centrifugation were diluted in 100 μL of water. The 
mixture was then heated at 95 °C for 20 min to lyse the cells. The cell debris was then 
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removed by mild centrifugation and the solution containing all the DNAs was dilute 
20 times for qPCR. The qPCR reactions were carried out in 25 µl final volume 
containing 5 µl diluted DNA samples, 1x Xtensa Buffer (Bioworks), 200 nM of each 
primer, 2.5 mM MgCl2 and 0.75 U of iTaq DNA polymerase (iDNA). The reactions 
were analyzed using a BioRad iCycler 4TM Real-Time PCR Detection System (Bio-
Rad) with SYBR Green I detection and the following  protocol: an initial denaturation 
of 1 min at 95 °C, followed by 40 cycles of 20 s at 95 °C, 20s at 60 °C, and 20s min at 
72 °C. A melt curve was then measured to check the melting temperature of the 
amplicon. For all the studies, technical duplicates or triplicates were carried out. 
Primers were listed in “Table 5.7 - Primers used for plasmid copy number 
measurement”.  The antibiotic resistant genes were measured to represent the amount 
of various plasmids with Cam-F/Cam-R, Kan-F/Kan-R and Spe-F/Spe-R primer pairs. 
For amorphadiene production study, the pathway genes were measured to represent 
the amount of various plasmids with hmgS-F/hmgS-R, MVK-F/MVK-R and ADS-
F/ADS-R primer pairs. The cysG-F/cysG-R primer pair was used to measure the cysG 
gene which is one copy in the genome to represent the copy number of genomic DNA. 
Table 5.7  Primers used in the study 
Primers used for plasmid construction 
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Chapter 6 CONCLUSION 
6.1 General conclusion 
Engineering is the application of scientific principles in order to design or construct 
new devices, machines or systems where convenient tools as well as predictive 
models are used to facilitate the optimization process. The successful engineering of a 
living organism to produce high value products with the desired outcomes is still in its 
infancy. This is largely due to the limited knowledge of the extremely complicated 
and intricate workings of the biological systems. Therefore, a combinatorial 
multivariant-modular approach is necessary to explore and identify the optimal 
condition for a biological system. This thesis was focused on the design and 
development of molecular tools for the engineering of metabolic pathways in E. coli 
to address the various unmet needs in the field. 
The biological pathway consisting of multiple enzymatic steps can be divided into 
multiple pathway modules. In these studies, the control and monitoring of the 
expression levels of GOI in the modules in vivo as well as the assembly and stable 
maintenance of the genetic materials in the host were challenges addressed by the 
establishment of toolkits which include, 1) a UNivariant Extrinsic Initiator Control 
System for microbes (µ-UNeICS) created for the systematic modulation and rational 
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optimization of the expression levels of GOI in multiple modules which replaced 
more currently used “try-and-error” approaches; 2) a cell-to-CT method which 
enabled the direct measurement of transcriptional levels in E .coli, thus, reducing pre-
analytical variability and increased profiling through-puts; 3) a cross-lapping in vitro 
assembly (CLIVA) method which is both enzyme-free and sequence-independent for 
the assembly of multiple modules into a plasmid in a single step, greatly accelerating 
the engineering process; and 4) a compatible antibiotic-free multi-plasmid system 
(CAMPS) that enabled the stable co-existence of unlimited number of artificially 
engineered compatible plasmids in an engineered host for scale-up production. 
Collectively, these methods were integrated into a robust workflow for the 
construction, control, monitor and maintenance of genes in E. coli which can be 
applied to studies beyond the scope of this thesis.  
The workflow developed herein was successfully applied to optimize the production 
of isoprenoids with either the DXP or MVA pathway in E. coli. With the CLIVA 
method, the overexpression targets of the endogenous DXP pathway were 
combinatorially investigated and the co-expressions of certain pathway modules were 
found to be inhibitory, caused by the high intracellular accumulation of a pathway 
intermediate – MEC. Co-expressing the co-factor supply systems for the enzymes 
consuming MEC enhanced productivity. The identification of such an unanticipated 
endogenous intermediate was guided with the discoveries in the combinatorial search 
and demonstrated the importance of monitoring metabolite changes when cells were 
overexpressing certain enzymes. 
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Next, the DXP or MVA pathway were partitioned into three pathway modules and the 
expression levels of the modules as polycistronic operons were simultaneously and 
systematically optimized with the µ-UNeICS method resulting in huge enhancement 
in the yield of isoprenoids (> 40 fold for DXP pathway and > 1000 fold for MVA 
pathway). Finally, the CAMPS helped to maintain the productivity of isoprenoids in 
cells grown in antibiotic-free minimum medium suitable for large scale industrial 
production. 
Besides identifying the optimum conditions for overexpression, the combinatorial 
multivariant-modular approach also provided a better understanding of the engineered 
systems including the discovery of novel pathway bottleneck in DXP pathway as well 
as the major confounding boundaries and the global optima on the landscapes of gene 
expression in both of the DXP and MVA pathways. As compared to the iterative “try-
and-error” method where one does not know if optima have been attained or not, the 
approach developed in this study allowed the selection of rational targets and 
conditions to attain global optima rapidly. 
Certain observations including the inhibitory effect of intracellular MEC, the 
existence of global as well as local optima for high productivity and the unanticipated 
finding of the efflux of metabolic intermediates under various conditions 
demonstrated our current limited understanding of the dynamics of the system and the 
availability of engineering tools is important for the exploration of such intricate 
space. 
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6.2 Recommendation of future works 
As mentioned, the interesting observations made in this thesis can be further explored 
to better understand the underlying regulatory mechanisms involved in high 
productivity of isoprenoids. For example, by identifying the confounding factors of 
those pathways, the search of the global optimum in a better defined landscape may 
result in a higher productivity and by knowing the inhibitory effect on isoprenoid 
production, the removal of excess intracellular MEC should increase productivity.  
Tuning the pathways in a finer manner may further help with the production of 
isoprenoids. For the DXP pathway, the simultaneous modulation of the whole 
pathway separated into different modules together with Fe-S cluster operons by the µ-
UNeICS method may be better than the current way of merely tuning known 
bottlenecks based on reports in the literature. With the current way of defining 
pathway modules, the MVA pathway responded more sensitively to pathway tuning 
as compared to the DXP pathway, which suggested the presence of multiple but yet to 
be defined biochemical bottle-necks. By redefining and reconstructing the pathway 
modules, it may be possible to generate a better high producer strain.  
It will be interesting to extend the studies of the desired strains by scale-up production 
in a well-controlled fermentation condition. The performances of CAMPS for various 
combinations of GOI should to be explored in small, medium and large scale 
C h a p t e r  6                                              P a g e  212 
 
fermentation processes. In the future, the combinations of CEG selected for CAMPS 
should be extended to larger numbers and the performances verified empirically. 
Larger panels of the engineered plasmids for compatibility purposes should also be 
generated to enable a wider capacity and dynamic range of gene expression and 
plasmid copy number.  
With the tools developed in this study, it will be interesting and useful to extend the 
utility for the manipulation of other cellular systems in metabolic engineering and in 
synthetic biology.  
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